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i 
Abstract 
 
Osteomyelitis is a severe bacterial infection that is considered to be one of the most-
difficult-to-treat infections. It causes the destruction of bone tissue and the treatment 
often includes surgical debridement that creates a defect in the bone. Because there may 
be bacteria left in the surrounding tissues, long courses of antibiotics are also required. 
Adequate antibiotic concentrations using oral or intravenous antibiotics may be difficult 
to achieve because of degenerated blood circulation. Local antibiotic delivery using 
implanted antibiotic-releasing materials in the defect site provides an efficient way of 
achieving high local antibiotic concentrations, and also decreases the side-effects that 
are often associated with oral or intravenous antibiotics. 
The objective of this thesis was to develop bioabsorbable and antibiotic-releasing (either 
rifampicin or ciprofloxacin) composite materials that can be used for the local antibiotic 
treatment of osteomyelitis and that also include a osteoconductive ceramic component 
to aid bone healing. Continuous antibiotic delivery for three to six months was 
requested. The materials developed are to be used together so that the surgeon can 
decide in which ratio to use them. The materials chosen for the study were medical 
grade poly(L-lactide-co-İ-caprolactone) as the bioabsorbable polymer matrix, ȕ-
tricalcium phosphate (ȕ-TCP) as the osteoconductive ceramic component, and the 
antibiotics ciprofloxacin and rifampicin that are clinically used as a combination in the 
treatment of osteomyelitis. All the materials used are approved for clinical use. Ten 
different composites of these materials plus plain poly(L-lactide-co-İ-caprolactone) 
were processed using extrusion and cut into pellet shaped samples (diameter 
approximately 2.5 mm and length 2.5 mm). Four of the composites had no antibiotic 
component, three composites contained 8 wt-% ciprofloxacin, and three contained  
8 wt-% rifampicin. A series of in vitro tests (Sörensen phosphate buffer, pH 7.4, 37 °C) 
were performed to evaluate the hydrolytic degradation and drug release behavior of the 
manufactured composites. The most promising antibiotic-releasing composites, showing 
continuous release, were also tested against two common osteomyelitis-causing model 
bacteria utilizing genetically engineered bioluminescent bacteria. 
The antibiotic containing composites with 50 wt-% of ȕ-tricalcium phosphate were the 
most promising with continuous drug release up to approximately 20 weeks. The 
antibiotic release occurred in several phases and the release was not similar for the two 
studied antibiotics. The differences were attributed mainly to different molecular size 
(ciprofloxacin 331 g/mol and rifampicin 823 g/mol) and differences in water solubility 
(For rifampicin in water at 30 °C, 1.5-1.7 mg/ml depending on the crystal form 
(Henwood et al. 2000) and for ciprofloxacin at 37 °C, 0.20 mg/ml at pH 7.8 and 0.22 
mg/ml at pH 6.9 (Breda et al. 2009)). The composites containing 50 wt-% ȕ-TCP also 
showed good effect against the common osteomyelitis-causing bacteria, Staphylococcus 
epidermidis and Pseudomonas aeruginosa. The hydrolytic degradation of the polymer 
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followed first order kinetics and the molar ratio of the comonomers changed, as the 
degradation proceeded. These composites have great potential to be used in the 
treatment of osteomyelitis or other bone related infections. In this work, only in vitro 
tests were performed, and thus the next step for these composites is preclinical testing.  
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Definitions 
 
Allograft Graft taken from another individual of the same species as the 
recipient. 
Autograft Graft taken from a source in the individual who receives it. The 
donor and the recipient are the same. 
Bioabsorbable Capable of being degraded or dissolved and subsequently 
metabolized within an organism. 
Biocompatibility The ability of a material to perform with an appropriate host 
 response in a specific application. 
Biodegradable Capable of being degraded by biological activity or system. 
Biofilm  A coherent cluster of bacterial cells embedded in a matrix that 
are more tolerant to most antimicrobials and the defense than 
planktonic bacterial cells. 
 Layer-like aggregation of cells and cellular products attached to 
a solid surface or substratum. 
Biomaterial Material intended to interface with biological systems to 
evaluate, treat, augment or replace any tissue, organ or function 
of the body. 
Bolus  A single dose of a drug or other medicinal preparation given all 
at once. 
Degradation Process of chain cleavage in a polymer. 
Erosion Mass loss. 
In vitro  Taking place in a test tube, culture dish, or elsewhere outside a 
living organism. (Lat. ‘In glass’). 
In vivo Taking place in a living organism (Lat. ‘In a living thing’). 
Osteoblast Bone forming cell. 
Osteogenic Capable of producing bone. 
Osteoconductive Capable of guiding bone growth on a surface. 
Osteoinductive Capable of inducing bone growth. 
Prophylaxis Prevention of disease or control of its possible spread. 
Systemic Affecting the body generally. 
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1 INTRODUCTION 
In the field of biomaterials, drug delivery of various active agents is a very important 
application area. Traditionally, drug-delivering materials have been developed with 
optimal drug delivery properties in mind. Nowadays, the development of drug-
delivering materials is heading towards multifunctional materials that can also perform 
other functions in addition to drug delivery. Major interest lies in applications where the 
goal of the biomaterials is to help the body to heal itself. Such biomaterials may be 
called third generation biomaterials and they often combine bioabsorbability and 
bioactivity with other functions such as drug release. (Hench and Polak 2002) 
Today, infectious diseases are still a major problem around the world despite the efforts 
in the development of antibiotics and the treatment methods. Infectious diseases kill 
more people worldwide than any other single cause (Muñoz-Bonilla and Fernández-
García 2012). A disease that is often considered as one of the most difficult-to-treat 
infections is osteomyelitis (Sia and Berbari 2006). Osteomyelitis is an infection of bone 
caused by bacteria that are usually very difficult to eradicate from the infected bone 
tissue (Chihara and Segreti 2010; Sia and Berbari 2006). The disease may lead to 
amputation or even death. The treatment of osteomyelitis is long and hard for the patient 
and expensive with long courses of antibiotics. Treatment of chronic osteomyelitis 
includes a radical surgical debridement of the infected tissue that leaves a defect in the 
bone called a dead space. The treatment of the dead space has often been done in two 
stages. The first stage has been to fill the dead space with biostable antibiotic-releasing 
poly(methyl methacrylate) beads that eradicate the remaining bacteria in the tissues 
surrounding the dead space. The second stage has been the removal of the antibiotic-
releasing beads followed by bone grafting. This method of treatment is not optimal 
because it involves two surgeries and increases the risks for the patient. Bioabsorbable, 
osteconductive and antibiotic-releasing composites offer the possibility to treat 
osteomyelitis in one stage and to reduce both the risks for the patient and the costs. Such 
materials have been requested in the literature and the research is going on to achieve 
these goals (Jiang et al. 2012). The development of such bone filling materials has been 
the goal in this thesis. In addition to the treatment of osteomyelitis, these materials can 
also be used as prophylaxis to prevent bone related infections. 
This thesis consists of a literature review, experimental section, and four original 
publications. The literature review provides an overview of the field of controlled 
antibiotic delivery applications intended for the treatment or prevention of bone 
infections. In addition, the medical background of osteomyelitis and implant-related 
infections as well as the treatment of them are addressed. In the experimental part, 
bioabsorbable and antibiotic-releasing composite materials were developed for use as 
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bone defect filler materials in the treatment of osteomyelitis and other bone related 
infections. The composites are composed of three FDA-approved components. A 
bioabsorbable polymer matrix provides bioabsorbability, drug releasing properties and 
the possibility of healing bone tissue to replace the material. Bioceramic, ȕ-tricalcium 
phosphate, offers osteoconductivity, e.g. it helps the bone tissue to grow and heal. Two 
different antibiotics, ciprofloxacin and rifampicin, were released in a continuous manner 
from the respective composites to eradicate bacteria. The optimal composition was 
investigated in the in vitro test series and the degradation and drug release properties of 
the materials were tested. The effect of the most promising composites against common 
osteomyelitis-causing bacteria Pseudomonas aeruginosa and Staphylococcus 
epiderdmidis was shown in vitro using genetically engineered bioluminescent bacterial 
strains. 
 
 3   
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2 LITERATURE REVIEW 
2.1 Controlled drug delivery 
2.1.1 Controlled drug delivery systems 
Medical drugs have been traditionally administered systemically via oral and 
intravenous (bolus injections or infusions) routes and via intramuscular or subcutaneous 
injections. In the case of intravenous infusion, a very constant drug concentration in the 
blood circulation is achieved. When the other administration routes are used, the drug is 
released immediately and the drug concentration in the body may fluctuate according to 
the doses taken (Figure 1).  Additionally, in cases when the doses are taken too 
frequently, a toxic level may be reached. For part of the time, however, the drug 
concentration is still below the minimum effective concentration. If longer time periods 
with effective drug concentration are desired, the only option is to increase the dose. By 
doing so, the drug concentration may reach the toxic level and increase the side effects. 
(Heller 1996) The drawbacks of the traditional delivery routes and not constant drug 
concentration are toxicity issues (side effects), patient discomfort, and the possible 
development of bacterial resistance. Moreover, the drug may take a longer time to reach 
the target and may not reach those areas that lack vascularization (Hanssen 2005; Parker 
et al. 2011). Additionally, because the whole organism treated with the drug is affected 
as the drug is distributed throughout the organism, unwanted side effects can increase. 
 
Figure 1. Drug concentration in traditional immediate release drug delivery and 
controlled drug delivery (modified from (Anonymous2003)). 
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In controlled drug delivery, the goal may be either to deliver the drug in a controlled 
manner or to target the delivery locally in the body or both (Anonymous2003). 
Examples of controlled drug delivery systems are plasters that release analgesic agents, 
hormones, or nicotine. Examples of targeted drug delivery are antibiotic-releasing 
poly(methyl methacrylate) (PMMA) beads that release gentamycin antibiotic in bone 
defects in the treatment of osteomyelitis (Zilberman and Elsner 2008) or contraceptive 
hormone-releasing intrauterine systems (Luukkainen 1991). Targeted drug delivery may 
be supplementary to the systemic drug administration or completely replace it (Hanssen 
2005). Several benefits can be achieved when drugs are administered either in a 
controlled manner or targeted to a specific site in the body. These benefits can include: 
reduced side effects, lower doses, better efficacy of the drugs, and drugs with a narrow 
therapeutic window or low bioavailability can be administered (Jain et al. 2005; Lao et 
al. 2011). Drug concentrations on the site of the delivery can be extremely high 
compared with those concentrations achieved by systemic administration, which 
increases the efficacy of the treatment. Especially, in the case of antibiotics, the high 
concentration achieved locally may be critical in eradicating bacteria (Hanssen 2005). 
However, care must be taken so that the local concentration does not exceed toxic levels 
and stays above the therapeutical level. Additionally, controlled release technology has 
the potential to reduce patient compliance problems and the adverse effects that cause 
roughly 10-14% of the hospitalizations in the U.S. This would mean major savings in 
the health care sector. (Rothstein and Little 2011) The development of new local 
delivery methods may also lead to new therapies because local drug delivery allows 
new administration routes and the possibility to better deliver complex drugs (e.g. 
proteins), which are normally destroyed in the gastrointestinal tract. From the 
commercial point of view, new drug delivery methods offer a good investment 
opportunity for the drug companies when there is a new way of delivery developed for 
an already existing drug. (Langer 1990) 
If the controlled drug delivery system is bioabsorbable, no removal of the device is 
required, which is an additional advantage. Usually, such systems utilize bioabsorbable 
polymers that degrade in the body to harmless degradation products that are removed by 
the body via normal metabolism. Bioabsorbable synthetic polymers can be tailored to 
meet specific drug release patterns and degradation rates (Mönkäre et al. 2010; Mönkäre 
et al. 2012; Pulkkinen et al. 2007). The addition of substances other than small 
molecular weight drugs, such as growth factors and peptides, may also be possible 
(Hanssen 2005; Mönkäre et al. 2010; Mönkäre et al. 2012; Pulkkinen et al. 2007). 
Bioabsorbable drug-releasing systems have been developed in various forms. Some 
examples of these are antibiotic-releasing screws (Veiranto et al. 2002; Veiranto et al. 
2004b), bone cements (Ginebra et al. 2012), pellets (Koort et al. 2006; Koort et al. 
2008), cylinders (Alvarez et al. 2008), fibers (Nikkola et al. 2008), nanofibers (Kim et 
al. 2012), and scaffolds (Mouriño and Boccaccini 2010). 
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In the case of bone related infections, local antibiotic delivery offers a way to overcome 
the difficulty of administering the drug to infected bone tissue that has poor blood 
circulation (Alvarez et al. 2008; Castro et al. 2003; Castro et al. 2005; Garvin et al. 
1994; Mäkinen et al. 2005a; Mäkinen et al. 2005b; Miyai et al. 2008; Tiainen et al. 
2009; Waknis and Jonnalagadda 2011). Previous studies have shown that with the local 
administration of antibiotics, the drug concentrations in the blood or other tissues are 
low, at least a decade lower than in the tissues surrounding the locally drug-releasing 
material (Koort et al. 2005; Koort et al. 2006; Koort et al. 2008). This naturally leads to 
decreased side effects such as nausea that has been often reported as the cause for the 
discontinuation of the antibiotic therapy or the continuation of the therapy but with a 
lower dose. (Bliziotis et al. 2007; Zimmerli et al. 1998) 
During the last decades, there have been a large number of scientific articles published 
regarding controlled drug delivery research and applications. However, only a few 
products that release drugs locally have reached the commercial stage. This may be due 
to the complexity of the research area and the numerous factors that influence the 
release of drug molecules from different polymeric systems. These factors include 
molar mass and molar mass distribution (polydispersity) of the polymer, permeability, 
the molecular size of the drug, polymer morphology (Frank et al. 2005; Hurrell and 
Cameron 2002), the chemical composition of both the polymer and the drug (Frank et 
al. 2005; Li et al. 1996), the size and shape of the device (Ahola et al. 2003), the 
porosity of the device, drug load, and drug/polymer interactions. (Lao et al. 2011; Li 
and Vert 1999; Nair and Laurencin 2007) These factors are very much dependent on 
each other and cannot be considered separately. Additionally, regulatory procedures and 
requirements cause the development phase of implantable drug delivery devices to be 
long and include expensive and time-consuming clinical studies. 
Some commercially available antibiotic-releasing products for the targeted drug 
delivery of bone tissue are collected in Table 1. 
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Table 1. Examples of commercial antibiotic-releasing products for the treatment or 
prevention of bone related infections. 
Product name Manufacturer / Distributer Drug Matrix Indication 
CiproScrew Bioretec Ltd. Ciprofloxacin PLGAa 
Fracture fixation in 
risk patients 
Septopal 
Biomet 
Deutschland 
GmbH 
Gentamycin PMMAb Osteomyelitis 
SmartSet GMV 
SmartSet GHV 
DePuy 2 Fast Set 
Bone Cement 
DePuy Gentamycin PMMAb 
Second stage of a 
two-stage revision 
for total joint 
arthroplasty, after 
the initial infection 
has been cleared. 
Simplex P 
Simplex SpeedSet 
Stryker Tobramycin PMMA
b 
P(MMA-S)c 
Fixation of 
prostheses to living 
bone in the second 
stage of a two-stage 
revision for total joint 
arthroplasty 
Refobacin Bone 
Cements 
Biomet Bone  
Cements 
Biomet Gentamycin PMMAb Primary implantation and revisions 
Palacos R+G 
Palacos MV+G 
Palacos LV+G 
Heraeus  
Medical Gentamycin PMMA
b Hip and knee joint 
replacement 
a: poly(lactide-co-glycolide) 
b: poly(methyl methacrylate) 
c: poly(methyl methacrylate-co-styrene) 
2.1.2 Mathematical theory of controlled drug delivery 
2.1.2.1 Delivery rates 
The pattern of active agent release from a system can vary over a wide range. The three 
patterns describing the release used most often are zero order release, first-order release, 
and square-root-of-time release. According to Baker (Baker 1987), these can be 
presented as follows: 
Zero-order release is the simplest case mathematically with constant active agent release 
and can be described with the following equation (Equation 1): 
ௗெ೟
ௗ௧
= ݇ (1) 
where Mt is the mass of active agent released, t is time, and k is constant. 
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In the first order release, the release rate of the active agent declines exponentially 
(Equation 2)  
ௗெ೟
ௗ௧
= ݇ܯ଴݁ݔ݌(െ݇ݐ) (2) 
where M0 is the mass of active agent in the system at time t=0.  
In the square-root-of-time release pattern, the release rate is proportional to the inverse 
of the square root of time (Equation 3) 
ௗெ೟
ௗ௧
= ௞
ξ௧
 (3). 
2.1.2.2 Models based on diffusion 
Controlled delivery systems can be classified according to the mechanism controlling 
the drug release from the system. The different classes are diffusion controlled, swelling 
controlled, osmotically controlled, and chemically controlled systems. In this section, 
only diffusion-controlled systems are addressed. The mathematical models that describe 
drug release are based on mass transport equations, and they are usually called kinetic 
models because they describe the time-dependent behavior of the drug release. 
(Narasimhan et al. 1999) 
There are various mathematical models that describe the release of active agents from 
different kinds of drug release systems. In the case of polymeric materials, the models 
are often based on Fick’s law of diffusion (Lao et al. 2011). Diffusion is a transport 
process caused by the random motion on the molecular level and it leads to the 
movement of molecules from the high concentration to the low concentration. Fick 
introduced this mass transport phenomenon in 1855. (Cussler 2008; Lao et al. 2011) 
Fick’s first law (Eqation 4) describes the steady state diffusion: 
ܬ = ܦ డ஼
డ௫
   (4) 
where J is the diffusion flux, C is the position dependent drug concentration in the 
sample, and x is the position (normal to the plane) in the sample, which is assumed to be 
planar (Narasimhan and Peppas 1997). 
Fick’s second law describes non-steady diffusion and takes into account the change of 
the concentration within the diffusion volume with respect to time as well as position 
(Cussler 2008; Lao et al. 2011). In three dimensions and with rectangular geometry, it 
has the following form (Crank 1975): 
డ஼
డ௧
= ܦ ቀడమ஼
డ௫మ
+ డమ஼
డ௬మ
+ డమ஼
డ௭మ
ቁ  (5) 
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where C is the concentration of the active agent; t, the time; and x, y, and z, the 
coordinates of the system. 
Fick’s second law is, however, quite simple. It does not take into account, for example, 
pressure or osmotic pressure. It can be used when binary mixtures are handled, but it 
cannot be used for very complex situations (Wesselingh 1993). 
The most known model of drug release is the Higuchi model (Equation 6). It describes 
the drug release from non-degradable, non-porous, film shaped monolithic systems, 
where the drug is dispersed as particles in the matrix (Higuchi 1963; Siepmann and 
Peppas 2011). It is based on the Fick’s first law of diffusion and it assumes that the 
dispersed drug particles are smaller in diameter than the thickness of the polymer 
matrix. In this way, the effects of the edges of the test specimens on the drug release can 
be ignored. It is also assumes that a pseudo-stationary state is predominant: the drug is 
dissolved into the matrix from the dispersed particles at the same rate as the drug is 
leaving the matrix. (Ginebra et al. 2006; Higuchi 1963; Lao et al. 2011; Narasimhan and 
Peppas 1997; Siepmann and Peppas 2011) 
ܯ௧ = ܣඥ(2ܦܥௌܥ଴ݐ)  (6) 
where Mt is the active agent released in time t, D is the diffusion coefficient of the drug 
in the polymer, Cs is the solubility of the active agent in the matrix, C0 is the initial drug 
concentration in the sample, and A is the cross-sectional diffusion area. 
Exact solutions of Fick’s second law have been provided and the solutions have been 
approximated to allow simpler mathematical equations to be used (Baker 1987; Lao et 
al. 2011). Two examples of these are Equations 7 and 8. Equation 7 is an approximation 
of the exact solution to Fick’s second law for one-dimensional diffusion in a film-
shaped test specimen and assumes a constant diffusion coefficient (Baker 1987; 
Siepmann and Peppas 2011): 
ெ೟
ெబ
= 4 ቀ஽௧
గ௟మ
ቁ
ଵ/ଶ
   (7) 
where M0 is the total amount of drug in the sample, Mt is the amount of drug released at 
time t, D is the diffusion coefficient, and l is the thickness of the sample. The equation is 
valid for short time periods (usually assumed 0 < ெ೟
ெబ
 < 0.6) and in cases when the initial 
drug concentration in the samples is lower than the solubility limit. Equation 8 is an 
approximation for the release after 40 % of the active agent has been released and is 
called a late-time approximation (Baker 1987) 
ெ೟
ெబ
= 1 െ ଼
గమ
݁ݔ݌ ቀ
ିగమ஽௧
௟మ
ቁ  (8). 
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It can be noted that both Higuchi’s equation (Equation 6) and Equation 7 give the 
release t1/2-dependence although the approaches behind these two equations are quite 
different (Siepmann and Peppas 2011). 
Peppas and coworkers introduced the so-called power law (Equation 9) in 1983. It is a 
semi-empirical model (Lao et al. 2011; Ritger and Peppas 1987) and the Equation has 
the following form: 
ெ೟
ெಮ
= ܽݐ௡ (9) 
where Mt and M are the amounts of drug released at time points t and infinity (M is 
often assumed to be the same as the drug load in the test specimen), a is a constant 
describing the geometrical and structural characteristics of the test specimen, and n is 
the release exponent describing the transport mechanism. This equation is valid for the 
first 60% of the cumulative release. For thin films, the exponent n has the values of 0.5 
for fickian diffusion, 0.5<n<1 for non-fickian transport and 1 for zero-order release. 
This equation can also be used for other geometries and, for example, for cylinder n = 
0.45 for fickian diffusion, 0.45<n<1 for non fickian (anomalous) transport, and 1 for 
zero order release. (Lao et al. 2011; Ritger and Peppas 1987) The power law has been 
subsequently modified to take into account the lag time and burst effects in the 
beginning of the release (Kim and Fassihi 1997). 
There are severe limitations to the diffusion models presented above. Although drug 
release is studied from three dimensional structures, the equations are often one-
dimensional (Zamoume et al. 2011). The assumption that the diffusion coefficient is 
constant throughout drug release is erroneous, for example, in cases where polymer 
degradation changes the diffusion properties (Siepmann and Peppas 2011). In cases 
where the release period is very short and polymer degradation is negligible, a constant 
diffusion constant may be valid. Because of the many limitations of the models, 
extensions have been developed such as the models where diffusion coefficient is not 
constant (Zamoume et al. 2011). For example, Higuchi’s model has been modified to 
include a diffusion coefficient that changes with time due to polymer degradation (Lao 
et al. 2011). Zamoume et al. have added a geometrical parameter to the diffusion 
coefficient that takes into account the distance of the drug molecule to the exit point 
(Zamoume et al. 2011). If the matrix is porous, the diffusion coefficient can be replaced 
by an effective diffusion coefficient Deff, because porosity obviously plays an important 
role in the release of active agents from the matrix (Ginebra et al. 2006). 
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2.1.2.3 Models for bulk degrading polymers 
Because the properties of degradable polymers change as the degradation proceeds, 
polymer degradation and erosion need to be taken into account. In the case of surface 
eroding polymers, the modeling of drug release is rather easy because of the linear 
fashion of the polymer erosion. Bulk eroding polymers, on the other hand, make the 
modeling more complex (Lao et al. 2011). 
A widely accepted way that bulk-degrading polymers degrade is according to first order 
kinetics: 
ௗெೢ
ௗ௧
ൌ െ݇ܯ௪ (10), 
and when integrated, the Equation has the following form:  
ܯ௪,௧ = ܯ௪,଴݁ݔ݌(െ݇ݐ)  (11) 
where Mw,t is the polymer molecular weight at time t, Mw,0 is the initial polymer 
molecular weight, and k is the degradation rate constant (Lao et al. 2011). 
As the polymer degrades, the simplest way of taking the changing permeability of the 
polymer matrix into account is to add a time-dependent factor to the diffusion 
coefficient. For example, Heller and Baker modified the Higuchi equation into 
following form (Baker 1987):  
ௗெ೟
ௗ௧
= ஺
ଶ
ቀ
ଶ௉஼బ
௧
ቁ
భ
మ (12) 
where A is the surface area of both sides of the film, P is the time dependent 
permeability of the drug in the matrix (equal to DCs in Equation 6), C0 is the initial drug 
concentration in the matrix, and Mt is the cumulative released drug at time t. 
Permeability was assumed to be dependent on the remaining number of bonds in the 
polymer. Omitting the intermediate steps, the final equation has the following form (Lao 
et al. 2011): 
ௗெ೟
ௗ௧
= ௌ
ଶ
ቂ
ଶ௉బ௘௫௣(௞௧)஼బ
௧
ቃ
ଵ/ଶ
 (13) 
where  P0 is the initial drug permeability in the polymer and k is the first order rate 
constant of the polymer degradation (see Equations 10 and 11). 
In another approach, the diffusion coefficient was assumed to be inversely dependent on 
polymer molecular weight. Additionally, the degradation of the polymer was assumed 
to occur according to the first order kinetics (Equation 11) (Charlier et al. 2000). The 
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model was based on the Higuchi model and showed good agreement with the 
experimental data also with longer times. 
Models that rely solely on diffusion are usually good in predicting mono-phasic release 
(Lao et al. 2011). If the release profile includes more than one phase, it is clear that 
more complex models are needed that take factors into account other than diffusion and 
the dependency of the diffusion coefficient on concentration or polymer degradation.  
2.1.2.4 Models for multiple release mechanisms 
Attempts to describe the drug release kinetics with single mathematical models have 
proven to be complex due to the multitude of factors that affect polymer-based drug 
delivery systems. Additionally, the equations are often one-dimensional whereas real 
systems are three-dimensional. Models for multiple release mechanisms are not further 
presented here and the interested reader is instructed to read an excellent review by Lao 
et al. (Lao et al. 2011), as a starting point. 
Nowadays, powerful software tools are available for the more accurate modeling and 
simulation of drug release. The tools utilize, for example, finite element method (FEM) 
(e.g. Comsol Multiphysics) and offer a way to simulate cases where several factors 
affect the drug release. (Kaunisto et al. 2013; Manzano et al. 2011; Moscicka-
Studzinska and Ciach 2012; Thakhiew et al. 2011) As more computing power is 
available than ever before, the multiphysics models are the next step in the modeling of 
controlled drug delivery from polymeric systems.  
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2.2 Bone related infections 
2.2.1 Osteomyelitis 
Osteomyelitis is a severe bone infection that leads to bone destruction and is considered 
to be one of the most difficult-to-treat infectious diseases. The disease may become 
chronic and lead to amputation or even death (Chihara and Segreti 2010; Nandi et al. 
2010; Sia and Berbari 2006). The term osteomyelitis is generally used for the condition 
where bone marrow is infected and the condition where both bone marrow and bone 
cortex are infected (Walter et al. 2012). The disease is caused by bacteria or other 
microorganisms, Staphylococcus aureus is the most common (60% of cases) (Gautier et 
al. 2012; Jones et al. 2004; Nandi et al. 2010). S. aureus are Gram positive, nonmotile, 
and non-spore-forming bacteria (Kiedrowski and Horswill 2011). The bacteria also have 
the ability to adhere to many types of surfaces and to develop biofilm (Harris and 
Richards 2006; Kiedrowski and Horswill 2011). Other osteomyelitis causing 
microorganisms include: Pseudomonas aeruginosa or other enterobacteria, 
Staphylococcus epidermidis, Escherichia coli, Aspergillus spp, and Mycobacterium 
avium. Virtually any organism has the potential to cause osteomyelitis and often the 
infection is polymicrobial, especially in cases where the bacterial inoculation has been 
through an open fracture (Chihara and Segreti 2010). Staphylococcal biofilms are very 
resistant to antimicrobial treatments as well as to host immune defenses (Kiedrowski 
and Horswill 2011). 
Osteomyelitis may be acquired from direct inoculation of the bacteria into the bone, via 
hematogenous seeding, or contiguous spreading of infection (Sia and Berbari 2006). 
Additionally, there is an ischemic form of osteomyelitis that is most often related to 
diabetic foot (Walter et al. 2012).  Normal healthy bone is highly resistant to infection, 
so osteomyelitis often occurs in patients with risk factors such as diabetes, decubitus 
ulcers, surgery, trauma, malnutrition, kidney or liver failure, respiratory failure, immune 
deficiency, malignant tumor, or intravenous drug abuse (Chihara and Segreti 2010; 
Walter et al. 2012). Foreign bodies, e.g. implants and external fracture fixation devices, 
may also offer a surface for the bacteria to attach to and lead to biofilm formation and 
finally to osteomyelitis (Kiedrowski and Horswill 2011). Infection rates reported for 
trauma surgery for the fixing of fractures vary between 1% and 5% for closed fractures 
and 3% and 50% for open fractures (Walter et al. 2012). Numerous reviews have 
addressed these problems (Esposito and Leone 2008; Harris and Richards 2006; Jain et 
al. 2007). 
In a biofilm model of osteomyelitis suggested by Walter et al., bacteria are first 
inoculated at the bone surface and start to form colonies. These colonies produce an 
extracellular matrix and develop into three-dimensional structures. The matrix acts as a 
diffusion barrier and protects the bacteria from mechanical influences from the body’s 
own defense mechanisms and from antibiotics. (Walter et al. 2012) A biofilm can be 
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defined as a “layer-like aggregation of cells and cellular products attached to a solid 
surface or substratum” (Zoubos et al. 2012). When bacteria attach to a surface (e.g. bone 
or implant) and start to grow and form biofilm, their phenotype is different from the 
planktonic, freely suspended bacteria. In biofilms, bacteria communicate via 
intercellular signals. The good resistance of biofilms against antibiotics and host defense 
systems is partly due to the slimy and sticky matrix where the bacteria are embedded. 
The formation and function of biofilms is not, however, fully understood (Zoubos et al. 
2012). There is also evidence that biofilms tend to form more easily on hydrophobic 
surfaces, such as many polymers, glass, and metal, than on hydrophilic surfaces 
(Zoubos et al. 2012). The formation of biofilms comprises several steps: rapid surface 
attachment; multi-layered cellular proliferation; and intercellular adhesion in an 
extracellular polysaccharide matrix (slime) that is excreted by the bacteria (Zimmerli 
2006; Zoubos et al. 2012). 
Osteomyelitis can be divided into acute and chronic osteomyelitis. There is, however, 
no uniform clinical definition for chronic osteomyelitis, and it can be difficult to define 
a threshold when acute infection becomes chronic. Many authors define their own 
criteria. (Walter et al. 2012) Often, acute osteomyelitis refers to the disease before 
osteonecrosis has occurred and chronic osteomyelitis to the stage where osteonecrosis, 
characterized by the presence of necrotic devascularized bone (sequesterum), has 
occurred (Chihara and Segreti 2010; Mouzopoulos et al. 2011). Osteomyelitis can be 
classified into several other subgroups according to location, duration of the disease, the 
microorganism causing the infection, or the route of the infection. According to Sia and 
Berbari, these can be classified clinically as long-bone osteomyelitis, open-fracture 
osteomyelitis, vertebral osteomyelitis, and SAPHO syndrome (synovitis, plantar 
pustulosis, hyperostosis and osteitis) (Sia and Berbari 2006). According to Waldvogel, 
osteomyelitis classification criteria are the duration of the disease, mechanism of the 
infection, and the presence of vascular insufficiency (Waldvogel et al. 1970). The 
Cierny-Mader system classifies osteomyelitis according to the portion of bone affected, 
the physiological condition of the host, and other risk factors (Cierny 3rd. et al. 2003). 
Additionally, osteomyelitis in patients with diabetes mellitus, vascular insufficiency, or 
rheumatoid arthritis can be considered as a special class, because of the challenges in 
the treatment (Walter et al. 2012). 
Diagnosis of osteomyelitis can be challenging because symptoms may be various and 
subtle. Appropriate diagnosis often requires combination of clinical findings, 
microbiological cultures of bone biopsies and other samples (sinus tract material, 
purulent fluid, soft tissues), laboratory tests, and imaging (Mouzopoulos et al. 2011; Sia 
and Berbari 2006). Symptoms of acute osteomyelitis may include pain, erythema, 
oedema, warmth, tenderness, necrosis of wound edges, and the abrupt onset of high 
fever (Mouzopoulos et al. 2011). Symptoms of chronic osteomyelitis may include fever, 
chills, fatigue, irritability, lethargy, and malaise (Chihara and Segreti 2010; 
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Mouzopoulos et al. 2011; Walter et al. 2012). The disease may also have quiescent 
periods of variable duration (Mouzopoulos et al. 2011). 
2.2.1.1 Treatment of osteomyelitis 
Although osteomyelitis has been known since the early stages of human development, 
diagnosis and treatment are still a challenge today. One reason for this is the variety of 
symptoms. With recent developments in antibiotic treatments, however, the 
haematogenous version of osteomyelitis has been almost completely wiped out in the 
industrialized world. On the other hand, post-traumatically or post-operatively acquired 
forms of osteomyelitis are on the increase. (Walter et al. 2012) 
Osteomyelitis in children is usually successfully treated with antibiotics without 
debridement of the infected bone tissue (Pääkkönen and Peltola 2011; Walter et al. 
2012). Treatment of osteomyelitis in adults, especially the chronic form, is more 
difficult, time consuming, and is also expensive (Calhoun and Mader 1997). Treatment 
often requires surgical intervention (Uckay et al. 2012). Depending on the patient’s 
condition, curative or palliative treatment can be chosen (Walter et al. 2012). These 
paths of treatment protocols are described in Figure 2. In the curative protocol, the first 
step includes radical surgery where all the infected tissues (both bone and soft tissues) 
and possible implants are removed. This protocol follows certain principles: the 
complete drainage of infected tissue, thorough debridement of necrotic tissue, the 
removal of possible implants or fixation devices, elimination of the dead space, 
complete soft tissue coverage and bone/fracture stabilization. (Sia and Berbari 2006; 
Walter et al. 2012) The surgical treatment is followed by a long course of intravenous or 
oral antibiotics because bacteria may be left in the surrounding tissues (Kankilic et al. 
2011; Parsons and Strauss 2004; Soundrapandian et al. 2007). Another option in the 
curative approach is amputation, which is very radical, carries high risks, and is very 
stressful for the patient (Walter et al. 2012). 
The relapse rate for osteomyelitis is high (20-30%) (Mouzopoulos et al. 2011; Sia and 
Berbari 2006; Walter et al. 2012). Usually, the high relapse rate is caused by inadequate 
debridement of the infected tissues (Mouzopoulos et al. 2011). Additionally, 10-30% of 
acute osteomyelitis cases become chronic (Walter et al. 2012). 
Often, a multidisciplinary approach, meaning co-operation between various healthcare 
professionals, is emphasized in the treatment of osteomyelitis (Bauer et al. 2012; 
Mouzopoulos et al. 2011). Such an approach has been rarely reported in scientific 
literature. In one study by Bauer et al., however, the outcome of a patient suffering from 
bone and joint infections was significantly improved, when the antibiotic therapy was 
decided on after a multidisciplinary meeting (Bauer et al. 2012). 
There is currently no clear consensus about the optimal duration, route of the antibiotic 
treatment, or the choice of the antibiotic (Guillaume et al. 2012; Haidar et al. 2010; 
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Lazzarini et al. 2005; Sia and Berbari 2006; Uckay et al. 2012). In the case of chronic, 
non-implant related osteomyelitis, the length of the antibiotic therapy after the 
debridement of the infected tissue has been mainly based on the opinions of experts. No 
scientific proof or international guidelines have been presented. (Haidar et al. 2010; 
Lazzarini et al. 2005; Rod-Fleury et al. 2011; Uckay et al. 2012) Lazzarini et al. 
concluded their review about the antibiotic treatment of osteomyelitis: “Despite three 
decades of research, the available literature on the treatment of osteomyelitis is 
inadequate to determine the best agent(s), route, or duration of antibiotic therapy.” This 
describes the field well. (Lazzarini et al. 2005) 
Usually, the length of the antibiotic treatment in the case of chronic osteomyelitis is 4-6 
weeks (Haidar et al. 2010; Mouzopoulos et al. 2011), but treatments also lasting up to 
three or even six months are used (Uckay et al. 2012). Recently, however, there have 
been suggestions that properly designed studies should be performed in order to find out 
the optimal treatment length. These suggestions have been based on the fact that 
surgical procedures have been improved substantially and thus may justify shorter 
antibiotic treatments (Haidar et al. 2010; Rod-Fleury et al. 2011). There is also a debate 
about whether the oral administration of antibiotics could replace the intravenous 
treatment in some cases and thus avoid the risks of intravenous catheters. This is 
because nowadays there are antibiotics available that achieve adequate concentrations in 
bone to eradicate osteomyelitis-causing bacteria. (Spellberg and Lipsky 2012) Some 
authors suggest that the treatment should be started with intravenous treatment that can 
be switched to oral treatment later on (Sendi and Zimmerli 2012). In a retrospective 
clinical study by Rod-Fleury et al., rather short antibiotic therapies were suggested and 
enhanced cure ratios were not found with oral antibiotic therapy over six weeks or 
intravenous therapy over one week. It must be noted that some of the subjects of the 
study were also treated with gentamycin releasing PMMA beads in addition to the 
antibiotic therapy. (Rod-Fleury et al. 2011) 
Prolonged intravenous courses of antibiotic therapy cause several problems including 
catheter related infections, catheter failures, costly antibiotics and supplies, patient 
discomfort, and poor patient compliance (Calhoun and Mader 1997). Additionally, the 
high doses of antibiotics used to achieve effective therapeutic doses at the infection site 
may lead to systemic toxicity and unwanted side effects. Too long antimicrobial 
treatment may also enhance the emergence of resistant bacteria (Uckay et al. 2012). 
A great challenge in the treatment of osteomyelitis or other bone related infections is the 
access of the required antibiotic to the site of the infection. The blood circulation in the 
infected tissue may be severely compromised, and thus orally or intravenously 
administered antibiotics may not reach the site of infection in the required 
concentrations. Another challenge is to keep the drug concentration above the 
therapeutic level and below the toxic level for a long enough time period. (Ginebra et al. 
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2006) Biofilms make the antibiotic treatment very challenging due to their resistance to 
antibiotics and also to the host defense (Kiedrowski and Horswill 2011). 
Another challenge is how to take care of the dead space in bone tissue that results from 
surgical debridement of infected tissues. Traditionally, the dead space resulting from the 
surgical debridement of the infected tissue has been treated using non-biodegradable 
gentamycin releasing poly(methyl methacrylate) (PMMA) beads that are implanted into 
the bone defect (Zilberman and Elsner 2008). The beads release gentamycin locally and 
should kill the remaining bacteria in the bone tissue because high local concentrations 
of antibiotics can be achieved and systemic complications avoided (Calhoun and Mader 
1997). The major drawback in the usage of the PMMA beads is that they are not 
biodegradable and they require removal, followed by bone grafting (Calhoun and Mader 
1997). If left implanted for a long time, the PMMA beads may become surrounded by 
dense scar tissue and their removal may be very difficult (Hanssen 2005; Nandi et al. 
2010). Additionally, they do not completely release the antibiotic, and bead failure has 
also been reported (McLaren 2004). The initial burst in the antibiotic release is large: 
60% of the antibiotic may be released within the first day. After the initial burst, the 
drug concentrations rapidly fall below therapeutic levels in two to four weeks or even 
faster (Calhoun and Mader 1997; Li et al. 2010). This means that supplementary 
systemic antibiotic treatment is often needed because local drug delivery has been 
suggested to last for at least six to eight weeks (Calhoun and Mader 1997; Li et al. 
2010). Other problems associated with the non-biodegradable PMMA beads include: 
low biocompatibility, thermal damage to the antibiotic during fabrication, poor drug 
elution properties, and the possibility of resistant bacteria development on the surface of 
the beads when low levels of drug is released during the latter stages of the release 
(Nandi et al. 2010; Neut et al. 2001). 
In the case of bone defects, the gold standard so far has been the use of autografts. 
However, tissue availability is limited and harvesting causes local morbidity and 
increases the risk of infection. (Hench and Polak 2002; Mouriño and Boccaccini 2010; 
Vallet-Regí and Arcos 2013) One option is the use of allografts or xenografts, but these 
carry the risks of graft rejection or transfer of pathogens (Mouriño and Boccaccini 
2010). Based on these limitations, the interest has lately been towards artificial and 
synthetic materials. An ideal bone substitute should be biocompatible, bioabsorbable, 
osteoconductive, osteoinductive, structurally similar to bone, easy to use, cost-effective, 
and should encourage patient bone regeneration. (Kolk et al. 2012; Mouriño and 
Boccaccini 2010) In the case of treating the dead spaces resulting from the treatment of 
chronic osteomyelitis or implant-related infections, antibiotic-releasing properties are 
also valuable. 
Biodegradable, osteoconductive, and antibiotic-releasing composites offer certain 
advantages in the treatment of chronic osteomyelitis. Antibiotic release can be 
prolonged to cover the time needed and different polymers offer variable 
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biodegradability, which in turn offers possibilities to treat various infections. 
Additionally, there is no need for the surgical operation to remove the implants because 
bone tissue can grow and replace the implant, as the implant slowly degrades (Calhoun 
and Mader 1997; Nandi et al. 2010). Antibiotic concentrations in infected bone tissue 
achieved by locally drug-releasing implants have been found to be several times higher 
than in the cases of intravenous or oral drug delivery in experimental animal models 
(Garvin et al. 1994; Hamanishi et al. 1996; Koort et al. 2006; Koort et al. 2008; Lucke 
et al. 2005; Mäkinen et al. 2005a; Mäkinen et al. 2005b; Miyai et al. 2008). It has been 
suggested that the antibiotic level at the infection site should be kept at the therapeutic 
level for at least 6-8 weeks to allow adequate infection control and healing (Calhoun 
and Mader 1997; Li et al. 2010). The bone reconstruction period is long and it can take 
3–4 months to reconstruct an adult bone (Jiang et al. 2012). 
There is a treatment algorithm based on osteoconductive antibiotic-releasing bone 
grafting materials proposed by Mäkinen (Mäkinen 2005). The protocol is presented as 
one treatment option on the right side of Figure 2. In this algorithm, one step in the 
treatment, i.e. bone grafting, can be avoided. Because all surgical procedures pose a risk 
for the patient, this is the preferable direction in the development of new treatment 
protocols. 
 
  
18 
 
Figure 2. Traditional and new proposed treatment options for the treatment of 
osteomyelitis (Modified from (Mäkinen 2005) and (Walter et al. 2012)). 
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2.2.2 Implant-related orthopaedic infections 
Prosthetic joints and internal fixation devices (nails, pins, and screws) are the most used 
implants in modern medicine (Zimmerli and Sendi 2011). They are used to relieve pain, 
to enable rapid fracture healing, and to improve the mobility and independence of 
patients (Sendi and Zimmerli 2012). The presence of an implant is known to increase 
the risk of infection and implant-related infections are a significant problem in modern 
medicine (Harris and Richards 2006; Zimmerli 2006; Zimmerli and Sendi 2011). 
Especially, internal fixation devices used in open fractures have high infection rates 
(30%) (Mouzopoulos et al. 2011; Zimmerli et al. 1998). As an implant is presented to 
the body, there is a “race for the surface” involving extracellular matrix (ECM) proteins, 
host cells, and bacteria (Harris and Richards 2006). Depending on the cascade of 
phenomena on the surface, bacteria may or may not be adhered to the surface layer. A 
six-hour “decisive period” after surgery has been identified where the success of the 
implant is determined. During this time, the implant is particularly vulnerable to 
bacterial adhesion. (Hetrick and Schoenfisch 2006; Zilberman and Elsner 2008) If 
bacteria are able to adhere on the implant surface, it may lead to bacterial growth, 
development of a biofilm, and infection. Thus, the prevention of bacterial adhesion on 
the surface of the implant during or right after the surgery is crucial. Bacteria that are 
able to grow biofilms typically cause infections associated with implants (Zimmerli 
2006). The pathogens encountered most often are Staphylococcus aureus and 
Staphylococcus epidermidis (Darouiche 2001). The bacteria may cause infection by 
direct inoculation during or even before (in the case of open fractures) surgery, post-
operatively (e.g. if the wound healing is disturbed), hematogenous seeding, and 
contiguous spreading from neighboring tissues (Sendi and Zimmerli 2011; Zimmerli 
and Ochsner 2003; Zoubos et al. 2012). 
Implant-related infections involve interaction between three factors: the infecting 
microorganism, the implant, and the host (Darouiche 2001; Zimmerli 2006). From 
these, device-related factors are the easiest to modify. Prevention of bacterial adhesion 
on the surface of the device is the key factor in preventing infection (Darouiche 2001). 
There are different factors playing a role in the attachment, the proliferation, and the 
biofilm formation of different bacterial species (Zimmerli 2006). Implant surface 
chemistry has been observed to influence the bacterial adhesion, e.g. stainless steel has 
been associated with higher rates of infection than titanium (Harris and Richards 2006; 
Kiedrowski and Horswill 2011). Bone cements also provide an attractive surface for 
bacterial adhesion. To prevent this, antibiotics are often mixed with the cements 
(Kiedrowski and Horswill 2011). In animal models, it has been observed that the 
presence of a foreign body alone can reduce the number of bacterial cells that are 
needed to cause infection (Kiedrowski and Horswill 2011; Zimmerli 2006). This is 
probably due to compromised host defense around the implant (Zimmerli 2006; 
Zimmerli and Sendi 2011). 
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Although the implant-related infections are rare, their number is increasing because the 
number of patients with orthopaedic implants is increasing (Sendi and Zimmerli 2012). 
Often, antibiotics are administered before and during the operation as prophylaxis, but 
regardless of this, infections still occur (Schmidmaier et al. 2006). Incidences of 
implant-related infections vary according to the type and site of operation, trauma, and 
patient condition (Schmidmaier et al. 2006). Overall, 5% of implants become infected 
during their lifetime (Walter et al. 2012). Of the patients having primary elective joint 
replacements, 0.5-1% (Kankilic et al. 2011) or 1-2% (Senneville et al. 2011) become 
infected, but in patients with diabetes or compromised vascularization the incidences 
range between 10% and 20%. Of the patients that have a revision surgery or trauma, 2-
20% of the cases become infected. (Kankilic et al. 2011) In a retrospective study 
reported by Achermann et al., it was found that the infection rate concerning elbow 
prostheses was as high as 7.5 % (Achermann et al. 2011). Bacterial adhesion to the 
surface of the implant can occur at any time during or after implantation, but the time 
period with the highest risk is the early postoperative period (Zimmerli 2006). External 
fracture fixations are less invasive than internal fixation plates, but still possess a risk of 
pin tract infection. If the infection is untreated, it may lead to osteomyelitis. (Harris and 
Richards 2006) 
Risk factors for orthopaedic-implant-related infections are old age, malnutrition, 
underlying joint disease, obesity, diabetes mellitus, malignant tumor, remote infection, 
prior native joint infection, and advanced HIV infection. Patients that have rheumatoid 
arthritis have a higher risk of prosthetic-joint-associated infection than patients that have 
osteoarthritis. Additionally, infection of the surgical wound may increase the risk of 
infection. (Zimmerli 2006) 
Diagnosis of implant-related infections can be challenging because of the variety of 
symptoms (Lazzarini et al. 2005). Typical first symptoms are systemic, such as fever, 
shivering, and tachycardia (Zimmerli 2006). In addition to these, local signs may be 
local pain, wound infection, warmth, a wet or gaping wound, and prolonged wound 
secretion (Zimmerli and Ochsner 2003; Zimmerli 2006). If the early stage infections are 
treated with short term antibiotics without further diagnostics, the result may be delayed 
infection with implant loosening, sinus tracts, or hidden abscess (Zimmerli 2006). 
Persistent or increasing pain and the loosening of the implant may also be signs of an 
implant-related infection (Zimmerli and Ochsner 2003). 
For accurate diagnosis, various methods are used including bacterial cultures on tissue 
samples as well as explanted implants, laboratory studies, and imaging with different 
methods (e.g. radiography, computed tomography (CT), ultrasonography, magnetic 
resonance imaging (MRI), and positron emission tomography (PET)) (Koort et al. 2004; 
Zimmerli 2006).  
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As in the case of osteomyelitis, there are no generally accepted criteria for the treatment 
of implant-related infections nor for the optimal duration of the antimicrobial treatment 
(Marschall et al. 2013; Zimmerli 2006). Implant-related infections never heal 
spontaneously (Zimmerli and Sendi 2011). Treatment is usually a combination of 
surgical treatments with adequate tissue debridement with or without prosthesis removal 
and prolonged antibiotic therapy (usually intravenous which can be switched to oral 
antibiotics later on) (Kankilic et al. 2011; Kiedrowski and Horswill 2011; Sendi and 
Zimmerli 2012; Senneville et al. 2011; Zimmerli 2006). Surgical intervention is not 
always possible because of the condition of the patient and thus there is a great need to 
develop less invasive treatment methods (Kiedrowski and Horswill 2011). Overall, the 
treatment is difficult, often requiring multiple surgeries, which lead to a decrease in 
quality of life and increase morbidity and mortality (Kankilic et al. 2011). The radical 
surgical treatment also causes bone and muscle destruction (Zimmerli 2006). There is 
no consensus whether the implant should be removed or retained in the case of acute 
infection. If the implant is stable, retaining is suggested (Mouzopoulos et al. 2011). Risk 
factors favoring implant removal in acute cases are heavy smoking, open fractures, and 
intramedullary devices (Mouzopoulos et al. 2011). Instead of the radical treatment, it 
has also been suggested that the patient should be treated with lifelong suppressive oral 
antimicrobial treatment without surgical intervention (Zimmerli 2006). This is not a 
curative alternative and may lead to other problems such as resistant bacterial 
development and toxicity (See Figure 2, palliative treatment route). 
Antibiotic treatments of implant-related infections are long. Zimmerli et al. have 
suggested 3-month antibiotic therapy for infected hip prostheses and 6-month therapy 
for infected knee prostheses. The first two weeks of the treatment should be intravenous 
and then switched to oral therapy if the antibiotic has good oral bioavailability. In the 
case of total removal of the foreign material, they suggest that the antimicrobial 
treatment can be shortened to six weeks. After the infection has been eradicated, re-
implantation is possible. (Zimmerli et al. 1998; Zimmerli 2006)  
Prosthetic joint loosening may also be caused by mechanical reasons (Darouiche 2001). 
The particles resulting from the mechanical wear of the prosthesis materials may induce 
osteolysis and lead to a loosening of the implant. This kind of loosening is called aseptic 
loosening. Many cases of aseptic loosening are actually caused by bacteria colonized on 
the surface but are undetected (Darouiche 2001; Zimmerli et al. 2004). This may be due 
to the difficulties of culturing the bacteria in laboratory conditions (Drancourt et al. 
1993). 
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2.2.3 Antibiotics for bone infections 
Antibiotics play a significant role in the treatment of osteomyelitis and implant-related 
infections. The choice of the antibiotic used in the treatment should be always based on 
the pathogen and its antimicrobial susceptibility. Gentamycin is a commonly used 
antibiotic in the treatment of osteomyelitis. (Mouriño and Boccaccini 2010) However, it 
is not recommended for use with methicillin resistant bacterial strains, due to several 
reports of gentamycin resistance (Jackson et al. 2011). Prolonged gentamycin use has 
also been associated with problems such as ototoxicity and nephrotoxicity (Ismail et al. 
2012). 
In addition to gentamycin, many antibiotics including ciprofloxacin, rifampicin, 
vancomycin, teicoplanin, and daptomycin are used in the treatment of osteomyelitis 
(Chang et al. 2011; Mouriño and Boccaccini 2010). Vancomycin is effective against 
methicillin-resistant Staphylococcus aureus (MRSA) (Jackson et al. 2011), but when it 
is administered intravenously, even in large doses, it does not reach the infection site 
effectively and may also cause some adverse reactions such as nephrotoxicity, 
ototoxicity, and gastrointestinal side effects (Gautier et al. 2012; Jiang et al. 2012). 
Additionally, emerging resistance to vancomycin has been reported (Gautier et al. 
2012). The thermal instability of vancomycin restricts its use in applications where high 
temperatures are used either in the production phase of the drug release system or in the 
setting reaction of a bone cement. Vancomycin is considered as a last resource antibiotic 
in severe MRSA infections (Kluin et al. 2009). 
An alternative to vancomycin is linezolid, which is a rather new antibiotic and so far the 
use has been restricted to cases requiring hospitalization. It is not the first choice 
treatment because it is reserved for more serious cases such as repeated infections 
caused by methicillin resistant Staphylococcus aureus. Linezolid penetrates human 
tissues easily. (Gautier et al. 2012) Newer antibiotics such as quinupristin and 
dalfopristin have also shown promising results in the treatment of osteomyelitis caused 
by resistant bacterial strains (Lazzarini et al. 2005). 
2.2.3.1 Ciprofloxacin 
Ciprofloxacin belongs to the family of quinolones that are widely used due to their 
broad spectrum, highly bactericidal activity, and favorable pharmacokinetic properties 
(Vallet et al. 2011; Van Bambeke et al. 2005). The first antibiotic belonging to this 
group was nalidixic acid and it was approved in 1962 (Bertino Jr. and Fish 2000). The 
structure-property relationships of quinolones are well understood and many derivatives 
of nalidixic acid have entered the market. Ciprofloxacin is a fluorinated derivative of 
nalidixic acid and it was discovered in 1982 (Arcieri et al. 1989). The chemical structure 
of ciprofloxacin is presented in Figure 3. It is widely used to treat urinary infections 
(Fong et al. 1986), osteomyelitis, and other bone and joint infections (Alvarez et al. 
2008; Levine and DiBona 2002). 
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Figure 3. Chemical structure of ciprofloxacin. 
The molecular weight of ciprofloxacin is 331.4 g/mol. Solubility in water at 37 °C has 
been reported to be 0.20 mg/ml at pH 7.8 and 0.22 mg/ml at pH 6.9 (Breda et al. 2009) 
and a LogP value of 0.28 (Takacs-Novak et al. 1992). 
Ciprofloxacin, like many other fluoroquinolones, is available both in oral and parenteral 
forms (Levine and DiBona 2002). It is well absorbed after oral administration and is 
widely distributed throughout the body with good tissue penetration (Fong et al. 1986; 
Levine and DiBona 2002). Blood concentrations achieve similar levels after oral 
administration than after parenteral administration and peak concentrations are achieved 
1-2 hours after administration (Levine and DiBona 2002). This is an advantage because 
adverse effects and risks of intravenous catheters can be avoided with oral 
administration (Lazzarini et al. 2005). It also allows the change from intravenous 
administration to oral administration of the same drug if needed. 
The pharmacokinetic features of ciprofloxacin depend strongly on the dosage given to 
the patient and also on the patient’s age (Levine and DiBona 2002; Mitscher 2005). The 
average volume of distribution of ciprofloxacin is in the order of 2-3 l/kg and the 
elimination half-life is 3-5 hours (Kettunen 2004). Ciprofloxacin is excreted unchanged 
by the kidneys, which has raised some ecological concerns (Näslund et al. 2008). 
The principle of the action of ciprofloxacin is the inhibition of the bacterial 
topoisomerase II (DNA gyrase), which triggers cell replication arrest and cell death 
(Herbold et al. 2001; Holtom et al. 2000; Levine and DiBona 2002). It may also have an 
effect on bacterial topoisomerase IV. Additionally, ciprofloxacin has been reported to 
inhibit mammalian topoisomerase II and, due to this, has shown genotoxicity in tests 
utilizing pro- and eukaryotic cells. It must be noted, however, that several orders of 
magnitude higher concentrations are needed than for the inhibition of bacterial DNA 
gyrase. (Herbold et al. 2001) 
Ciprofloxacin has a broad spectrum of activity that includes the bacteria that cause the 
most cases of osteomyelitis, including Staphylococcus aureus. Thus, it is one of the 
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most used antibiotics in the treatment of osteomyelitis. (Castro et al. 2005; Koort et al. 
2005; Overbeck et al. 1995; Puga et al. 2012; Tiainen et al. 2012)  Good tissue 
penetration can be achieved even in poorly vascularized areas (Castro et al. 2005; Koort 
et al. 2005; Puga et al. 2012). Minimum inhibitory concentrations (MIC) against the 
common osteomyelitis causing bacteria are rather low. The MICs are for S. aureus 0.1-
1.0 ȝg/ml (Overbeck et al. 1995; Tiainen et al. 2012), for S. epidermidis 0.1-0.8 ȝg/ml 
(Chin and Neu 1984), and for P. aeruginosa 0.1-1.2 ȝg/ml (Kwok et al. 1999; 
MacGowan et al. 1999). Good tissue penetration into the surrounding tissues has also 
been reported in local administration of ciprofloxacin (Overbeck et al. 1995; 
Ramchandani and Robinson 1998; Tiainen et al. 2012). 
Generally, ciprofloxacin is well tolerated (Bertino Jr. and Fish 2000; Herbold et al. 
2001). Adverse effects that have been reported are gastrointestinal effects such as 
nausea, vomiting and diarrhea, central nervous system effects (convulsive seizures, 
headache and dizziness), dermatologic effects, (Arcieri et al. 1989; Ball 1989), and 
changes in blood chemistry (Arcieri et al. 1989). These effects are generally mild and 
reversible when the treatment is ended (Bertino Jr. and Fish 2000). For intravenously 
administered ciprofloxacin, local effects at the site of the infusion have been the most 
reported adverse effects. It has been also reported that there is no correlation between 
the daily dose of intravenous ciprofloxacin and the occurrence of adverse effects, but 
there is correlation between the duration of the therapy and the occurrence of adverse 
effects. (Arcieri et al. 1989) 
There are, however, some concerns about ciprofloxacin being toxic to articular cartilage 
tissue and joints, especially when administered long-term and in high doses (LeBel 
1988). The effects have been studied, for example, on adult human cartilage in vitro 
(Menschik et al. 1997; Mont et al. 1996), juvenile beagle dogs (Stahlmann et al. 2000; 
Von Keutz et al. 2004), and juvenile rats (Li et al. 2004). The results indicate that 
ciprofloxacin has a toxic effect on chondrocytes, especially at high doses. Ciprofloxacin 
has been also reported to inhibit the proliferation of osteoblast-like cells in vitro (Miclau 
et al. 1998) and the osteoblastic cells of mouse (Holtom et al. 2000). It has to be noted, 
however, that these studies have been performed either in vitro, or in animal studies, 
and thus the results cannot be directly translated to human bone and cartilage tissue. 
Nevertheless, because of these results, ciprofloxacin is not recommended for children, 
pregnant women, or nursing mothers. (Bertino Jr. and Fish 2000; Hanssen 2005; Levine 
and DiBona 2002) 
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2.2.3.2 Rifampicin 
Rifampicin is a semisynthetic antibiotic and belongs to the group of rifamycins that are 
a well-known class of antibiotics. Rifamycins are a subgroup of ansamycins that are 
named according to the chemical structure where an aromatic moiety is bridged by an 
aliphatic chain called an ansa chain (Lat. handle) (Cellai et al. 1982). Rifampicin shows 
polymorphism because it exists in three different forms: amorphous and crystalline 
forms I and II (Agrawal et al. 2004; Freire et al. 2009). This is believed to be because of 
its complex structure, various possibilities to form hydrogen bonds, conformational 
exchanges, and ionization states (Henwood et al. 2000). Rifamycins inhibit the bacterial 
DNA-dependent RNA polymerase and are thus bacteriocidical (Cellai et al. 1982). 
A rifampicin molecule is rather large and has a molecular weight of 823 g/mol (Figure 
4). Solubility in water at 30 °C has been reported to be 1.5-1.7 mg/ml, depending on the 
crystal form (Henwood et al. 2000). Rifampicin is considered to be lipophilic with the 
logP value of 2.7 (Marchidanu et al. 2013). 
Rifampicin has been shown to have surprisingly good effect against staphylococci in 
their various modes of growth. It is known to penetrate biofilms well and also to prevent 
biofilm formation. The reason for this is, however, unknown. (Kiedrowski and Horswill 
2011) When rifampicin is used alone, there is rapid development of resistant bacterial 
strains. Because of this, rifampicin should never be used alone. (Bliziotis et al. 2007; 
Coiffier et al. 2013; Kiedrowski and Horswill 2011; Perlroth et al. 2008) MIC values 
reported in the literature for rifampicin are 0.013 ȝg/ml against S. aureus (Guillaume et 
al. 2012), and 0.015 ȝg/ml against S. epidermidis (Leite et al. 2011). The values against 
P. aeruginosa vary greatly and values of 32-64 ȝg/ml (Yee et al. 1996) and 8-16 ȝg/ml 
(Timurkaynak et al. 2006) have been reported. 
 
Figure 4. Chemical structure of rifampicin. 
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Rifampicin is well absorbed from the GI tract and is widely distributed into most body 
tissues and fluids (Acocella 1978; Roth 1984). Rifampicin penetrates into the bone 
tissue in relation to the concentration in plasma, which is about half of the rifampicin 
concentration in plasma. The pharmacokinetics show large variability between 
individuals. (Pargal and Rani 2001) The elimination of rifampicin from bone is slower 
than from plasma (Roth 1984), and the biological half-life or rifampicin in plasma has 
been reported to be 2.5-5.4 hours (Acocella 1978; Pargal and Rani 2001; Sreenivasa 
Rao et al. 2001). Peak drug concentration in plasma typically occurs 2 hours after oral 
administration into an empty stomach (Pargal and Rani 2001). Le Guellec et al. found 
that rifampicin stability was better in rifampicin-containing plasma samples taken from 
patients treated with rifampicin than in plasma samples where rifampicin was added in 
the laboratory. They suggest possible in vivo stabilization of the rifampicin molecule. 
(Le Guellec et al. 1997) 
Because of the good penetration into biofilms, rifampicin has been used together with 
other antibiotics in the treatment of osteomyelitis and other bone related infections 
(Bliziotis et al. 2007; Kiedrowski and Horswill 2011; Perlroth et al. 2008). In a recent 
review by Sendi and Zimmerli, it was said that: “Rifampicin is now a standard 
combination partner in the treatments of staphylococcal infections.” (Sendi and 
Zimmerli 2012) The advantages of rifampicin combination therapy have been reported 
several times in the literature (Coiffier et al. 2013). It has even been suggested that 
rifampicin should always be used, in combination with other antibiotics, in the cases of 
implant-related infections because of its excellent efficacy against bacteria adhered to 
surfaces (Zimmerli 2006). Senneville et al. concluded in their retrospective study of 
prosthetic joint infections caused by S. aureus that rifampicin combination therapy was 
associated with a better outcome for the patients when compared with other antibiotic 
regimens (Senneville et al. 2011). Perlroth et al. have reviewed the use of rifampicin in 
Staphylococcus aureus infections. In general, in in vivo and human studies, the 
combination of ciprofloxacin with rifampicin has been more effective than 
monotherapy, especially in prosthetic device infections and osteomyelitis. (Perlroth et 
al. 2008) In a double-blinded randomized clinical trial performed by Zimmerli et al., the 
efficacy of rifampicin was studied as a supportive antibiotic in implant-related 
infections. The patients had stable implants that were not removed during the study. The 
results clearly showed that the outcome was better in the group where patients were 
treated with rifampicin in addition to other antibiotics (first 2 weeks intravenous 
flucloxacillin or vancomycin and then switched to oral ciprofloxacin). The treatment 
was successful even without implant removal. An additional advantage of the 
combination therapy was the prevention of emerging ciprofloxacin resistance. 
(Zimmerli et al. 1998) Rifampicin has also been studied together with other 
fluoroquinolones in the treatment of deep sternal wound infections and studies have 
shown that using rifampicin together with fluoroquinolones improves the outcome 
(Khanlari et al. 2010).  
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2.3 Controlled antibiotic delivery in bone applications 
2.3.1 Macroscopic systems 
During the last decades, there have been numerous approaches in the local treatment or 
prophylaxis of bone related infections. Synthetic biodegradable polymers, meaning 
mostly polymers based on lactide, glycolide, and caprolactone have been extensively 
studied as drug delivery systems both alone and in composites (Dash and Konkimalla 
2012; Makadia and Siegel 2011; Nair and Laurencin 2007). These polymers offer the 
possibility of tailoring the polymer properties, for example by copolymerization and 
blending (Albertsson and Varma 2003; Puga et al. 2012; Woodruff and Hutmacher 
2010), and they degrade in a tissue environment via hydrolysis and the degradation 
products are excreted via normal metabolic pathways (Albertsson and Varma 2003). 
Enzymatic activity may also be involved in the degradation process (Dash and 
Konkimalla 2012). 
An ideal antibiotic-releasing implant for the treatment of bone-related infections should 
combine antibiotic delivery and bone regeneration. In cases where the size of the bone 
defect is greater than what the bone is able to heal spontaneously (critical size defect), 
bone regeneration by other means is crucial (Vallet-Regí and Arcos 2013). The implant 
material should deliver the antibiotic in a continuous manner and in high enough 
concentrations.  Moreover, it should accommodate the space required (e.g. dead space 
in osteomyelitis after the debridement of infected tissue) and should provide a structural 
function (Hanssen 2005). Antibiotic release should occur in a limited time period to 
prevent the development of resistant bacterial strains (Pavithra and Doble 2008). 
Because entrance of infectious microorganisms cannot be totally prevented with 
surgical precision, such implant materials can be used not only for infection treatment 
but also as prophylaxis (Vallet-Regí and Arcos 2013). 
Traditionally, the dead spaces resulting from the surgical treatment of osteomyelitis 
have been treated using commercial gentamycin releasing PMMA beads (Ginebra et al. 
2006). There are several drawbacks related to PMMA beads: they are not degradable in 
biological systems and require removal. The delivery of other antibiotics such as 
vancomycin from PMMA beads has also been studied (rat model). The conclusion has 
been that the drug delivery from the PMMA matrix is not very efficient and also 
includes a large burst in the beginning of the release period. Moreover, the release falls 
rapidly to concentrations below MIC (Li et al. 2010). Additionally, bacteria may adhere 
to the surfaces of the beads despite their antibiotic-releasing nature. In a study by Neut 
et al., gentamycin releasing beads were retrieved from 20 patients. It was found that 18 
of them had bacteria present, although 12 of the patients were considered free of 
infection. The majority of the isolated bacterial strains were also gentamycin resistant. 
(Neut et al. 2001) 
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Interest towards biodegradable alternatives has been growing and systems that both 
deliver the antibiotic to the site of the infection and help the bone to heal have been 
requested (Jiang et al. 2012). The challenges facing controlled drug delivery using 
biodegradable polymers are potential dose dumping if the device does not work 
properly, inconsistent release, and drug-polymer interactions (Makadia and Siegel 
2011). 
2.3.1.1 Bone cements 
Antibiotic-releasing bone cements are important materials in the treatment and 
prevention of bone-related infections (Bourne 2004). Today, they represent the gold 
standard in orthopaedic surgery, for example in the prevention and treatment of 
infections after total hip and knee arthroplasties (Hanssen 2005; Tan et al. 2012). The 
very first antibiotic-releasing bone cements were normal PMMA bone cements that 
were mixed with antibiotics by the surgeons themselves. Buchholz and Engelbrecht had 
already started the development of antibiotic-releasing bone cements in 1970 (Buchholz 
and Engelbrecht 1970). In 1977, there were publications about mixing PMMA bone 
cements with antibiotics (Ger et al. 1977). The antibiotic delivering cements were first 
utilized as prophylaxis to prevent infections but soon they began to be used in the 
treatment of implant-related infections and osteomyelitis (Hanssen 2005). Gentamycin 
and tobramycin are the two antibiotics most used in combination with bone cements 
(Hanssen 2005). Also, daptomycin, vancomycin, teicoplanin, clindamycin, cephalothin, 
erythromycin, oxacillin, cefuroxime, colistin, methicillin, tetracycline, lincomycin, 
dicloxacillin, grepafloxacin, and bactrim have been studied in PMMA bone cements 
(Bourne 2004; Chang et al. 2011; Efstathopoulos et al. 2008). Antibiotic-releasing 
PMMA bone cements were subsequently approved for clinical use in Europe and have 
been used for over two decades (Luginbuehl et al. 2010). In the United States, they were 
approved in the 2000s, but their use is restricted to joint revisions following the 
elimination of an active infection (Bourne 2004; Zilberman and Elsner 2008). 
PMMA based bone cements are not biodegradable and thus do not provide the 
possibility of bone regeneration. The porous surface of the cement may also offer a 
surface where bacteria can attach, and this can lead to serious infections. Drug release 
kinetics from PMMA cements are rather poor. The antibiotic concentrations released 
from the PMMA cements are low and may rapidly fall below MIC (Jackson et al. 2011). 
Additionally, the drug release may not be complete and if prolonged with low antibiotic 
concentrations, resistant bacterial strains may develop (Jackson et al. 2011; Tan et al. 
2012). To overcome these problems, PMMA cements with a chitosan derivative 
(hydroxypropyltrimethyl ammonium chloride chitosan) have been developed. With 
these cements, better stem cell proliferation and osteogenic differentiation than pure 
PMMA cements were found. However, their function in in vivo conditions has not been 
studied yet. (Tan et al. 2012) Additives such as sodium chloride and dextran have been 
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found to improve the drug release behavior of linezolid, vancomycin and fusidic acid 
from PMMA cements (Jackson et al. 2011). 
Bone cements based on calcium phosphates (CaP) were discovered in the 1980s 
(Ginebra et al. 2012). Today, there are several commercial varieties available but they 
do not have antibiotics incorporated in them (Bohner et al. 2005). The main advantages 
of CaP bone cements over the traditional PMMA cements are bioactivity and 
osteoconductivity. In addition, the setting reaction is not exothermic making the setting 
reaction temperature in the tissue environment low, minimizing the risk of tissue 
damage. This offers the possibility to incorporate heat sensitive drugs or other 
biomolecules in the cements. CaP cements are bioresorbable and the resorption rate 
depends on the composition and microstructure. The main drawbacks of these kinds of 
cements are their poor mechanical properties that limit their use to non-load bearing 
locations. (Ginebra et al. 2012) Additionally, the incorporation of drugs into calcium 
phosphate cements may cause changes in the rheological properties of the cements as 
well as in the setting times, the microstructure of the resulting cement, and the 
mechanical properties. There are no general rules how this happens because it depends 
on the molecular structure and the chemical nature of the incorporated drug. (Ginebra et 
al. 2012; Ginebra et al. 2006; Vallet-Regí and Arcos 2013) 
The setting reaction of CaP bone cements is a combination of dissolution and 
precipitation reactions and the result is very porous cement (Chen et al. 2003; Ginebra 
et al. 2012). The setting times and the porosity can be modified in several ways such as 
liquid to powder ratio and the powder size of the ceramic (Bohner et al. 2005; Laycock 
et al. 2011; Schnieders et al. 2011). Although the highly porous structure compromises 
the mechanical properties, it also offers some advantages such as enhanced resorbability 
and an increased ability of the cements to bind drug molecules on their surfaces 
(Ginebra et al. 2012). Additionally, the drug release properties can be tailored by 
changing the porosity of the bone cement (Bohner et al. 1997; Schnieders et al. 2011). 
Drug release from calcium phosphate cements is often characterized by an initial phase 
as the cement is setting followed by a diffusion-controlled release that is influenced by 
the material and drug characteristics (Habraken et al. 2007). One method to control the 
drug release profile and especially the burst in the beginning is to incorporate of the 
drug into polymer microparticles and then mix them into the cement. This approach can 
also be used to improve the handling properties of the cements. (Bohner et al. 1997; 
Habraken et al. 2007; Schnieders et al. 2011). 
The use of calcium phosphate cements as drug delivery systems has been extensively 
reviewed by Ginebra et al. (Ginebra et al. 2012; Ginebra et al. 2006). They can be used 
to deliver not only small molecular size drugs such as most antibiotics, analgesics and 
anticancer drugs (Ginebra et al. 2012; Otsuka et al. 1997) but also larger molecular size 
biomolecules such as proteins (Otsuka et al. 1994) and growth factors (Ginebra et al. 
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2012; Ginebra et al. 2006). However, the drugs to be incorporated in phosphate bone 
cements that have been studied the most are antibiotics (Ginebra et al. 2012). 
Although antibiotic-releasing bone cements have been proven to be very efficient and 
usable in different bone applications, they are not very widely commercialized (Ginebra 
et al. 2006). They can be used either in the treatment of bone related infections or as a 
prophylactic strategy to prevent infections (Bohner et al. 1997; Ginebra et al. 2006). The 
problems that arise and prevent the use and industrial production of drug-releasing bone 
cements from being expanded are a lack of knowledge of drugs on the part of implant 
manufacturing companies and the lack of interest in bone cements of pharmaceutical 
companies, due to the small market for bone cements (Ginebra et al. 2006). 
Bioactive glass cements have also been studied, but the drug release from these cements 
has been rather short term, maximum 2 weeks, with a large burst in the beginning of the 
release. The cements were also reported to shrink, which makes them not very useful in 
filling bone defects. (Otsuka et al. 1992; Otsuka 1994)  
2.3.1.2 Bioabsorbable polymeric systems 
The bioabsorbable polymers used as matrix materials for controlled antibiotic delivery 
for bone tissue applications include polylactides (Cao et al. 2012; Veiranto et al. 2002), 
polycaprolactone (Puga et al. 2012), polyurethanes (Kwok et al. 1999; Li et al. 2010), 
various copolymers of lactides, glycolide and caprolactone (Calhoun and Mader 1997; 
Veiranto et al. 2004a; Veiranto et al. 2004b), polyhydroxyalkanoates (Gursel et al. 
2002; Gürsel et al. 2001; Korkusuz et al. 2001; Türesin et al. 2001), poly(trimethyl 
carbonate) (Kluin et al. 2009; Neut et al. 2009), polyanhydrides (Chiu Li et al. 2002; 
Stephens et al. 2000), and collagen (Ipsen et al. 1991; Knaepler 2012).  
Although a great number of studies have been published in the field of antibiotic-
delivering materials for bone applications both in vitro and in animal models (rat, 
rabbit), very few materials have reached the commercial market. One example of a 
commercialized product is ciprofloxacin-releasing bone fixation screw made of 
poly(lactide-co-glycolide) that can be used as prophylaxis in patients with increased risk 
factors for developing an infection (Veiranto et al. 2004a; Veiranto et al. 2004b). The 
Finnish company Bioretec Ltd has commercialized the bone fixation screws. 
Local antibiotic-releasing systems based on bioabsorbable polymeric systems have been 
studied and reviewed by many research groups (Alvarez et al. 2008; Mäkinen et al. 
2005b; Miyai et al. 2008; Zilberman and Elsner 2008). However, the drug release 
properties of these polymers may not be optimal, and often processing methods are used 
that are either not feasible on an industrial scale or involve the use of solvents that may 
be a problem if solvent residues remain in the final product (Calhoun and Mader 1997; 
Cao et al. 2012; Kankilic et al. 2011; Kluin et al. 2009; Puga et al. 2012). Proving that 
no residues of solvents are present in the final product may be difficult. An additional 
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challenge is that materials based purely on polymers do not offer osteocoductive 
properties and thus do not aid bone healing. 
Although animal model results concerning polymer based antibiotic-releasing systems 
have been promising (Calhoun and Mader 1997; Koort et al. 2005; Koort et al. 2006; 
Koort et al. 2008; Kundu et al. 2012), it has to be noted that that animal models cannot 
replicate complex human bone infections such as osteomyelitis and implant-related 
infections (Lazzarini et al. 2005). Animal models have also been criticized because of 
the initial inoculation used in the infection model. Since it has been suggested that 
bacteria growing in biofilms cause most bone related infections, the same approach 
should be also used in animal models to get more consistent results. The initial 
inoculation in the animal models should be also made using bacteria that are already 
forming biofilms. (Williams et al. 2012) 
Puga et al. studied the release of ciprofloxacin hydrochloride from macroscopic systems 
of a blend of rather low molecular weight PCL (42500 g/mol) and poloxamine, which is 
a surfactant comprised of a block copolymer of ethylene oxide and propylene oxide. 
The results clearly showed a dependence of poloxamine in the blend. A higher 
poloxamine to PCL ratio resulted in faster ciprofloxacin hydrochloride release. The 
release continued steadily for 60 days and the kinetics fitted best with the Higuchi 
model. The study also showed promising results in the eradication of Staphylococcus 
aureus in vitro and good compatibility with osteoblasts in cell cultures. (Puga et al. 
2012) In a study by Cao et al., levofloxacin-releasing poly(D,L-lactide) beads were 
reported to release levofloxacin in a continuous manner for 46 days and were effective 
against Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli in 
inhibition zone tests (Cao et al. 2012). Biodegradable vancomycin-releasing 
polyurethane beads have been developed and studied in a rat model by Li et al. The 
continuous release of vancomycin continued for 8 weeks and the implants were as 
active against S. aureus as PMMA beads. (Li et al. 2010) Vancomycin-releasing beads 
of poly(DL-lactide-co-glycolide) were studied by Calhoun et al.. They used a localized 
rabbit tibial osteomyelitis model and concluded that biodegradable antibiotic-releasing 
beads may be more effective than parenteral antibiotic therapy in the treatment of 
osteomyelitis. (Calhoun and Mader 1997) 
The release of gentamycin and vancomycin was studied from poly(trimethyl carbonate) 
(PTMC) by Kluin et al. The advantage of the PTMC polymer is that the degradation 
products are not acidic. PTMC is also surface eroding in the presence of lipase enzyme. 
Surface erosion is considered an advantage in controlled drug delivery applications, 
especially in the delivery of large drug molecules that are not able to diffuse through 
polymer matrices. Additionally, zero-order release is easier to achieve than by using 
bulk degrading polymers. The in vitro results showed that surface erosion in the 
presence of lipase enzyme significantly enhanced the release of both vancomycin and 
gentamycin. The release results were reported up to 30 days. (Kluin et al. 2009) 
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Natural polymers offer an attractive alternative for drug delivery matrices because of 
their excellent biocompatibility. However, disadvantages include batch-to-batch 
variations, poor mechanical properties, and difficulties in processing. Additionally, 
animal based natural polymers possess the risk of transferring pathogens. Gentamycin-
releasing collagen implants have been used clinically both as prophylaxis and in the 
treatment of osteomyelitis. (Ipsen et al. 1991; Knaepler 2012) When compared with 
gentamycin-releasing PMMA beads, the collagen implants have been as effective, but 
fewer re-operations have been needed for the collagen treated group. Collagen has also 
been claimed to have positive effects on wound healing. (Knaepler 2012) 
When ciprofloxacin has been administered locally, good penetration into bone tissue has 
been observed. Overbeck et al. studied ciprofloxacin release from polyglycolide 
cylinders in rabbits and found that the drug penetration in bone was better than for 
gentamycin released from PMMA beads. During the first week of implantation, 
concentrations greater than the MIC of ciprofloxacin against Staphylococcus aureus 
were found at a distance up to 30 mm from the implant. (Overbeck et al. 1995) In a 
study by Tiainen et al., therapeutic levels of ciprofloxacin were measured in a rabbit 
model 5 mm away from the implantation site of ciprofloxacin-containing PLGA 
miniscrews for eight weeks (Tiainen et al. 2012). Ramchandani and Robinson reported 
therapeutic levels of ciprofloxacin measured at a distance up to 70 mm from PLGA 
microcapsule implants for six weeks in a rabbit model (Ramchandani and Robinson 
1998). 
2.3.1.3 Ceramics and glasses 
Calcium phosphate ceramics possess excellent properties with regard to bone tissue. 
Their chemical composition is close to the mineral phase in bone and they have 
excellent biocompatibility (Bose and Tarafder 2012; Habraken et al. 2007; Vallet-Regí 
and Ruiz-Hernández 2011). Additionally, they provide osteoconductivity and even 
osteoinductivity when combined with growth factors, bioactive proteins, or osteogenic 
drugs (Bose and Tarafder 2012). Ceramics have been used clinically in hip and other 
joint prosthesis, dental applications, maxillofacial reconstruction, spinal fusion, and as 
bone defect fillers (Vallet-Regí and Arcos 2013). Depending on the chemical structure 
and crystal form, calcium phosphate ceramics can be classified as hydroxy apatite (HA), 
tricalcium phosphate (Į-TCP or ȕ-TCP depending on the crystal form), biphasic 
calcium phosphate (BCP), amorphous calcium phosphate (ACP), carbonated apatite 
(CA), and calcium deficient HA (Habraken et al. 2007). From these, hydroxy apatite 
and ȕ-tricalcium phosphate are the most used ones, ȕ-TCP being more resorbable than 
HA (Bose and Tarafder 2012). They are available as granules, pastes, cements, coatings 
and porous devices (Vallet-Regí and Arcos 2013). The degradation of calcium 
phosphate ceramics depends on their composition, crystallinity, crystal form, and phase 
purity. These ceramics can be processed into various shapes and sizes and antibiotics 
can be incorporated in them. Also, other drugs and even growth factors have been 
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incorporated in the ceramics (Bose and Tarafder 2012; Habraken et al. 2007). The major 
drawback in the use of ceramics is their brittleness, which makes the handling of them 
challenging. If used as blocks, ceramics have to be shaped to fit the bone defect.  This 
may be difficult and labor intensive and poor tissue to implant contact may result. 
(Ginebra et al. 2006; Habraken et al. 2007) Drug release from ceramic materials 
depends strongly on the chemical structure of the ceramic, type of the drug and drug 
load (Habraken et al. 2007). Drug release patterns from purely ceramic materials may 
be difficult to control because highly porous ceramic materials are unable to retain the 
drug for a long time (Mouriño and Boccaccini 2010). For example, linezolid loaded 
calcium deficient hydroxy apatite blocks were able to release linezolid for a maximum 
26 days in vitro (Gautier et al. 2012). 
Drugs can be incorporated either during the processing of the bioceramic or at the end 
of the processing. Because the processing of ceramics includes extremely high 
temperatures, the incorporation of temperature sensitive drugs cannot be made during 
processing. (Vallet-Regí and Arcos 2013) There are, however, several methods to 
incorporate drugs after the thermal treatment of ceramics. Wet granulation and 
impregnation are examples of these methods. (Gautier et al. 2012; Vallet-Regí and 
Arcos 2013) 
Both single antibiotic delivery and simultaneous delivery of two antibiotics have been 
investigated with ceramic materials. Kundu et al. studied the simultaneous release of 
ceftriaxone and sulbactam from porous ȕ-TCP both in vitro and in a rabbit osteomyelitis 
model. The majority of both of the studied antibiotics was released during first week 
and comparable results were obtained for both of the antibiotics in vitro. The porosity of 
the ceramic had an effect on the drug release. In the rabbit model, they concluded that 
infection was eradicated and new bone was formed in the group treated with the 
ceftriaxone and sulbactam-releasing ȕ-TCP implants. (Kundu et al. 2012) Takigami et 
al. reported a series of 8 patients treated successfully with antibiotic-loaded porous 
hydroxy apatite blocks in two-stage revision surgery of an infected hip joint prosthesis. 
The antibiotic loaded to the ceramic was chosen according to the bacteria found in 
cultures obtained pre-operatively. (Takigami et al. 2010) Vogt et al. studied the release 
of gentamycin and vancomycin from mixed calcium sulphate and calcium carbonate (1 
wt-% gentamycin or vancomycin). A high burst for four days and continuous release of 
small amounts of antibiotic for three weeks was reported. (Vogt et al. 2007) 
One approach to achieve both adequate drug release and osteoconductivity provided by 
calcium phosphate ceramics has been to coat the ceramics with a biodegradable 
polymer, where the drug has been incorporated. Such an approach was carried out by 
Luginbuehl et al. where ȕ-TCP granules were coated with P(DL-LA) and PLGA 
containing tetracycline. Good biocompatibility of such materials was found in a sheep 
model and tailorable drug release properties were reported. (Luginbuehl et al. 2010) 
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Nanoscale HA, which has been successfully used to repair bone defects, has also been 
investigated as a drug delivery material in an experimental osteomyelitis animal model 
(rabbits). In a study by Jiang et al., vancomycin delivery using nano-hydroxy apatite 
was found to be effective in inhibiting the proliferation of the infection.  They suggested 
that nano-HA is more suitable than conventional HA for drug delivery applications. 
(Jiang et al. 2012) 
Calcium sulphates have also been researched as antibiotic delivery materials for 
musculoskeletal infections. Parker et al. studied two varieties of calcium sulphates 
(naturally sourced and synthetic) enhanced by the addition of potassium sulphate 
(K2SO4) as a daptomycin-releasing material. The in vitro release times were only 2 days 
in this preliminary study. (Parker et al. 2011) 
Silica-based bioactive glasses, which were first developed by Larry Hench, (Hench 
1973; Hench and Paschall 1973; Hench 2006), have been used as antibiotic delivery 
materials (Domingues et al. 2004; Thanyaphoo and Kaewsrichan 2012). Bioactive 
glasses are able to form a covalent bond with bone tissue and have been applied, for 
example, as bone replacement in periodontal diseases and maxillofacial reconstructions 
(Jones 2013; Vallet-Regí and Arcos 2013). Conventional methods for producing 
bioactive glasses utilize high temperatures, but nowadays they are also produced using 
sol-gel processing where high temperatures are not required (Habraken et al. 2007). 
Thus, temperature sensitive drugs can be incorporated in the glass during processing 
(Vallet-Regí and Arcos 2013). Antibiotics that have been experimentally incorporated 
in bioactive glasses include vancomycin (Thanyaphoo and Kaewsrichan 2012; Xie et al. 
2009), tetracycline (Domingues et al. 2004), and gentamycin (Mouriño and Boccaccini 
2010). Because the mechanical properties of bioactive glasses are not good, ceramics 
have been added to them to produce glass-ceramic composites that have better 
mechanical properties (Habraken et al. 2007). 
The recent development of mesoporous silica matrices composed of ordered porous 
SiO2 structures, that have narrow pore size distribution and a large surface area may 
offer new possibilities for antibiotic delivery for bone applications. These materials 
have been reviewed by Vallet-Regí and Arcos. (Vallet-Regí and Arcos 2013)  
2.3.1.4 Composites 
Composites offer a very attractive combination of the bioabsorbability, drug release 
properties, and good processability of polymers together with the bioactivity of ceramic 
materials, especially calcium phosphates and bioactive glasses (Habraken et al. 2007; 
Mouriño and Boccaccini 2010). Neither of these material groups has good mechanical 
properties, but in composites the brittleness of the ceramics can be avoided by 
combining them with viscoelastic polymers. Both synthetic and natural polymers have 
been studied in composite materials. In the case of synthetic polymers, polymer 
properties can be tailored to meet the required degradation and drug-releasing profiles. 
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(Habraken et al. 2007) Composite materials that combine controlled antibiotic delivery 
and also contribute to bone regeneration are the most ideal local antibiotic delivery 
vehicles in orthopaedics (Hanssen 2005). As some of the antibiotics may, however, 
affect bone regeneration, especially in high doses, a balance between the antibiotic 
treatment to eradicate bacteria without compromising bone regeneration must be found 
(Hanssen 2005). 
The composite approach towards drug-releasing materials often includes incorporating 
the ceramic as particles in a biodegradable polymer matrix (Habraken et al. 2007). 
Numerous approaches have been reported in the literature. Some antibiotic-releasing 
composites of bioabsorbabale polymers and ceramics and their release characteristics as 
well as their production methods are presented in . The antibiotic release from Table 2
the composites is often characterized by a large burst in the beginning of the release that 
typically lasts for one to two days. The release may be as high as 50-60 % of the drug 
loaded in the system (Baro et al. 2002; Kankilic et al. 2011). If needed, the burst and the 
following phase of continuous release can be modified, for example, by dip coating the 
composite with polymer (Fang et al. 2012; Kankilic et al. 2011; Soriano and Évora 
2000). 
 
Table 2 
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2.3.1.5 Allografts and autografts 
One approach to deliver antibiotics locally to bone defects is the use of antibiotic 
impregnated bone grafts (autografts and allografts). In the use of allografts, there is 
always the risk of transmitting pathogens. Demineralized human bone matrix has been 
studied in vitro as a gentamycin-delivering material and has been found to deliver 
gentamycin continuously for 13 days (Lewis et al. 2012). There is great variability in 
the literature concerning antibiotic-impregnated bone grafts and their comparison is 
very difficult. Anagnostakos and Schröder  have reviewed this topic (Anagnostakos and 
Schröder 2012). The concentrations released from antibiotic impregnated bone grafts 
are often higher than the concentrations achieved with antibiotic-releasing PMMA 
cements. The reported elution times of various antibiotics from bone grafts are only 
three weeks at maximum (Anagnostakos and Schröder 2012), which is considered too 
short a time period for the treatment of osteomyelitis. Additionally, it has been observed 
that the elution times are strongly depended on the impregnation time (Witsø et al. 
1999). However, antibiotic impregnated bone grafts have been clinically used 
successfully in the treatment of various orthopaedic infections (Anagnostakos and 
Schröder 2012). 
Antibiotics have been incorporated in bone grafts (autografts or allografts) by e.g. 
soaking them in antibiotic loaded solutions before insertion, manually mixing, or by 
using more complex methods such as iontophoresis (Anagnostakos and Schröder 2012; 
Hanssen 2005). There are, however, very little data available about the antibiotic 
concentrations reached in this way (Hanssen 2005). 
2.3.2 Micro- and nanoparticles 
Most recently, interest in micro- and nanoparticles has been growing. Microparticles 
(microspheres and microcapsules) are spherical particles in the size range of 50 ȝm – 2 
mm and can have drugs either encapsulated or entrapped in them. Nanoparticles 
(nanospheres and nanocapsules) are particles in the sub-micron (< 1 ȝm) scale. (Dash 
and Konkimalla 2012) 
Nano-sized particles have been developed to improve the pharmacokinetics and 
accumulation of antibiotics. At the same time, they may also reduce the side effects of 
the drugs (Huh and Kwon 2011). There is also the hope that nanostructured drug-
delivery systems may offer new tools in the fight against resistant bacteria (Huh and 
Kwon 2011). Because they can be injected, particles (microspheres, microcapsules, 
nanocapsules, nanospheres) offer the advantage that they do not require a surgical 
insertion (Makadia and Siegel 2011). Additionally, they offer a large surface area-
tovolume ratio (Dash and Konkimalla 2012). Drug release from the particles may be 
controlled by diffusion or degradation of the polymer or it may be a combination of 
both of the phenomena (Dash and Konkimalla 2012; Makadia and Siegel 2011). 
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The major drawback of micro- and nanoparticles is that the processing methods are 
often based on organic solvents (Dash and Konkimalla 2012; Ismail et al. 2012; 
Makadia and Siegel 2011). This may be problematic if solvent residues are left in the 
particles. Some drugs may also be denatured if in contact with organic solvents. It is 
also possible to produce particles without harmful solvents using supercritical fluid 
technology (i.e. supercritical carbon dioxide) in a rapid expansion or anti-solvent 
precipitation process. (Dash and Konkimalla 2012) 
Ismail et al. have, for example, developed gentamycin-releasing PLGA microspheres. 
The gentamycin release from the particles showed a very high burst. The authors 
proposed a solution for this problem that is a combination of different dosage forms to 
achieve an ideal release profile. (Ismail et al. 2012) This approach is very interesting. 
Although slow, continuous release was achieved for only four weeks in the study, this 
approach could work for other dosage forms for longer times. Balmayor et al. recently 
reported the development of gentamycin-releasing starch/chitosan microparticles for 
short-term drug delivery. These particles also showed a large burst in the beginning of 
the release in vitro. (Balmayor et al. 2012) 
Nanoparticles based on calcium phosphate ceramics have also been developed and 
studied. Their primary advantage over biodegradable polymer nanoparticles is that their 
degradation products are Ca2+ and  PO3-4 ions which are naturally found in the human 
body and in the blood stream in rather large concentrations (1-5 mM). (Bose and 
Tarafder 2012) 
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3 AIMS OF THE WORK 
The aims of this thesis work were the following:  
x To develop bioabsorbable and antibiotic (either ciprofloxacin or rifampicin) 
releasing composites which also contain an osteoconductive ceramic component. 
The ciprofloxacin-containing composites are intended to be used together with 
rifampicin-containing composites in the local antibiotic treatment of osteomyelitis 
and other bone related infections. The materials are to be used together so that the 
surgeon can decide the ratio in which to use them.  
x To find out the degradation as well as ciprofloxacin-releasing and rifampicin-
releasing properties of the composites and to evaluate their suitability for the 
treatment of osteomyelitis in vitro. The requested length of the release of 
ciprofloxacin and rifampicin was from three to six months and degradation in a 
similar time scale. 
x To prove the efficiency of the ciprofloxacin and rifampicin-releasing composite 
materials against osteomyelitis-causing model bacteria in vitro and also to study 
the usability of bioluminescent bacteria in inhibition zone tests. 
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4 MATERIALS AND METHODS 
4.1 Materials 
The materials and reagents used in this work are presented in Table 3 along with the 
suppliers. The molecular structures of the two active agents, ciprofloxacin and 
rifampicin, are presented in Figure 3 and Figure 4 in the section 2.2.3, respectively. The 
general copolymer structure of lactide and İ-caprolactone is presented in Figure 5. The 
copolymer, which was chosen as the polymer matrix based on preliminary experiments, 
was a commercial medical grade copolymer obtained from Purac Biomaterials and it 
was a copolymer of L-lactide and İ-caprolactone with the comonomer ratio of 70/30 (L-
lactide to İ-caprolactone). The abbreviation PLCL is used in this work to describe the 
copolymer. 
Table 3. Materials and reagents used in this work. 
Material/reagent Supplier Used in 
Ciprofloxacin Uquifa, Mexico II, IV 
Rifampicin Orion, Finland III, IV 
ȕ-tricalcium phosphate 
(granule size < 38 ȝm) Plasma Biotal, United Kingdom I, II, III, IV 
Poly(L-lactide-co-İ-caprolactone) 
Mw 229 000 g/mol and 245 000 g/mol  
(2 batches)  
Purac, Gorinchem, the Netherlands 
(two batches, one for composites 
without antibiotics and one for antibiotic 
containing composites) 
I, II, III, IV 
Na2HPO4 J.T. Baker, the Netherlands I, II, III, IV 
KH2PO4 J.T. Baker, the Netherlands I, II, III, IV 
Chloroform Riedel-de Haën AG, Germany I, II, III 
Chloroform J.T. Baker, the Netherlands II, III 
 Deuterochloroform Merck, Germany I, II, III 
Glycerol Sigma-Aldrich, Malaysia IV 
Ampicillin Sigma-Aldrich, China IV 
Erythromycin Sigma-Aldrich, China IV 
Gentamycin sulphate Sigma-Aldrich, China IV 
Glucose Prolabo, Merck Eurolab, UK IV 
Isopropyl-ȕ-D-
thiogalaktopyranoside (IPTG) Fermentas, Lithuania IV 
Trypton Lab M Limited, UK IV 
Yeast extract Lab M Limited, UK IV 
Sodium Chloride Merck, Germany IV 
Agar Merck, Germany IV 
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Figure 5. Molecular structure of the poly(lactide-co-İ-caprolactone) polymer. 
 
4.2 Methods 
4.2.1 Manufacturing of the composite materials 
Composite materials were manufactured as follows: Prior to processing, the materials 
were dried in vacuum at room temperature for 72 hours. Processing was done using a 
co-rotating custom-built intermeshing twin-screw extruder (length to diameter (L/D) 
ratio of the extruder screws 22.5) and the processing was done using nitrogen 
atmosphere to avoid moisture-induced degradation during processing. The polymer, ȕ-
tricalcium phosphate (ȕ-TCP), and active agents were delivered in the process with 
separate gravimetric screw feeders and the mixing of the materials took place in the 
extruder. Total feed rate was 200 g/h in all of the cases. A haul-off unit was used to 
guide the extrudate from the die and the diameter of the billets was fine-tuned by 
adjusting the speed of the haul-off unit. The materials were processed into rod-shaped 
billets with a diameter of approximately 2.5 mm. The manufactured composites, their 
compositions and abbreviations that are used throughout this work are presented in 
Table 4. 
Pellet shaped samples (length approximately 2.5 mm) were cut from the billets. 
Examples of the manufactured pellets are shown in Figure 6. Before degradation and 
drug release studies were carried out, the samples were packed and sterilized using 
gamma irradiation (minimum dose 25 kGy). 
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Table 4. Compositions in mass percentages of the manufactured composites of PLCL, ȕ-
TCP and the antibiotics rifampicin and ciprofloxacin and their abbreviations. 
Number Name PLCL 
70/30 
ȕ-TCP Ciprofloxacin Rifampicin Used 
in 
1 Plain PLCL 100    I 
2 PLCL+TCP10 90 10   I 
3 PLCL+TCP20 80 20   I 
4 PLCL+TCP35 65 35   I 
5 PLCL+TCP50 50 50   I, IV 
6 PLCL+C 92  8  II 
7 PLCL+TCP50+C 42 50 8  II, IV 
8 PLCL+TCP60+C 32 60 8  II 
9 PLCL+R 92   8 III 
10 PLCL+TCP50+R 42 50  8 III, IV 
11 PLCL+TCP60+R 32 60  8 III 
 
 
Figure 6. Pellet shaped composite samples. PLCL+TCP50 on the left, 
PLCL+TCP50+R in the middle and PLCL+TCP50+C on the right.  
 
4.2.2 Residual monomer measurements 
The determination of residual L-lactide and İ-caprolactone monomer contents of the 
PLCL copolymer were performed by Ramboll Analytics Oy (Lahti, Finland). The İ-
caprolactone and L-lactide contents were measured after chloroform extraction of the 
samples using gas chromatography (DC8000, CE Instruments, Rodano, Italy) and an FI-
detector after chloroform dilution. The measuring resolution was 0.02%. 
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4.2.3 In vitro degradation of the polymer 
The buffer solution used in the in vitro testing was Sörensen buffer solution (pH 7.4) 
and it was prepared according to the standard ISO 15814 (ISO 15814). The chemicals 
used for the buffer solution were sodium hydrogen phosphate (Na2HPO4) and potassium 
dihydrogen phosphate (KH2PO4). Degradation tests were conducted at 37 °C in vitro 
following the standard ISO 15814 (ISO 15814). First, weighed test specimens were 
placed in brown glass bottles with 20 ml Sörensen buffer solution. A test sample 
consisted of 15 pellets weighing approximately 300 mg in total and a set of five parallel 
test samples were tested at each time point separately. The bottles were placed in an 
incubator shaker (Infors Multitron, Infors Bottmingen, Switzerland) at  
37 °C. The pH of the buffer solution was measured once a week with a calibrated pH 
meter (Mettler Toledo, SevenMulti) and the buffer solutions were changed every two 
weeks in the beginning of the test series and once a week as the degradation accelerated. 
Test samples were withdrawn at predetermined time points, which were 2, 4, 6, 8, 10, 
12, 16, 20, 26, 39 and 52 weeks. 
4.2.4 Measurement of mass loss and, water absorption and pH 
After the test samples were withdrawn from the shaking bath, they were rinsed twice 
with distilled water and the surfaces of the pellets were carefully wiped with tissue 
paper. The test samples were weighed immediately after wiping. Next, the test samples 
were dried for at least three days at ambient conditions and for one week in vacuum. 
After vacuum drying, the test samples were weighed again to obtain the dry masses. 
Dried test samples were stored in a desiccator for further analysis. 
The mass loss was calculated as the difference between the initial mass of the test 
sample and the mass of the dried test sample divided by the initial mass of the test 
sample. The water absorption was calculated as the difference between the mass of the 
wet test sample and the mass of the dried test sample divided by the mass of the dried 
test sample. 
4.2.5 Measurements of molar weights of the polymers 
The number average and weight average molecular weights (Mn and Mw respectively) 
and polydispersity (PD) values of the copolymers were determined at room temperature 
by size exclusion chromatography (SEC) (Waters Associates system equipped with a 
Waters 717plus autosampler, a Waters 510 HPLC solvent pump, four linear PL gel 
columns (104, 105, 103 and 100 Å) connected in series, and a Waters 2414 differential 
refractometer). Chloroform (Riedel-de Haën AG, stabilized with 1% ethanol) was used 
as solvent and eluent. The samples were filtered through a 0.5 ȝm Millex SR filter. The 
injected volume was 200 ȝl and the flow rate was 1.0 ml/min. Monodisperse 
polystyrene standards were used for primary calibration. 
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4.2.6 Measurement of thermal properties 
The thermal properties of the composites were measured using DSC Q1000 differential 
scanning calorimeter (TA Instruments, Delaware, USA). The samples were heated twice 
to ensure that their thermal histories were similar during the second heating. Nitrogen 
was used as a sweeping gas. The heating rate was 20 °C/min, the cooling rate 50 
°C/min, and the temperature range was from -60 °C to +200 °C. The results were 
analyzed using Universal Analysis Software. Second heating cycle was used for the 
analysis of glass transition temperatures (Tg) and first heating cycle for the analysis of 
melting temperatures (Tm) and melting enthalpies (heats of fusion, ǻHf). Five parallel 
samples were tested for each material and time point. Averages and standard deviations 
were then calculated. 
In order to detect the possible melting peaks of the active agents ciprofloxacin  
(265-275 °C (Dorofeev et al. 2004)) and rifampicin (approximately 190 °C (Agrawal et 
al. 2004)) in the composites, samples of 5-7 mg of the composites were heated up to 300 
°C at the rate of 20 °C/min using DSC. Additionally, samples of pure rifampicin and 
ciprofloxacin were studied the same way. The melting peaks in the mentioned ranges, if 
detected, give information about the active agent being at least partly dispersed in the 
polymer matrix and not totally dissolved. 
4.2.7 Determination of molecular structure 
The proton NMR spectra were measured from selected samples of composites without 
antibiotics and the composites containing rifampicin or ciprofloxacin. The samples were 
measured using a Varian Mercury 300 MHz NMR Spectrometer (Varian Associates 
Inc., Palo Alto, California, USA) at room temperature. Tetramethylsilane (TMS) was 
used as an internal standard, and chemical shifts were measured relative to TMS. The 
1H NMR spectra were measured at room temperature in standard 5 mm tubes in 
deuterochloroform (Merck, Germany). The data were gathered until the quality of the 
spectrum was sufficient, and the number of scans varied between 190 and 512. The 
proton NMR spectra of the samples were processed and analyzed using SpinWorks 3.1 
and ACD/Spectrus software. Phase correction and baseline correction were applied to 
all spectra. 
4.2.8 Measurement of ceramic content 
The ȕ-TCP content of the test samples was measured using thermogravimetric analysis 
(TGA Q500 (TA Instruments, Delaware, USA)). Approximately 20 mg of a sample was 
used and the samples were heated starting from room temperature at a rate of 20 °C/min 
up to 700 °C. Five parallel samples were tested at each time point of each composite, 
and the results were then analyzed using Universal Analysis Software. 
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4.2.9 Determination of the microstructure of the samples 
The microstructure of the composites was observed using scanning electron microscopy 
(SEM) (Philips XL-30 SEM equipped with a LaB6 filament with SE and BSE detectors, 
Philips, the Netherlands) with an acceleration voltage of 12.0 kV. The micrographs 
were taken both on the surface of the samples and on cryogenically fractured samples 
that were coated with gold (Edwards S150 Sputter Coater) prior to microstructure 
examination. 
4.2.10 Antibiotic release tests 
The drug release tests were conducted at 37 °C in vitro. Weighed test samples (each test 
sample consisted of 15 pellets) were placed in brown glass bottles along with 20 ml 
Sörensen buffer solution. Five parallel test samples were tested for each composite 
material. The bottles were placed in an incubator shaker (Infors Multitron, Infors 
Bottmingen, Switzerland) at 37 °C. At predetermined time intervals, the buffer solution 
was withdrawn from each of the bottles and replaced with fresh solution. The amount of 
buffer solution and the periodical change to fresh buffer solution enabled sink 
conditions to be valid throughout the test series. Sink condition is usually referred as a 
condition where the concentration of the active agent in the solution does not affect the 
dissolution of the active agent from the device to the medium. Typically the limit for 
sink condition is considered as 5% of the saturation concentration (Baker 1987). The 
solubility of rifampicin in water at 30 °C has been reported to be 1.5-1.7 mg/ml 
depending on the crystal form of rifampicin (Henwood et al. 2000). Solubility of 
ciprofloxacin at 37 °C has been reported to be 0.20 mg/ml at pH 7.8 and 0.22 mg/ml at 
pH 6.9 (Breda et al. 2009). These solubilities were noticed to be adequate in ensuring 
sink conditions in this method. The amount of released antibiotic (ciprofloxacin or 
rifampicin) was determined from the buffer solution using a Unicam UV 500 
spectrometer (ThermoSpectronic, Cambridge, United Kingdom) at maximum 
absorption wavelength of 271 nm for ciprofloxacin and 226 nm for rifampicin. A 
wavelength area from 190 to 400 nm for ciprofloxacin and 190 to 650 nm for rifampicin 
was scanned in order to detect possible changes in the molecular structures of the 
antibiotics (ciprofloxacin and rifampicin) that cause deviation in the UV-spectrum. 
Ciprofloxacin and rifampicin concentrations were calculated using Beer-Lambert law 
and standard curves prepared with known concentrations of both of the antibiotics. 
4.2.11 Statistical testing 
Mann-Whitney U test was used to determine if there was a statistical difference in the 
drug release results between the composites containing 50 wt-% and 60 wt-% of ȕ-TCP. 
The significance level of p < 0.05 was used. 
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4.2.12 Initial and final antibiotic content measurements 
Samples of about 150 mg were weighed from each manufactured composition 
containing antibiotics. The samples were dissolved in 50 ml of chloroform (J.T. Baker, 
the Netherlands). The amount of ciprofloxacin or rifampicin in the chloroform solution 
was determined using a Unicam UV 540 Spectrophotometer (ThermoSpectronic, 
Cambridge, United Kingdom) at a maximum absorption wavelength of 284 nm for 
ciprofloxacin and 349 nm for rifampicin. The concentrations of the antibiotics in the 
solution were calculated using Beer-Lambert law and standard curves prepared with 
known concentrations of the antibiotics. 
4.2.13 Inhibition zone testing using bioluminescence imaging 
The effects of the antibiotic-releasing composite materials against common 
osteomyelitis causing bacteria were tested using bioluminescence imaging based on the 
ability of genetically engineered bacteria to emit light. This method gives more 
information of the developing inhibition zones than the conventional inhibition zone 
method. The antibiotic containing composite materials chosen for this study were the 
composites containing 50 wt-% of ȕ-TCP based on the drug release results. Composite 
of PLCL and 50 wt-% of ȕ-TCP was used as control. 
Two different engineered bacteria strains were used as biosensor cells: Pseudomonas 
aeruginosa PAO-LAC carrying plasmid pUCP24GW (Moir et al. 2007), and 
Staphylococcus epidermidis ATCC-14990 carrying plasmid pAT19-lux-hlaP-frp. None 
of the bacteria strains were actually pathogenic. 
Bacteria were cultured on antibiotic L-agar plates overnight at 30 °C, and suitable 
colonies were moved into liquid culturing in Luria-Bertani (LB) medium (5 g/l yeast 
extract, 10 g/l tryptone, 5 g/l NaCl). The bacteria were cultured overnight at 30 °C and 
300 rpm with suitable antibiotics. If the bacteria did not produce luminescence in the 
morning, 1/50 dilution was made in a culture tube and it was incubated at 37 °C and 300 
rpm for three hours. The level of luminescence of the cultures was measured by using 
Plate ChameleonTM multilabel counter 1.001 (Hidex Ltd., Turku, Finland). At volume of 
200 µl, counts of 1.1-2.3×106 (S. epidermidis), and 1.1-2.3×106 (P. aeruginosa) were 
found optimal. 
Layers of LB-agar (agar 15 g/l, 2 ml) were cast into 6-well plate, and the controls and 
antibiotic containing composite pellets were placed on top of them (one pellet per well). 
Bacteria culture of 350-500 ȝl per well was mixed with 1 ml of soft LB-agar (agar 
concentration 7.5 g/l) solution and cast on top of the first layers. The amount of 
bacterial culture was dependent on the luminescence level. After solidification, the plate 
was taken to the imaging station of Xenogen VivoVision IVIS® Lumina luminescence 
camera (Caliper LifeSciences, USA). Images were taken every 20 minutes for 16 hours 
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with exposure time of 30 seconds. The pictures were analyzed using Living Image® 3.1 
program (Caliper LifeSciences, USA). The intensities of the light emitted from the wells 
were analyzed as well as the development of the inhibition zones around the antibiotic-
releasing pellets. The results are presented as false color photos, where dark blue and 
purple were interpreted as dead bacteria with no bioluminescence. The red and yellow 
colors were interpreted to indicate situation where the bacteria are in contact with 
subinhibitory concentrations of the antibiotics and produce strong light emission that is 
presumably due to the nonspecific activation of central metabolic pathways. These red 
and yellow zones are called stress zones (SZ). Green color was considered to be 
unaffected bacteria because this was the usual light intensity in the control wells. 
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5 RESULTS 
5.1 The effects of processing and sterilization on the 
materials  
The processing of the materials with twin-screw extrusion caused only slight decrease in 
the molar weights of the PLCL copolymer in the composites without antibiotics and the 
composites containing rifampicin. The Mw of the copolymer seemed to decrease more 
in the composites containing ciprofloxacin. The results of the Mw determined using SEC 
are presented in Table 5. Sterilization using gamma-irradiation caused significant 
degradation in all studied composites. The decrease of molecular weights during 
gamma-irradiation is a well-known fact with biodegradable polymers e.g. lactide based 
polymers (Daculsi et al. 2011; Paakinaho et al. 2009). It is based on the random chain 
scission due to the high-energy irradiation (Plikk et al. 2006). The measured doses of 
gamma-irradiation were 28.7-34.0 kGy for composites without antibiotics and 29.3-35.0 
kGy for the composites with antibiotics. It has also been suggested that gamma-
irradiation may cause cross-linking for pure poly-İ-caprolactone (Cottam et al. 2009), 
but such an effect was not seen in these results. Cross linking would cause decrease in 
the Mn and increase the Mw of the polymer. Here, a significant decrease in both Mn and 
Mw was seen. 
Table 5. Mw of the polymer matrix of the composites as raw material, after processing 
and after sterilization. 
Composite 
Mw (g/mol) Â 103 
PLCL 
raw material 
After  
processing 
After 
Ȗ-irradiation 
Plain PLCL 229 227 195 
PLCL+TCP10 229 228 187 
PLCL+TCP20 229 228 177 
PLCL+TCP35 229 226 163 
PLCL+TCP50 229 226 166 
PLCL+C 245 227 196 
PLCL+TCP50+C 245 237 134 
PLCL+TCP60+C 245 239 120 
PLCL+R 245 241 172 
PLCL+TCP50+R 245 244 151 
PLCL+TCP60+R 245 245 143 
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The percentual decrease of the molecular weights (both Mn and Mw) of the composites 
without antibiotics during gamma irradiation is presented in Figure 7. Gamma 
irradiation caused more degradation to the composites with higher ȕ-TCP content and 
the dependency was almost linear (shown with the trend lines). This may be due to that 
the samples were not stored in totally dry conditions before sterilization and the 
composites may have absorbed some moisture from air, which causes more degradation 
during the sterilization step. The composites with high ȕ-TCP contents may absorb 
more water than the plain copolymer or the composites with low ȕ-TCP contents. This 
causes more degradation in the composites with high ȕ-TCP contents. Additionally, 
increased interfacial area between the ceramic particles and polymer may enhance the 
uptake of water.  
 
Figure 7. The percentual decrease in the Mw and  Mn of the composites of PLCL and  
ȕ-TCP during sterilization using gamma irradiation (28.7-35.0 kGy). 
The residual L-lactide and İ-caprolactone monomer contents were measured from the 
raw material (plain PLCL) as well as from the processing batches of composites with 
and without the antibiotics. The results are presented in Table 6 as averages and 
standard deviations of the measurements. The residual İ-caprolactone monomer 
contents were below detection limit in all the samples and the residual L-lactide 
monomer content did not increase during processing. 
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Table 6. Residual L-lactide and İ-caprolactone monomer contents in the raw material 
and after the processing of the composites. 
 Raw material 
(n=4) 
PLCL+TCP 
(n=6) 
PLCL+TCP+C 
(n=6) 
PLCL+TCP+R
(n=4) 
L-lactide (wt-%) 0.08 ± 0.02 0.08 ± 0.02 0.05 ± 0.02 0.06 ± 0.02 
İ-caprolactone  
(wt-%) 
< 0.02 < 0.02 < 0.02 < 0.02 
5.2 Degradation of the materials 
5.2.1 pH of the buffer solution 
pHs of the buffer solutions were measured and the buffer solutions were changed 
periodically in all of the degradation test series to ensure that the pH stayed between 
values 7.2-7.6. 
As the hydrolytic degradation of the polymer proceeded, acidic degradation products 
were released to the surrounding buffer solution. Lower pH values were measured from 
the time point of 12 weeks onwards, and there was a clear need to change buffer 
solution more often than in the beginning of the degradation test series. In the 
degradation test series of the antibiotic containing composites, the buffer was changed 
in the same rate as the drug release samples were taken, to avoid the effect of 
accumulating drug on the degradation of the composites. Overall, the pH of the buffer 
solution retained close to 7.4, which is the initial pH of the Sörensen buffer solution, for 
the most parts of the test series. 
5.2.2 Molecular structure 
The molecular structures of the polymer and antibiotic constituents of the composites 
were analyzed using NMR in order to gain information about the degradation of the 
polymer and the molecular structure of the antibiotics. Of special interest was the effect 
of sterilization using gamma irradiation on the molecular structures of the antibiotics. 
The NMR measurements were done at time points of 0 (after processing and 
sterilization), 26 and 52 weeks of the in vitro test series and the samples measured were: 
plain PLCL, PLCL+TCP50, PLCL+C, PLCL+TCP50+C, PLCL+R, and 
PLCL+TCP50+R. Additionally, plain rifampicin sample was measured as well as the 
raw material PLCL. There were two different raw materials batches used for the 
manufacturing of the composites. One batch was used for the composites without 
antibiotics and another batch was used for all antibiotic-containing composites. 
Because polymer degradation is dependent not only on the comonomer ratio but also on 
the microstructure of the polymer, e.g. sequence lengths and randomness of the polymer 
  
52 
structure, a closer look at the molecular structure needed to be taken in order to 
understand polymer degradation behavior (Fernández et al. 2012; Herbert 1993). 
Polymer 
The chemical shifts of the protons remained constant in all of the studied samples. The 
signals of the 1H NMR spectra were assigned to the polymer molecule, as shown in 
Figure 8. Some signals were overlapping and could not be used for the analysis. The 
most informative signals of the PLCL copolymer were the signals at į 5.16 for the –CH 
group proton of the lactide comonomer, at į 4.05-4.13 for the Į-oxy methylene protons 
of the İ-caprolactone comonomer, and at į 2.3-2.4 for the protons of the methylene 
group of İ-caprolactone that was bonded to the carbonyl group. The signals of the 
caprolactone protons at į 4.05-4.13 and at į 2.3-2.4 were clearly split into two parts 
according to the position in the polymer chain. The triplet at į 4.13 indicated the CH2 
group in the İ-caprolactone fragment bonded to an L-lactide unit and the broader 
multiplet at į 4.05 indicated the Į-oxy methylene group bonded to another İ-
caprolactone unit. (Fernández et al. 2012; In Jeong et al. 2004) The signal at į 2.3-2.4 
was split the same way. The triplet at į 2.4 indicated a group bonded to a L-lactide 
group and the broader multiplet at į 2.3 corresponded to a group that is bonded to 
another İ-caprolactone group (Fernández et al. 2012; In Jeong et al. 2004). This 
information could be used for the calculation of the average sequence lengths of the L-
lactide and İ-caprolactone comonomers. The comonomer ratios of the copolymer were 
calculated as the ratio of the integral of the signal at į 5.16 to the average integrals of 
the caprolactone signals at į 4.05-4.13 and at į 2.3-2.4 (Fernández et al. 2012). The 
results are shown in Table 7. 
 
Figure 8. Peak assignment of the 1H NMR spectrum of the PLCL raw material to the 
molecular structure of the PLCL copolymer. 
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Table 7. Comonomer molar ratio (L-lactide to İ-caprolactone) of the PLCL copolymer 
at different time points of the in vitro test series (pH 7.4, 37 °C). 
Time 
(weeks) 
Plain 
PLCL 
PLCL+TCP50 PLCL+C PLCL+TCP50+C PLCL+R PLCL+TCP50+R 
0 68/32 68/32 68/32 68/32 69/31 69/31 
26 75/25 70/30 68/32 68/32 78/22 71/29 
52 83/17 79/21 75/25 77/23 84/16 80/20 
 
The L-lactide and İ-caprolactone sequence lengths and randomness were studied from 
the results of the 1H NMR analysis according to the text by Herbert (Herbert 1993) and 
Fernández et al. (Fernández et al. 2012). The number average sequence lengths, ñ, of 
the comonomers were calculated using Equations 14 and 15: 
෤݊௅஺ = ଶ(௅஺)(௅஺ି஼௅) (14) 
෤݊஼௅ = ଶ(஼௅)(௅஺ି஼௅) (15) 
where (LA) and (CL) are the molar fractions of the L-lactide and İ-caprolactone 
comonomers in the copolymer and (LA-CL) is the average dyad relative fraction, which 
can be calculated from the 1H NMR data of the copolymer (Fernández et al. 2012). 
Additionally, the randomness factor, R, can be calculated using the Equation 16: 
ܴ = (௅஺ି஼௅)
ଶ(௅஺)(஼௅) (16) 
If the randomness factor is 1, it means that the polymer has a totally random structure 
and if it is 0, the copolymer is a block copolymer (Fernández et al. 2012). The results of 
the average sequence length calculations and the randomness factors for all of the 
composites are presented in Table 8. 
The randomness of all the studied materials decreased as the degradation proceeded. 
Only the composite of PLCL+C showed behavior that differed from the other 
composites. In this particular composite, the decrease of randomness was not 
substantial. The average sequence lengths of the comonomers showed that L-lactide 
tends to form long blocks and İ-caprolactone blocks were shorter on average, mainly 
between 6-7 units long. The notable increase in the average sequence length of the L-
lactide comonomer as the degradation proceeded showed that the short blocks of L-
lactide were removed from the polymer chains, as the copolymer was hydrolytically 
degraded. There was only a slight increase in the İ-caprolactone sequence length as the 
degradation proceeded, which indicated that the sequence length was not much affected 
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by the hydrolytic degradation although the İ-caprolactone comonomer fraction in the 
copolymer decreased. 
The decrease of the randomness factor R supports the interpretation that the random 
parts of the copolymer were removed from the polymer structure and more blocky 
structures, consisting mainly of L-lactide units, remained as the hydrolytic degradation 
proceeded. 
 
Table 8. Number average sequence lengths of L-lactide and İ-caprolactone in the PLCL 
copolymer and randomness factors (R) for the copolymer at different time points of the 
in vitro test series (pH 7.4, 37 °C). 
Sample name 
Time  
in vitro 
(weeks) 
L-lactide 
sequence 
length 
İ-caprolactone 
sequence 
length 
Randomness 
factor, R 
Raw material  
(used for the composites 
without antibiotics) 
0 12.70 5.88 0.25 
Raw material  
(used for the antibiotic 
containing composites) 
0 12.22 5.74 0.26 
PLCL 26 16.85 6.32 0.22 
PLCL 52 28.85 7.07 0.18 
PLCL+TCP50 0 11.92 5.77 0.26 
PLCL+TCP50 26 14.10 6.27 0.23 
PLCL+TCP50 52 20.61 6.80 0.20 
PLCL+C 0 12.94 6.02 0.24 
PLCL+C 26 13.02 6.44 0.23 
PLCL+C 52 15.15 6.26 0.23 
PLCL+TCP50+C 0 12.99 5.99 0.24 
PLCL+TCP50+C 26 12.07 6.49 0.23 
PLCL+TCP50+C 52 22.77 7.15 0.18 
PLCL+R 0 11.41 5.44 0.27 
PLCL+R 26 21.23 6.31 0.21 
PLCL+R 52 31.28 6.97 0.18 
PLCL+TCP50+R 0 11.32 5.57 0.27 
PLCL+TCP50+R 26 14.60 6.11 0.23 
PLCL+TCP50+R 52 23.25 7.10 0.18 
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Ciprofloxacin 
Signals of ciprofloxacin protons were visible in the 1H  NMR  only  in  the  0  week  
samples. At 26 or 52 weeks, the ciprofloxacin content in the samples was below the 
limit that could be detected using NMR. Thus, the molecular structure of ciprofloxacin 
during in vitro test series could not be analyzed. The signal assignment of ciprofloxacin 
molecule to the peaks in the 1H NMR spectrum is shown in Figure 9. Some signals were 
overlapping with the signals of the polymer and thus could not be used for analysis. The 
integrals of protons of the quinoline ring at 8.80 and 8.06 ppm (a and b in Figure 9) 
were in good agreement with the stoichiometric proportion 1:1 in both ciprofloxacin-
containing samples where ciprofloxacin signals were detected. Additionally, the signals 
of cyclopropane proton at 3.55 ppm (c), and the 8 protons in the piperazine ring, which 
appear as a multiplet at 3.25 ppm (d), show good agreement with the stoichiometric 
values 1:8. Based on these results, it can be concluded that the ciprofloxacin molecule 
maintained its original structure throughout the processing and sterilization steps. This 
result supports the findings of Koort et al. and Alvarez et al. who concluded that 
processing and gamma-sterilization do not affect the bactericidal effect of ciprofloxacin 
(Koort et al. 2005; Koort et al. 2006; Koort et al. 2008; Mäkinen et al. 2005b; Alvarez et 
al. 2008). 
 
 
Figure 9. Part of the 1H NMR spectrum of PLCL+C after processing and sterilization 
and positions of the peaks assigned to the protons in the ciprofloxacin molecule. 
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Rifampicin 
The molecular structure of rifampicin was studied from three samples (pure rifampicin, 
PLCL+R and PLCL+TCP50+R after processing and sterilization). Rifampicin signals 
were not seen in other samples due to the rather low sensitivity of NMR and low content 
of rifampicin in the samples. The 1H spectrum of pure rifampicin was compared to the 
spectra of the 0 week samples. 1H NMR analysis of rifampicin reported by Cellai et al. 
(Cellai et al. 1982) was also used when the signals were assigned to the protons of the 
rifampicin molecule. Proton assignment is presented as Figure 10 and spectra as an 
Appendix. 
In the composite samples, some signals of the rifampicin molecules were overlapping 
with the polymer signals and could not be analyzed accurately. These were some of the 
protons in the ansa chain (protons 16, 18, 20, 21, 22, 24, and 31), protons 32 of the 
naphtalene ring, and protons 59 of the methyl group attached to the piperazinyl ring. 
Amide proton and the OH-groups of the naphthalene ring were clearly visible at ߜ 11.98 
ppm 13.11 ppm and 13.41 ppm, respectively. Their chemical shifts were stable and the 
integrals were in good stoichiometric ratio. The protons of the methylene group located 
above the plane of the naphthalene ring (protons 45) showed a signal below 0 at ߜ -0.31 
ppm in pure unprocessed rifampicin and processed PLCL+R and PLCL+TCP50+R 
samples. The fact that this signal is identical in all the samples proves that the ansa 
chain has retained its original configuration. Otherwise, the signal of this group would 
have appeared elsewhere in the spectrum. The ansa bridge protons 13, 14, 15, 17, 19, 
23, and 25 were clearly visible, stable when compared between the samples, and were in 
good stoichiometric agreement with the rifampicin structure. The signals of the protons 
37, 39, and 41 of the methyl substituents of the ansa chain and the signals of the protons 
54 and 56 of the piperazine ring were in the shoulder of a large polymer signal and thus 
their accurate integration was not possible. Additionally, signals of the equivalent 
protons 53 and 57 of piperazine ring appeared at ߜ 3.02 overlapping with signals of the 
protons 19 and 47 and thus could not be accurately integrated. However, their combined 
integral showed that there was no change between samples in either the positions of the 
signals or their integrals. 
As a conclusion of the NMR analysis, it can be stated that no deviations of the original 
rifampicin structure were found after the analysis of the composite samples (PLCL+R 
and PLCL+TCP50+R) and pure rifampicin sample. Thus, rifampicin maintained its 
original structure during processing and sterilization steps. 
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Figure 10. Chemical structure, atom numbering and 1H chemical shifts of rifampicin. 
5.2.3 Molecular weights of the PLCL copolymer 
The molecular weights (both Mw and Mn) of PLCL in all the studied composites 
decreased rapidly during the 52-week in vitro test period. There were small differences 
in the initial Mw and Mn, but the degradation proceeded similarly in all the studied 
composites. Typical degradation results are presented in Figure 11, where the Mws of 
the composites containing 50 wt-% of ȕ-TCP are presented. The Mws of all the 
antibiotic containing composites are shown as Figure 6 and Figure 4 in publications II 
and III respectively. The Mns of the composites without antibiotics are shown as Figure 
3 in publication I. The SEC distribution curves showed emerging bimodality from the 
20 week time point onwards. An example presenting the bimodality is shown as Figure 
4 in the Publication I.  
The rapid decrease of the Mw was due to the random chain scission of the ester bonds in 
the polymer backbone, which occurs first in the amorphous sections of the polymer and 
proceeds later to the crystalline parts (Li and Vert 1999). 
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Figure 11. Examples of the decrease in the Mw of the composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and 50 wt-% ȕ-tricalcium phosphate (TCP) with and without 
antibiotics (ciprofloxacin (C) and rifampicin (R))(8 wt-%) as a function of time in vitro 
(pH 7.4, 37 °C). 
The molecular weights (Mw) decreased according to the first order kinetics (Equation 11 
in section 2.1.2.3) (Lao et al. 2011; Li and Vert 1999; Pitt et al. 1981): 
ܯ௪ǡ௧ ൌ ܯ௪ǡ଴݁ݔ݌(െ݇ݐ)  (11) 
where Mw,t is the polymer molecular weight at time t and Mw,0 is the initial polymer 
molecular weight and k is the degradation rate constant. When plotted to logarithmic 
scale the decrease of molecular weight is linear. This is valid until the onset of mass loss 
(Li and Vert 1999; Pitt et al. 1981). 
Fitting the Equation 11 to the experimental results using the t in hours and least squares 
regression analysis gave the degradation rate constant k values that are presented in 
Table 9. The values are all reasonably close to each other except the PLCL+C, which 
has slightly higher degradation rate constant. 
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Table 9. The rate constants for the molecular weight decrease (k) for the hydrolytic 
degradation of the PLCL copolymer in the studied composites in vitro (pH 7.4, 37 °C). 
Composite k Â10-3 (1/h) 
Plain PLCL 1.7 
PLCL+TCP10 1.7 
PLCL+TCP20 1.6 
PLCL+TCP35 1.4 
PLCL+TCP50 1.4 
PLCL+C 2.1 
PLCL+TCP50+C 1.5 
PLCL+TCP60+C 1.4 
PLCL+R 1.7 
PLCL+TCP50+R 1.5 
PLCL+TCP60+R 1.4 
 
5.2.4 Water absorption and mass loss of the composites 
Water absorption and mass loss were clearly affected by the ȕ-TCP contents of the 
composites as well as the antibiotics in them. The results of the mass loss and water 
absorption measurements are presented as Figures 6, 6 and 4 in the publications I, II and 
III respectively. As a summary, the results from the water absorption and mass loss 
measurements of the composites without antibiotics are collected in Figure 12 and the 
results of the composites containing ciprofloxacin or rifampicin are collected in Figure 
13. The bars showing standard deviations were omitted for clarity. 
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Figure 12. Water absorption and mass loss of the composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) (presented as mass change as 
a function of time, pH 7.4, 37 °C). Standard deviations were omitted for clarity (n=5). 
 
 
Figure 13. Water absorption and mass loss of composites of poly(L-lactide-co-İ-
caprolactone) (PLCL), ȕ-tricalcium phosphate (TCP), and ciprofloxacin (C) or 
rifampicin (R) (presented as mass change as a function of time, pH 7.4, 37 °C). 
Standard deviations were omitted for clarity (n=5). 
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The antibiotic containing composites tended to absorb more water in the beginning of 
the degradation test series (weeks 0-12) than the composites without antibiotics. 
Additionally, increasing ȕ-TCP content in the composites caused more water absorption 
in the same time period, probably caused by the hydrophilicity of ȕ-TCP (Figure 12) 
(Bernstein et al. 2010). The polymer mass loss was slow during the first ten weeks of 
the test series. The slight mass loss seen in the experiments during this time period was 
mainly due to the antibiotic release.  
After the time point of 12 weeks, mass loss of the composites increased due to the fact 
that chain scission caused by hydrolysis had proceeded to the point where short polymer 
chain fractions were able to diffuse out from the matrix causing mass loss. This 
behavior was seen more in the plain copolymer samples and in samples where polymer 
fraction was large. The water absorption behavior of the composites changed so that the 
composites with low ȕ-TCP contents absorbed more water than the composites with 
high ȕ-TCP contents (Figure 12). In composites with antibiotics, such behavior was not 
seen and the water absorption for the antibiotic containing composites with 50 wt-% or 
60 wt-% ȕ-TCP proceeded similarly. On the other hand, the antibiotic content had an 
effect also on the water absorption. The rifampicin containing composite without ȕ-TCP 
had identical water absorption behavior to the plain copolymer after the time point of 12 
weeks. Rifampicin is able to form hydrogen bonds (Agrawal et al. 2004; Freire et al. 
2009; Henwood et al. 2000; Henwood et al. 2001) due to its complex structure and thus 
may affect water absorption of the composites. The water absorptions of the composites 
without antibiotic were not measurable after 26 weeks (plain copolymer after 20 weeks) 
due to the degraded structure of the samples. 
5.2.5 Ceramic content of the composites 
Ceramic contents of the composites, measured using thermogravimetric analysis, 
increased as the degradation proceeded in all of the composites (Figure 14). 
Additionally, the results of the ȕ-TCP dissolution test series showed very slow 
dissolution (results not included in this thesis but are reported in publication I). At 10-12 
weeks, polymer degradation had proceeded to a stage when mass loss started and this 
can be seen as increase in the ceramic content curves shown in Figure 14. There were 
no differences in the ceramic content behavior of the composites containing 50 wt-% of 
ȕ-TCP without antibiotic and with antibiotic (triangular symbols in Figure 14). Also the 
ceramic content curves of the composites containing 60 wt-% of ȕ-TCP and rifampicin 
or ciprofloxacin showed no difference. The deviations between the five tested samples 
in all of the cases were very small, thus the standard deviations are not visible in Figure 
14. Twin-screw extrusion as a production method produces very homogenous samples 
and the variation between them was thus very small. 
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Figure 14. ȕ-TCP contents of the composites of poly(L-lactide-co-İ-caprolactone) 
(PLCL), ȕ-tricalcium phosphate (TCP), and ciprofloxacin (C) or rifampicin (R). Results 
presented as averages with standard deviations (n=5).  
5.2.6 Thermal properties 
Thermal properties of the composites were measured using differential scanning 
calorimeter with the heating rate of 20 °C/min and with two heating cycles to ensure 
similar thermal histories of the samples in the second heating cycle. The original Tg data 
are shown as Figures, 10, 8 and 6 in Publications I, II and III respectively. 
Representative Tg data are shown as Figure 15. Standard deviations are omitted for 
clarity. They are, however, seen in the figures in the original publications. There was a 
clear decrease in the Tg of all of the composites during the first weeks of the degradation 
test series. The decrease lasted until the time point of 12-20 weeks depending on the 
composite. The decrease in Tg was most pronounced in composites without antibiotics 
and PLCL+R and reached the minimum at 12 weeks. In other composites the decrease 
was less and the minimum was reached at 16-20 weeks. 
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Figure 15. Changes in the Tgs of some of the studied composites of poly(L-lactide-co-İ-
caprolactone) (PLCL), ȕ-tricalcium phosphate (TCP), and ciprofloxacin (C) or 
rifampicin (R) during in vitro degradation test series. Standard deviations are omitted 
for clarity. 
Melting temperatures of the composites were measured from the first heating of the 
DSC analysis. During second heating, the melting peaks were not visible anymore due 
to the fast cooling of the samples after the first heating that results an amorphous 
structure of this copolymer. The melting enthalpies were also analyzed and corrected to 
correspond to the polymer or polymer + drug part of the composite. There was some 
tendency for cold crystallization towards the end of the degradation test series. The 
composites without antibiotics and composites containing rifampicin behaved almost 
similarly. The melting peaks were mostly bimodal and they were mainly between 110-
125 °C throughout the test series.  
The heat of fusion (ǻHf), which describes the crystallinity of a polymer, is presented for 
representative samples in Figure 16. The original data is shown in Figures 11, 8, and 6 
in publications I, II and III respectively.  The ǻHf of the plain PLCL, PLCL+TCP10, 
PLCL+TCP20, PLCL+TCP35, PLCL+TCP50, PLCL+R, PLCL+TCP50+R, 
PLCL+TCP60+R and PLCL+C increased steadily throughout the test series. The 
composites of PLCL+TCP50+C and PLCL+TCP60+C showed a peculiar behavior. 
There was a dramatic increase in the crystallinity of the samples during the first weeks 
of the in vitro test series until the 8 week time point. After that, the crystallinity started 
to decrease and from the 16 week time point, followed the behavior of increasing 
crystallinity until the end of the test series. 
  
64 
 
Figure 16. The heats of fusion (ǻHf) of the polymer component in the composites of 
poly(L-lactide-co-İ-caprolactone) (PLCL), ȕ-tricalcium phosphate (TCP), and 
ciprofloxacin (C) or rifampicin (R) during the in vitro degradation test series. Standard 
deviations are omitted for clarity (n=5). 
Melting peaks around 236-245 °C were observed when ciprofloxacin containing 
composites were heated up to 300 °C using DSC. For pure ciprofloxacin, the melting 
peak was observed at 272 °C. On the other hand, melting peaks of 265-275 °C and 255-
257 °C have been reported in the literature with a comment that the heating rate and the 
purity of the sample have an effect on the result (Dorofeev et al. 2004). These 
observations suggest that at least part of the ciprofloxacin antibiotic is dispersed in the 
composites. If ciprofloxacin would be totally dissolved in the polymer, no melting peak 
of ciprofloxacin would be seen in the composite samples (Baker 1987). 
The DSC study done with pure rifampicin and the rifampicin containing composites 
showed a clear melting peak at 196 °C for the pure rifampicin sample but not for any of 
the composites. This suggests that rifampicin is dissolved in the polymer matrix in the 
composites. Rifampicin molecule has a number of functional groups in the molecular 
structure and thus may be able to form hydrogen bonds and van der Waals bonds with 
the polymer (Agrawal et al. 2004; Freire et al. 2009; Henwood et al. 2000; Henwood et 
al. 2001). The ability of the polymer and active agent to form these secondary bonds 
affects greatly on the solubility of the active agent in the polymer.  
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5.2.7 Microstructure 
Scanning electron micrographs were taken both on the surfaces of the pellet shaped 
samples and on cryogenically fractured samples. Extrusion as a manufacturing method 
does not produce porous materials as such but the incorporation of ceramic component 
to the process introduces some porosity to the extruded material (Niemelä et al. 2005; 
Niemelä et al. 2011). Images of the samples showing porosity both on the surfaces and 
on the fractured surfaces can be seen in the Figures 12, 9 and 7 of the publications I, II, 
and III respectively. Selected micrographs are gathered to Figure 18. One example of ȕ-
TCP particles inducing porosity in the composite material is shown as Figure 17. 
Similar porosity induced by bioactive glass particles has been also reported earlier 
(Niemelä et al. 2005). 
No porosity was observed in the plain PLCL after processing or during the 52 week in 
vitro test period. In the PLCL+TCP10, there were no significant porosity seen after 
processing either, but degradation induced some pore formation on the surfaces of the 
samples. This is shown as Figure 18 A. In Figure 18 B, the fractured surface of 
PLCL+TCP50 composite after 52 weeks in vitro is shown. 
Antibiotic containing composites looked somewhat different than the composites 
without antibiotics. There was some porosity seen throughout the test series. Samples of 
PLCL+TCP60+C and PLCL+TCP60+R after 52 weeks in vitro are shown in Figure 18 
C-F. Surfaces of the samples are shown in C and E and fractured surfaces in D and F, 
respectively. There are pores reaching the size of 100 ȝm which has been reported to 
enhance bone ingrowth (Shore and Holmes 1993). 
 
Figure 17. A detail of the surface of the composite of poly(L-lactide-co-İ-caprolactone) 
with 20 wt-% of ȕ-tricalcium phosphate (TCP) after processing. 
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Figure 18. SEM micrographs of the composites. A) surface of  PLCL+TCP10 at the 
time point of 52 weeks in vitro, B) fractured surface of PLCL+TCP50 at 52 weeks in 
vitro, C) surface of PLCL+TCP60+C 52 at weeks in vitro, D) fractured surface of 
PLCL+TCP60+C 52 at weeks in vitro, E) surface of PLCL+TCP60+R 52 at weeks in 
vitro, F) fractured surface of PLCL+TCP60+R at 52 weeks in vitro. 
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5.3 Antibiotic release 
5.3.1 Ciprofloxacin 
The initial ciprofloxacin contents of the composites were measured as 7.0 ± 0.4 wt-% 
for PLCL+C, 8.1 ± 0.1 wt-% for PLCL+TCP50+C, and 7.5 ± 0.2 wt% for 
PLCL+TCP60+C. Cumulative ciprofloxacin release from the composites is presented as 
Figure 19 and daily release as Figure 20. The release occurred in three distinct phases. 
The first phase was the burst in the beginning of the release and it can be seen well in 
the daily release profile (Figure 20). The burst lasted for one day and the daily release 
doses started to decrease after that. The burst is normally attributed to the drug 
molecules on the surface and near the surface of the sample and they are able to be 
dissolved into the surrounding medium rapidly (Baker 1987; Duvvuri et al. 2006). In 
these studied materials, the burst was small. The second phase of the release was until 
the 5-week time point, where there is a clear inflection point seen in the cumulative 
release curve of PLCL+C and PLCL+TCP50+C. The daily release curve shows a rapid 
increase in the ciprofloxacin release of PLCL+C and PLCL+TCP50+C around the time-
point of 5 weeks. There is a very small peak seen also in the daily release profile of 
PLCL+TCP60+C. The PLCL+C showed a lag phase in the ciprofloxacin release until 
the time point of 5 weeks with almost negligible release. The second phase of the 
release was due to diffusion of the drug molecules through the matrix or through the 
pores in the composites. At this time period, the mass loss of the polymer was not yet 
significant (see Figure 13) and thus polymer erosion did not play a role in the antibiotic 
release. However, due to the hydrolytic degradation, the size of the polymer chains had 
decreased and enabled higher permeability of the drug in the polymer. Polymers based 
on İ-caprolactone are known to be well permeable for drug molecules under 400 g/mol 
of molecular weight (Pitt 1990; Woodruff and Hutmacher 2010). The permeability is 
also known to be affected by the comonomer ratio in the İ-caprolactone containing 
copolymers (Pitt et al. 1979). The copolymer used in this work, contained only  
30 mol-% of İ-caprolactone comonomer and thus the permeability is considerably less 
than for pure poly-İ-caprolactone, because the L-lactide comonomer decreased the 
permeability of the copolymer. As a consequence, PLCL+C shows very slow 
ciprofloxacin release in the first five weeks of the release test series and differs 
substantially from the release curves of the PLCL+TCP50+C and PLCL+TCP60+C. 
The phase of the release from the beginning to the 5-week time point obeys the first 
order kinetics for all ciprofloxacin-containing composites, where the release rate of the 
active agent is dependent on the concentration of the active agent in the test specimen 
and can be described with the Equation 2 in section 2.1.2.1. The Equation can also be 
presented as: ln(ܯ଴ െܯ௧)ൌ-kt൅lnܯ଴ (17) 
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where Mt is the released drug at the time t, M0 is the initial drug load in the system, and 
k is the rate constant. When the logarithm of the remaining drug load (M0-Mt) in the 
sample is plotted as a function of time, a straight line results. This is shown in Figure 
21, where the release kinetics has been studied in two distinct phases. The R2 was 0.99 
for PLCL+TCP50+C and PLCL+TCP60 for the first five weeks of the drug release 
study and 0.97 for the PLCL+C. 
In the third phase of the release, polymer degradation started to affect the drug release. 
The fitting to the theoretical first order kinetic model is shown in Figure 21. The R2 was 
0.99 for all three composites for the time after five weeks. In the third phase of the 
release, polymer erosion, degradation, and diffusion through the polymer matrix and 
through the pores in the composite all have an effect on the release (Baker 1987).  
Mann-Whitney U test was performed to the cumulative ciprofloxacin release results of 
the composites containing 50 wt-% and 60 wt-% of ȕ-TCP throughout all the measured 
time points. There was a statistically significant difference (Mann-Whitney U test, P < 
0.05) in the cumulative ciprofloxacin release results of PLCL+TCP50+C and 
PLCl+TCP60+C until the time point of 26 weeks, where the release had ceased to 
almost negligible level. When the statistical analysis was done on the daily release of 
ciprofloxacin (Figure 20), the same kind of result was obtained. There was a statistically 
significant difference in the daily release of PLCL+TCP50+C and PLCL+TCP60+C 
until the time point of 27 weeks. 
 
Figure 19. The cumulative release (at 37 °C, pH 7.4) of ciprofloxacin from composites 
of poly(L-lactide-co-İ-caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) with 
initial TCP contents of 0 wt-%, 50 wt-% and 60 wt-% and initial ciprofloxacin (C) 
content of 8 wt-%. Results shown as averages with standard deviations (n = 5). 
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Figure 20. The daily release (at 37 °C, pH 7.4) of ciprofloxacin from composites of 
poly(L-lactide-co-İ-caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP ) with 
initial TCP contents of 0 wt%, 50 wt-% and 60 wt-% and initial ciprofloxacin (C) 
content of 8 wt-%. Results shown as averages with standard deviations (n = 5). 
 
Figure 21. Fitting the ciprofloxacin release results of second and third phase of the 
release to the first order kinetic model. 
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5.3.2 Rifampicin 
Although rifampicin is known to be very stable in solid form, in mildly alkaline aqueous 
solutions and in presence of atmospheric oxygen it oxidizes quite readily to rifampicin 
quinone. This can be seen as a change in the UV-spectrum of a rifampicin solution as 
well as a change in the color of the solution from reddish orange or yellow to purple. 
Rifampicin quinone has a partly similar UV-spectrum to rifampicin. The presence of 
rifampicin quinone interferes with spectrophotometric and also with microbiological 
techniques, because it also shows antibacterial activity (Bain et al. 1998). 
In dissolution studies, ascorbic acid or sodium ascorbate have been used as antioxidants 
to prevent rifampicin oxidation. The release tests described in the literature have been 
lasting no more than 36 hours (Sreenivasa Rao 2001; Sreenivasa Rao et al. 2001). In our 
preliminary tests, we noticed that neither ascorbic acid nor sodium ascorbate can be 
used in tests lasting more than a few hours due to the decomposition of the antioxidants 
in conditions used for hydrolytic tests. In addition, a third antioxidant was tested (2-
phospho-L-ascorbic acid trisodium salt) but it did not show any activity in preventing 
rifampicin oxidation. 
Another approach that was tested was the utilization of an isosbestic point in the UV-
spectrum of rifampicin and rifampicin quinone. Isosbestic point is a specific wavelength 
at which two (or more) chemical species have the same absorptivity. Several possible 
points of the UV-spectra of rifampicin were studied. In the literature, an isosbestic point 
at the wavelength of 330 nm has been reported for rifampicin and rifampicin quinone 
(Bain et al. 1999). We measured the UV/Vis spectra of rifampicin in Sörensen 
phosphate buffer solution kept at 37 °C in an incubator shaker at different time points. 
The results of the changing UV/Vis spectra are shown in Figure 22. There is an 
isosbestic point seen at the wavelength of 226 nm and it was used in our rifampicin 
content measurements. At the wavelength of 226 nm, the absorbance remains the same 
although the rest of the rifampicin spectrum is changed over time. There were also some 
other possible points, which were at 265 nm, 318 nm, 363 nm, 410 nm, and 517 nm, but 
the one at 226 nm proved to be the best. At this point we could calculate the rifampicin 
content of the solution despite that it has partly oxidized to rifampicin quinone. The fact 
that rifampicin quinone degrades further to other compounds affects the accuracy of this 
method. The accuracy is at its best if the measurements are made in short intervals, not 
letting the dissolution medium stay unchanged for long periods. If the measurements are 
made in two-three day intervals, the accuracy should be sufficient. 
At later stages of the release test period, when the polymer degradation had advanced, a 
broad UV-peak in the beginning of the scanned area was induced. This broad peak, 
however, did not interfere significantly with the use of the isosbestic point at 226 nm. 
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Figure 22. UV/Vis-absorption spectra for rifampicin in Sörensen phosphate buffer 
solution (pH 7.4) kept at 37 °C and measured at different time points. 
The measured initial rifampicin contents were 6.5 wt% for PLCL+R, 7.9 wt% for 
PLCL+TCP50+R and 7.8 wt% for PLCL+TCP60+R. The low rifampicin content in the 
PLCL+R was apparently due to the extrusion process and that the antibiotic feeding was 
not at the desired level. 
Cumulative release of rifampicin from the studied composites is presented in Figure 23. 
The release occurred in four phases, the burst in the beginning of the release being the 
first one. The inflection points in the release curves around 8 and 17 weeks separate the 
other three phases. The daily release of rifampicin is presented as Figure 24. In the daily 
release curves, the accelerations around the time points of 8 and 17 weeks can be seen 
well. 
Rifampicin release was rather complex, due to the different phases in the release. Thus, 
the release phases had to be considered separately. The first phase was the burst, which 
lasted for two days. After that, the release rates of PLCL+TCP50+R and 
PLCL+TCP60+R decreased constantly until the time point of approximately 7 weeks. 
The release from the PLCL+R was very slow in this time period. During the second 
phase, the release from the composites fitted well to the square root of time kinetics 
with correlation factors of 0.99 for PLCL+TCP50+R and PLCL+TCP60+R. The slow 
release of PLCL+R fitted with R2 of 0.97. 
For comparison, the release results were also fitted to the to the power law kinetics 
equation (Equation 18) (Baker 1987; Ritger and Peppas 1987): 
ெ೟
ெಮ
ൌ ݇ݐ௡ (18) 
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where Mt/M is the fractional drug release, k is the release rate constant, t is time and n 
the release exponent. The release exponent n has values of 0.45 for Fickian diffusion 
and cylindrical geometry (Baker 1987). For Case II diffusion (or anomalous), the n has 
values of 0.45<n<1. During the second phase of the release, the rifampicin release from 
PLCL+TCP50+R and PLCL+TCP60+R had values for n of 0.53 and 0.44 respectively. 
The result suggests that the rifampicin release occurs by Case II diffusion from the 
PLCL+TCP50 and by Fickian diffusion from PLCL+TCP60+R during the second phase 
of the release (Baker 1987). 
The third phase of the release started around the 8-week time point, where there is an 
inflection point seen in the cumulative release curves. In the third phase (between 8 and 
17 week time points), the drug release was influenced by the increased permeability of 
the polymer caused by polymer degradation. Additionally, the polymer erosion started 
to play a role increasing the release rate. The third phase of the release of 
PLCL+TCP50+R obeyed again the t1/2 kinetics very well (R2=0.99). The release from 
PLCL+TCP60+R had at this point reached 60% of the total cumulative release, where 
the most models are not valid anymore (Lao et al. 2011). 
A fourth phase in the release was observed in the release of PLCL+R and 
PLCL+TCP50+R but not in the PLCL+TCP60+R. The inflection points in the release 
curves were at the time point of 17 weeks. It coincided well with the increased mass 
loss from the composites, which was already notable at the time point of 17 weeks and 
can be seen in Figure 13. The Mw of the polymer had decreased to the level of 9000-
14000 g/mol (Figure 11) at this point. From the PLCL+TCP60+R, the available drug for 
the release was apparently released already at this time point and thus no phase change 
was seen there. 
The drug release decreased to almost negligible level after 35 weeks and at this point 
70-85% of the total rifampicin loaded in the composites had been released. There was 
still some rifampicin left in the samples, which was revealed by the reddish brown color 
of the samples. However, no further drug release was observed. The tests were 
terminated at the time point of 56 weeks and the remaining rifampicin in the composites 
was measured the same way than the initial rifampicin contents in the beginning of the 
test series. The proportion of the initial rifampicin still in the samples after the 
termination of the test series was 10.7% for PLCL+R, 5.0% for PLCl+TCP50+R and 
3.4% for PLCL+TCP60+R. When combined with the measured released rifampicin, the 
total rifampicin amount detected did not reach 100% for any of the composites. This 
was probably because rifampicin oxidized to rifampicin quinone that was further 
degraded to compounds with no UV-absorbance and explains why part of the rifampicin 
seems to have disappeared (Bain et al. 1998). 
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Figure 23. The cumulative release of rifampicin from composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) with initial TCP contents of 0 
wt-%, 50 wt-% and 60 wt-% and initial rifampicin (R) content of 8 wt-%. Results shown 
as averages with standard deviations (n = 5). 
 
 
Figure 24. The daily release of rifampicin from composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) with initial TCP contents of 0 
wt-%, 50 wt-% and 60 wt-% and initial rifampicin (R) content of 8 wt-%. Results shown 
as averages with standard deviations (n = 5). 
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There was a statistically significant difference (Mann-Whitney U test, P < 0.05) in the 
cumulative rifampicin release results of the composites containing 50 wt-% and 60 wt-
% of ȕ-TCP throughout the test series (Figure 23). When similar analysis was done on 
the daily release of rifampicin (Figure 24) from the composites containing 50 wt-% and 
60 wt-% ȕ-TCP, there was a statistically significant difference between the composites 
excluding the time periods of 5-8 weeks, 13.5-15.5 weeks, from the time point of 44 
weeks to the end and the single time point of 10.4 weeks (73 days). 
5.4 Inhibition zone measurements 
The effect of the antibiotic-releasing composites against the common osteomyelitis 
causing bacteria, Staphylococcus epidermidis and Pseudomonas aeruginosa, were tested 
using bioluminescence imaging. The composites selected for these experiments based 
on the most promising in vitro drug release results, with the most constant release rates, 
were the ones containing 50 wt-% of ȕ-TCP for both antibiotics. The well plate 
incubated with bioluminescent S. epidermidis and PLCL+TCP50+C pellets is shown in 
Figure 25 and PLCL+TCP50+R pellets in Figure 26 after 14 hours of incubation. 
Similar results of bioluminescent P. aeruginosa and PLCL+TCP50+C and 
PLCL+TCP50+R are presented as Figure 27 and Figure 28 respectively after 14 hours 
of incubation. Additionally, Figure 29 shows how one such plate looks to the naked eye 
after 16-hour incubation. This illustrates the conventional over-night-grown method in 
the inhibition zone measurements. 
Both of the studied bacteria, S. epidermidis and P. aeruginosa responded to the 
antibiotics released from the composite pellets. The formation of the inhibition zones 
could be seen as growing dark blue areas surrounding the antibiotic-releasing pellets 
already after four hours. The inhibition zones grew until 12 hours of incubation and 
after that the changes were detected in the light emission levels. The dark blue color 
indicated dead bacteria and the bright circles of red and yellow surrounding the 
inhibition zones indicated bacteria that were in contact with subinhibitory 
concentrations of the antibiotics. These zones were called stress zones. This refers to the 
phenomenon where the bacteria are in contact with subinhibitory concentrations of 
antibiotic and produce strong light emission that is presumably due to the nonspecific 
activation of central metabolic pathways. As the release of the antibiotics proceeded, the 
stress zones led the expanding inhibition zones. The green color in Figures 25-28 was 
considered to be unaffected bacteria because this was the usual color in the control 
wells. The development of the inhibition zones is illustrated with the Figures 1-4 in the 
publication IV, where the bioluminescence imaging results of 6-well plates cultured 
with S. epidermidis (Figure 1, IV) and P. aeruginosa (Figure 2, IV) exposed to 
PLCL+TCP50+C, and S. epidermidis (Figure 3, IV) and P. aeruginosa (Figure 4, IV) 
exposed to PLCL+TCP50+R are shown. The development of the inhibition zones are 
shown at 2-hour intervals. 
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The inhibition zones around the rifampicin-releasing pellets were formed faster than 
around the ciprofloxacin-releasing pellets, but overall their inhibition zones were 
smaller than those of the ciprofloxacin-releasing pellets. The initial burst observed in 
the in vitro release tests from the rifampicin-containing composite pellets (Figure 24) 
was observed to be larger than from the ciprofloxacin-containing pellets (Figure 20). 
This explains the faster initial formation of the inhibition zones around the rifampicin 
releasing pellets. Although ciprofloxacin-containing pellets showed a lower initial burst, 
the final areas of the inhibition zones after 14 hours of incubation were greater. This 
was probably due to ciprofloxacin molecule being smaller than the rifampicin molecule 
and thus the diffusion out from the pellet and in the agar may be faster than for 
rifampicin. 
 
Figure 25. Bioluminescent S. epidermidis and ciprofloxacin containing pellets 
(PLCL+TCP50+C) on the lower row and controls without antibiotic on the top row 
after 14 hours of incubation. Dark blue color is interpreted as dead bacteria, green as 
unaffected bacteria, and red and yellow as bacteria in stress zones. 
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Figure 26. Bioluminescent S. epidermidis and rifampicin containing pellets 
(PLCL+TCP50+R) on the lower row and controls without antibiotic on the top row 
after 14 hours of incubation. Dark blue color is interpreted as dead bacteria, green as 
unaffected bacteria, and red and yellow as bacteria in stress zones. 
 
 
Figure 27. Bioluminescent P. aeruginosa and ciprofloxacin containing pellets 
(PLCL+TCP50+C) on the lower row and controls without antibiotic on the top row 
after 14 hours of incubation. Dark blue color is interpreted as dead bacteria, green as 
unaffected bacteria, and red and yellow as bacteria in stress zones. 
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Figure 28. Bioluminescent P. aeruginosa and rifampicin containing pellets 
(PLCL+TCP50+R) on the lower row and controls without antibiotic on the top row 
after 14 hours of incubation. Dark blue color is interpreted as dead bacteria, green as 
unaffected bacteria, and red and yellow as bacteria in stress zones. 
 
Figure 29. Inhibition zones as seen by naked eye after 16 hour incubation with S. 
epidermidis and ciprofloxacin containing pellets on the lower row. Controls without 
antibiotic are on the top row.  
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6 DISCUSSION 
In the treatment of osteomyelitis, long-term antibiotic courses are required. With orally 
or intravenously administered antibiotics, a concentration adequate to eradicate bacteria 
in the infection site is often difficult to achieve. Due to the multitude of infection-
causing bacteria, there have been suggestions in the literature that it would be 
advantageous if different drugs could be combined in a way that the decision of the 
drugs to be used could be made during surgery, just before implantation (Arruebo et al. 
2010; Ginebra et al. 2006). The materials developed in this work answer this material 
need. The materials also provide a platform technology for the development of other 
drug-releasing materials and combinations of them. As a result of this work, we offer 
composite materials that are ready for preclinical testing and have potential to be used in 
the local treatment of osteomyelitis and other bone-related infections alone or together 
and, at the same time, act as osteoconductive bone filler materials. The surgeon, who is 
treating a patient with osteomyelitis or other bone-related infections can decide in which 
ratio to use the antibiotic-releasing materials because they are separate materials and can 
be mixed in the desired ratios. 
The use of combination therapy of two different antibiotics has been justified with 
synergistic effects of two antibiotics against the causative bacteria. The synergistic 
effects are an accelerated bacterial count decline, a wider antibacterial spectrum with 
two antibiotics, and a reduction in the risk of resistant strain development to one of the 
antibiotics. (Coiffier et al. 2013)  
The materials used in this work were commercially available FDA approved materials. 
The antibiotics, ciprofloxacin and rifampicin, were chosen based on the literature 
review and experts’ opinions. The poly(L-lactide-co-caprolactone) copolymer was 
chosen based on the good drug-release properties found in preliminary tests. The 
ceramic component, ȕ-TCP, is known to be osteoconductive and, along with hydroxy 
apatite, is the most well-known ceramic bone substitute (Neumann and Epple 2006). 
Due to the brittleness of ceramics, their use is sometimes limited and composites with 
polymers may improve their mechanical properties. In the following sections, different 
aspects of the composites materials developed in this work and their behavior in vitro 
are discussed. 
6.1 Effect of processing and sterilization on the materials 
The processing of degradable polymers by extrusion often causes a significant decrease 
in  the  Mw of the polymer (Södergård and Stolt 2002). This decrease is caused by the 
high temperature and shear forces in the extruder (Crowley et al. 2007; Repka et al. 
2007). If moisture is present in the material, the decrease of Mw is ever higher (Li and 
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Vert 1999; Lim et al. 2008; Södergård and Stolt 2002). The degradation of the materials 
can be, however, prevented by adjusting the processing parameters and by carefully 
drying the polymer as well as preventing the moisture of the surrounding air from 
entering the extruder equipment during processing. In our study, all these measures 
were taken to prevent the excessive degradation of the polymer matrix of the 
composites during extrusion. Additionally, care was taken in feeding the polymer, 
antibiotics, and ȕ-TCP into the extruder. Overall, as a production method, extrusion is 
fast, continuous, reproducible, and easy to scale up to an industrial scale (Crowley et al. 
2007; Repka et al. 2007). The samples produced using extrusion are very homogenous 
and deviations between them are small (Crowley et al. 2007; Repka et al. 2007; Wilson 
et al. 2012). An additional advantage is the absence of solvents (Crowley et al. 2007; 
Repka et al. 2007). Due to the efficient mixing caused by the shear forces in the process, 
the dissolution rates of poorly soluble drugs can be enhanced because they can be 
molecularly dispersed in the polymer carrier during the process (Wilson et al. 2012). 
In this work, the degradation of the polymer material during processing, seen as the 
decrease in Mw of the polymer, was very small in the composites without antibiotics. It 
may be even, that in some cases, the decrease seen could fall into the measurement 
inaccuracy of the size exclusion chromatography that was used to measure the 
molecular weights of the polymers. Higher degradation during processing was observed 
with composites containing the antibiotics (ciprofloxacin or rifampicin), and the 
composites containing ciprofloxacin degraded more than the composites containing 
rifampicin. In the antibiotic containing composites, more degradation was seen in the 
composites without ȕ-TCP than in the ones with ȕ-TCP. One would expect this to be 
other way round because ȕ-TCP particles are expected to cause shear forces and friction 
in the polymer melt during extrusion which in turn cause scission of the polymer chains 
(Crowley et al. 2007; Repka et al. 2007). 
Sterilization using gamma irradiation caused significant degradation of the polymer 
matrix. There was a linear dependency of decrease in the Mw and  Mn of the polymer 
matrix in the composites. The higher the ȕ-TCP content in the composite was, the more 
degradation gamma irradiation caused. The samples that were sent for gamma 
irradiation were not packed in nitrogen, and no other measures were taken to keep the 
samples totally dry. They were stored in desiccator, but during packing and shipping the 
composites with a higher ȕ-TCP content were likely to absorb more moisture in the 
material. This would consequently cause more degradation to those composites with a 
higher moisture content. 
Residual lactide monomer has been reported to affect the degradation of lactide-based 
polymers and accelerate the mass loss and loss of mechanical properties (Paakinaho et 
al. 2009). In this study, the residual L-lactide monomer content was seen not to change 
during processing and sterilization, and thus it can be assumed that the monomer 
content did not have an effect on the polymer degradation. Additionally, the measured 
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levels of İ-caprolactone monomers were below detection limit in all the samples, and 
therefore it suggests that İ-caprolactone monomer did not have an effect on the 
degradation. 
6.2 Hydrolytic degradation of the materials 
Lactide-based copolymers are known to be hydrolytically unstable and degrade in the 
presence of water. Water molecules attack the ester bonds in the polymer and thus break 
the polymer backbone to smaller fractions. This is normally seen as a decrease in the 
molecular weight of the polymer and it also has an effect on the other properties of the 
polymer including mechanical, thermal, and water absorption properties as well as the 
microstructure of the polymer (Fernández et al. 2012; Hiljanen-Vainio et al. 1996; 
Hiljanen-Vainio et al. 1997; Malin et al. 1996). Mechanical properties were not studied 
here, but the other properties with regard to the degradation process were investigated 
using several analytical methods. 
The properties of copolymers of İ-caprolactone and lactides as well as the degradation 
behavior are strongly dependent on the molecular structure, meaning the comonomer 
ratio, the type of lactide used and how random the copolymer is, the flexibility of the 
polymer chain, the presence of polar groups, molecular mass, crystallinity, and 
orientation (Albertsson and Varma 2003; Fernández et al. 2012; Malin et al. 1996). In 
this study, the 1H NMR analysis showed a clear change in the comonomer ratio (L-
lactide / İ-caprolactone) of the copolymer, as hydrolytic degradation proceeded. This 
effect was accompanied by an increasing average sequence length of L-lactide. This 
was observed in all the composites and it was supported by the results of thermal 
analysis where an increase in the Tgs of the copolymer was seen as a function of time in 
vitro. It is well known that the Tgs of copolymers of L-lactide and İ-caprolactone are 
strongly dependent on the comonomer composition. The Tg increases dramatically even 
with small increments of the L-lactide content (Pitt 1990). The 1H NMR results clearly 
showed that the copolymer PLCL was rather blocky. The randomness of the copolymers 
of lactides and İ-caprolactone is greatly affected by polymerization conditions and 
depends on the polymerization temperature and time (Albertsson and Varma 2003; 
Hiljanen-Vainio et al. 1996; Hiljanen-Vainio et al. 1997; Södergård and Stolt 2002). 
These comonomers tend to form blocks and it is rather challenging to produce a 
completely random copolymer structure using them (Fernández et al. 2012). 
Changes in the comonomer ratio of copolymers of L-lactide and İ-caprolactone during 
hydrolytic degradation have been reported, for example, by In Jeong et al. (In Jeong et 
al. 2004) and Lemmouchi et al. (Lemmouchi et al. 1998). The results of In Jeong et al. 
are similar to ours with a copolymer initially having more L-lactide in the structure than 
İ-caprolactone. Lemmouchi et al. reported increasing İ-caprolactone fraction during 
hydrolytical degradation of a copolymer having initially more İ-caprolactone in the 
structure than L-lactide (74/26 ratio of CL/LA). The connection of these results lies in 
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the ability of the comonomers to crystallize. It has been reported that 14 units are 
required for L-lactide units to be able to form crystals (Sarasua et al. 1998). 
Additionally, Lemmouchi et al. postulated that in the copolymer of their study, it was 
the İ-caprolactone units that were able to form crystals (Lemmouchi et al. 1998). This 
leads to the interpretation that the comonomer with a larger initial fraction, and 
eventually also with longer sequence lengths, is able to crystallize in the copolymer and 
is degraded slower than the comonomer with lower initial fraction. Additionally, both In 
Jeong et al. and Lemmouchi et al. proposed that the degradation starts in the amorphous 
regions of the polymer, and this is accepted nowadays in practice in the biomaterial 
field (Södergård and Stolt 2002; Lemmouchi et al. 1998; In Jeong et al. 2004). 
In conclusion, the 1H NMR analysis showed that the PLCL copolymer was blocky 
having some random parts in the structure. The random parts were removed as the 
hydrolytic degradation proceeded and the blocky characteristic of the copolymer 
increased. The bonds between the L-lactide and İ-caprolactone comonomers were most 
susceptible to hydrolytic degradation in this studied PLCL copolymer. 
The hydrolytic degradation of the polymer matrix, i.e. the decrease of the molecular 
weight, obeyed first order kinetics meaning that the degradation occurred by random 
scission in the polymer backbone (Lao et al. 2011; Li and Vert 1999). The ȕ-TCP 
content did not have a notable effect on the degradation and nor did either of the studied 
antibiotics. There are factors that have been reported in the literature that may affect the 
degradation of these kinds of composites. Bernstein et al. have reported results of 
composites containing nanosized tricalcium phosphate and polycaprolactone with very 
high ȕ-TCP contents (85 vol-% and 95 vol-%) (Bernstein et al. 2010). ȕ-TCP was 
proposed to enhance the hydrolytic degradation of polycaprolactone due to the 
increased hydrophilicity. On the other hand, a buffering effect of the dissolution 
products of ȕ-TCP against the acidic degradation products of the polymer has been 
proposed (Ara et al. 2002; Lin et al. 1999). The buffering effect would lead to slower 
degradation of the polymer component in the composite. These two factors, increased 
hydrophilicity and buffering, work in opposite ways and, if simultaneous, their overall 
effect on the degradation may be evened out.  
Water absorption tells about the hydrophilicity of the material. During the in vitro 
degradation test series, changes in the water absorption and differences between the 
studied materials were observed. These can be explained with the different phases in the 
polymer degradation as well as the differences in the composition of the materials. 
Although rifampicin is considered lipophilic, there are groups in the molecule capable 
of hydrogen bonding and they may have an effect on water absorption. Ciprofloxacin is 
claimed to be more hydrophilic than rifampicin, which explains well the greater water 
absorption in the beginning of the test series. Additionally, the interphases between 
dispersed ciprofloxacin particles and the polymer may act as channels for water 
absorption. ȕ-TCP is hydrophilic (Lei et al. 2007) and thus may accelerate the water 
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absorption of the composites. This was seen especially in the first 12 weeks of the test 
series. After 12 weeks, the water absorption behavior changed, and the composites with 
the highest polymer content showed the greatest water absorption. The polymer 
degradation had at this point reached a level where there were more hydrophilic end 
groups available in the polymer, which in turn increased the water absorption. Also, 
mass loss of the composites, due to the polymer erosion, started around the 12-week 
time point. Mass loss of hydrolytically unstable polyesters starts when the molecular 
chains have been cut to fractions that are small enough, i.e. monomers and oligomers, to 
be dissolved in the surrounding hydrolysis medium. Mws of 5000 g/mol for poly-İ-
caprolactone and 15000 g/mol for poly-DL-lactide have been reported to enable the start 
of mass loss (Sawhney and Hubbell 1990). In this study, mass loss started after 10 
weeks in vitro and, at this point, the Mw of the polymer in the composites without 
antibiotics had decreased to 12000-15000 g/mol. For ciprofloxacin containing 
composites, the Mw values were in the range of 19000-22000 g/mol and for rifampicin 
containing composites 16000-23000 g/mol. During the very first weeks of the test 
series, some mass loss was observed, but it was mainly due to the drug release from the 
antibiotic-containing composites. 
There was bimodality seen in the SEC curves of the degrading PLCL polymer starting 
from week 20 in vitro. Traditionally, bimodality seen in the SEC distribution curve has 
been explained by the autocatalytic effect in the inner parts of the polymer (Daculsi et 
al. 2011; Li et al. 1990; Li 1999; Sawhney and Hubbell 1990). In the composites studied 
here, this was unlikely because of the porous structure of the composites induced by the 
ȕ-TCP granules in the structure. The porous structure enabled the short chain 
degradation products to escape from the inner parts on the samples and thus did not 
catalyze the degradation reaction further. It was seen in the 1H NMR analysis that the 
PLCL polymer was rather blocky and the random parts degraded first. This structure 
was pronounced as the hydrolysis proceeded and might have caused an increase in a 
certain part of the SEC distribution curve as the blocky parts consisting mainly of L-
lactide units remained in the copolymer and the number of the other parts in the 
copolymer decreased. 
pH results fitted well with the mass loss results. At the same time with accelerated mass 
loss, there was a decrease seen in the pH values of the buffer solution acting as the 
hydrolysis medium. The medium was changed to keep the pH between 7.2-7.6. The 
decrease in the pH values was caused by the degradation of the PLCL copolymer, which 
had proceeded to the level that enabled mass loss of the polymer. The polymer was 
degraded down to oligomers and monomers that, in this case, were acidic and were 
released into the surrounding medium. 
The results of the Tg measurements supported the results of the 1H NMR analysis that 
showed a change in the comonomer ratio of the polymer during the in vitro test series. 
This change explained the increase in the Tg towards the end of the test series.  The Tgs 
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of copolymers of lactides and İ-caprolactone are known to be strongly dependent on the 
comonomer ratio (Pitt 1990). Even very small increments in the lactide content have a 
noticeable effect on the Tg. Before the increase of the Tg, there was a decrease in the 
beginning of the degradation test series (0-10 weeks). This was apparently due to the 
degradation of the polymer by random chain scission that produced shorter polymer 
chains, as the molecular weight decreased. (Li and Vert 1999; Li et al. 1990) 
There was an increase in the measured heats of fusion, i.e. crystallinity, of all the 
composites throughout the in vitro test series. All the composites showed steadily 
increasing crystallinity with the exeption of the composites of PLCL+TCP50+C and 
PLCL+TCP60+C. In these two composites, there was a dramatic increase followed by a 
decrease in the crystallinity, during the first weeks of the in vitro test series. This 
behavior can be attributed to the simultaneous presence of ciprofloxacin and ȕ-TCP in 
the samples, as this was not observed for any other composites. The increase of 
crystallinity is normally due to both the degradation of the amorphous parts of the 
copolymer and to the increased mobility of the polymer chains, as they get shorter due 
to the degradation. These more mobile chains are able to rearrange themselves and form 
crystals. 
The DSC analysis of the antibiotic containing composites, which were conducted in 
order to find out if the antibiotics were dissolved or partially dispersed in the polymer 
matrix, showed interesting results. The ciprofloxacin-containing composites showed 
clear melting peaks indicating at least partially dispersed ciprofloxacin in the polymer 
matrix. In the rifampicin-containing composites, no melting peak of rifampicin was 
observed indicating dissolved antibiotic in the polymer matrix and strong interactions 
between rifampicin and the copolymer. 
In the ceramic content measurements, steadily increasing ceramic contents were 
observed for all the composites containing ȕ-TCP. This was due to the very slow 
dissolution of ȕ-TCP and polymer mass loss, as the polymer degraded. This kind of 
behavior may, however, be beneficial in the bone healing process. As the polymer 
component degrades and is lost from the composite, the ceramic component stays in the 
bone defect and can aid the bone healing, due to its bioactive properties. 
Microstructure analysis done with scanning electron microscopy showed some porosity 
in the samples with ȕ-TCP content over 20 wt-%. The addition of ȕ-TCP particles 
induced porosity in the composites and some of the pores were seen to reach the size of 
100-200 ȝm which has been reported to enhance bone ingrowth (Shore and Holmes 
1993). 
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6.3 Drug release 
The two studied antibiotics showed different drug release behavior from the composites. 
The difference was partially due to the difference in the size of the molecules of 
ciprofloxacin and rifampicin. Ciprofloxacin is a smaller molecule than rifampicin and is 
thus able to diffuse easier through the polymer matrix. On the other hand, a rifampicin 
molecule has many functional groups in the molecular structure and, based on the 
structure, is able to form hydrogen bonds (Agrawal et al. 2004; Freire et al. 2009; 
Henwood et al. 2000; Henwood et al. 2001) with the polymer, which in turn may lead to 
better solubility of the drug in the polymer (Coleman et al. 1991). 
At the very beginning of the release tests, both antibiotics showed a 1-2 day burst 
release. This was the phase where the molecules located on or near the surface of the 
test specimens were released. Although the rifampicin molecule is larger than 
ciprofloxacin molecule, the burst of rifampicin was generally stronger than the burst of 
ciprofloxacin. The poor solubility of ciprofloxacin in water may inhibit the rapid release 
of ciprofloxacin molecules located on or near the surface of the test specimens. Also, 
the fact that rifampicin was at least partially dissolved in the polymer matrix and that it 
is easily dissolved in water may have enhanced the burst. 
Initial burst in the drug release has often been claimed as an unwanted phenomenon 
(Zamoume et al. 2011; Kankilic et al. 2011). It may, however, be beneficial in the cases 
when the target is to destroy any remaining bacteria after the surgical debridement of 
infected tissue. If the burst is at least moderate, it may help to achieve the required 
antibiotic concentration in the tissue and eradicate bacteria or to prevent the attachment 
of bacteria to the operated bone or implant (Kundu et al. 2012; Luginbuehl et al. 2010; 
Mouriño and Boccaccini 2010; Zilberman and Elsner 2008). Especially in the case of 
orthopaedic implant-related infections, the prevention of bacteria adhesion on the 
surface of the implant during or right after the surgery is extremely important. After 
surgery, a six-hour “decisive period” has been identified in which the success of the 
implantation is determined. During this period, the implant is particularly vulnerable to 
bacterial adhesion. (Hetrick and Schoenfisch 2006; Zilberman and Elsner 2008) Several 
approaches, often very complex ones, e.g. manipulation of the drug loading in the 
matrix radially, have been studied in order to avoid the burst phenomenon in the 
beginning of the release as well as to achieve close to zero order (i.e. linear) drug 
release (Rothstein and Little 2011; Zamoume et al. 2011). These are often very 
complicated to produce and thus are not feasible for industrial production. Additionally, 
they often include the use of harmful organic solvents (Calhoun and Mader 1997; Jones 
et al. 2011), which can, as residues, be problematic if used in vivo (Puga et al. 2012). At 
least, proving that the solvent residues are totally absent can be a challenging task. 
The presence of the inflection points in the cumulative release profiles of both of the 
antibiotics is characteristic for a release mechanism combining diffusion and erosion 
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mechanisms (Baker 1987). In this work, the release in the second phase, i.e. after the 
burst, was due to a combination of diffusion through the polymer matrix, which was in 
fact almost negligible, and through the pores introduced to the composites by the 
addition of ȕ-TCP. This was quite evident when the cumulative release profiles of 
composites without the ceramic and with the ceramic were compared. Additionally, the 
polymer erosion was not notable in this time period. There was a significant difference 
in the release profiles of both ciprofloxacin and rifampicin between the composites with 
50 wt-% and 60 wt-% of ȕ-TCP, although the difference in the ceramic content was not 
that large. This was probably because of increased porosity caused by the increased 
ceramic content between 50 wt-% and 60 wt-% of ȕ-TCP. 
When the molecular weight of a polymer decreases, the diffusion properties of the 
polymer change considerably. As the number of shorter polymer chains in the polymer 
matrix increases, they are able to move more and permeability increases. Here, this 
observation was supported by the thermal properties results, where a decrease in Tg was 
measured in the beginning of the test series showing more flexible polymer chains, as 
degradation proceeded. On the other hand, crystallinity of the polymer increased during 
degradation and the amorphous regions, where the diffusion happens, were reduced.  
There was a clear acceleration of the antibiotic release both in the ciprofloxacin and 
rifampicin composites (Figure 20 and Figure 24). This acceleration occurred at around 5 
weeks for ciprofloxacin and at around 8 weeks for rifampicin. The three-week 
difference in the onset of the acceleration was probably due to the difference in the 
molecular size of the antibiotics, rifampicin being larger than ciprofloxacin. Thus, 
ciprofloxacin was able to diffuse easier through the polymer matrix and through the 
pores in the composite structure. The third phase of the release was governed by 
diffusion accelerated by polymer degradation and increasing permeability as well as 
polymer erosion, which started to play a role after 10 weeks. 
In ciprofloxacin release, no further phase changes were observed after the change at the 
5-week time point. In rifampicin release, there was a further phase change seen at the 
time point of 17 weeks, where the mass loss of the composites also accelerated. The 
fourth phase of the release was governed by the diffusion and mass loss. 
During the time of in vitro tests, rifampicin release did not reach 100% cumulative 
release. The release decreased to a negligible level and part of the rifampicin still 
remained in the composites. In the literature, there is evidence about rifampicin being 
incorporated in the crystalline domains of poly-İ-caprolactone (Jones et al. 2011). This 
may also explain why part of the rifampicin antibiotic seemed to be trapped in the 
polymer matrix in the experiments carried out in this thesis. If the release test series 
would have been continued long enough to allow the crystalline domains of the polymer 
matrix to degrade, the rest of the rifampicin may also have been released. 
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When the released rifampicin and the amount of the rifampicin remaining in the 
composites were combined, the total amount of rifampicin did not reach 100% of the 
initial rifampicin. One reason for this was likely the instability of rifampicin in aqueous 
solutions and in the presence of atmospheric oxygen, which enables the rifampicin to be 
oxidized to rifampicin quinone and further to other products that do not have UV-
absorbance. Because the release test series was long, part of the rifampicin had time to 
oxidize to other products even though the measurements were done at short intervals. 
Additionally, it has been reported that rifampicin degrades more in solutions with a low 
rifampicin concentration (Jindal et al. 1995). Unfortunately, this affects the accuracy of 
this method. However, the method can be used to estimate the rifampicin release and 
compare the composites with each other. This may not, however, be such a problem in 
vivo, because possible in vivo stabilization has been reported by Le Guellec et al. (Le 
Guellec et al. 1997). In their study, rifampicin stability was better in rifampicin-
containing plasma samples taken from patients than in plasma samples where rifampicin 
was added in the laboratory. They suggest that rifampicin may be more stable in vivo 
than in vitro. This means that the stability problems encountered in laboratory 
conditions may not be an issue in implanted, rifampicin-delivering materials. 
With a non-eroding system, the drug release would slowly decrease as time goes on 
because the release is often proportional to the drug concentration in the device and to 
the diffusion path of the drug to the surface. In the case of a bioabsorbable system, the 
increased permeability and polymer erosion accelerate the release (Baker 1987). In our 
approach, the decline in the drug release was counterbalanced with the increased 
permeability of the composite matrix to allow drug release to continue at nearly the 
same rate as in the beginning of the release. In the beginning of the release, there was a 
burst, but as already mentioned above, it was moderate and thus is not considered 
unwanted, but optionally beneficial.  
6.4 Inhibition zone testing 
Bioluminescence imaging (BLI) has been used widely in research e.g. for stem cell 
differentiation (De Boer et al. 2006; Vilalta et al. 2009), vascularization (Gafni et al. 
2006; Zhang et al. 2004), apoptosis (De Boer et al. 2006), controlled release of genes 
(Peterson et al. 2009; Shin and Shea 2010), inflammation of tissue (Hanada and 
Yoshimura 2002), implant-related bacterial infections (Engelsman et al. 2009; 
Kadurugamuwa et al. 2003), and in osteomyelitis animal model (mouse) (Funao et al. 
2012). It can also be used to test the effect of antibiotic-releasing materials against 
osteomyelitis-causing bacteria in vitro. The method, using whole bacteria cells as 
biosensors, offers several advantages: it is easy to use, it is non-invasive, and it has high 
throughput and low costs (Close et al. 2011; De Boer et al. 2006). In the case of 
inhibition zone testing, the method provides more information than the conventional 
method because information on the bacteria and their reactions can be followed in real 
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time when exposed to the antibiotics. In this study, the effect of the ciprofloxacin and 
rifampicin-releasing composites was tested against two different model bacteria strains 
that were genetically engineered to emit light. The antibiotic-releasing materials for the 
bioluminescence testing were chosen based on the antibiotic release results. The most 
promising composites were the ones with 50 wt-% of ȕ-TCP for both of the antibiotics. 
Composites without antibiotics were used as controls in the bacterial cultures. The 
controls were noticed not to have any effect on the bacteria and shows that the PLCL 
copolymer and ȕ-TCP do not have antibacterial effects. Both of the antibiotic-releasing 
composites had an effect on the bacteria and generally the ciprofloxacin-releasing 
materials produced larger inhibition zones than the rifampicin-releasing materials. 
Ciprofloxacin-releasing composites also showed a smaller initial burst in the release and 
a slower development of the inhibition zone in the beginning of the bacterial culture. 
These effects correspond well with the in vitro antibiotic release results. The first signs 
of antibiotic activity were seen after four hours of incubation. The inhibition zones and 
the stress zones, which were shown as bright yellow and orange areas around the 
inhibition zones, reached maximum during the first twelve hours of incubation. No 
significant changes were noticed after that. The fast response of the bacteria to the 
antibiotic was due to the burst, which is very typical for these kinds of drug-releasing 
materials, and is caused by the release of the antibiotic molecules at or near the surface 
of the composite pellets.   
The results gained using bioluminescent bacteria show that the manufactured composite 
materials release the two antibiotics, ciprofloxacin and rifampicin, in levels high enough 
to eradicate common osteomyelitis-causing bacteria. 
In this study, the antibiotic-releasing composites were studied separately. It would be, 
however, important to study their synergistic effect against osteomyelitis-causing 
bacteria because they are intended to be used together. Rifampicin should never be used 
alone because of the rapid development of resistant bacterial strains that can result 
(Bliziotis et al. 2007; Perlroth et al. 2008). Additionally, the simultaneous 
administration of two or more antibiotics that have synergistic action is often used 
(Chusri et al. 2009; Mesak and Davies 2009). 
The method, using bioluminescent bacteria as sensors in inhibition zone testing, proved 
to be efficient in assessing the effects of antibiotics against the bacteria. It provides 
more information than that provided by conventional inhibition zone testing. We 
suggest that bioluminescent imaging can be used as an efficient tool in the product 
development phase of controlled antibiotic delivery materials preceding in vivo tests.  
  
88 
7 SUMMARY AND CONCLUSIONS 
Numerous research groups around the world have addressed the problems of local drug 
delivery and the local antibiotic treatment of osteomyelitis. However, only a few 
applications have so far reached the commercial stage. Today, osteomyelitis remains a 
disease that is problematic and expensive to treat and, additionally, is painful for the 
patient. A search for the perfect treatment protocol is still going on. 
In this study, promising composite materials for the treatment of osteomyelitis and other 
bone related infections were developed. The composites are bioabsorbable and release 
antibiotics to eradicate osteomyelitis-causing bacteria. Additionally, the composites 
include an osteoconductive component, ȕ-tricalcium phosphate. The in vitro release 
behavior of both of the studied antibiotics, ciprofloxacin and rifampicin, from the 
composites containing 50 wt-% of ȕ-tricalcium phosphate was found to be promising, 
despite that the behavior did not follow the ideal zero-order release. The release 
behavior of the two antibiotics was not identical. However, the release occurred in a 
comparable time scale and at a comparable rate. The release was continuous and 
ciprofloxacin was released in the time period of approximately 20 week; whereas the 
continuous rifampicin release lasted almost 25 weeks. 
Both antibiotics retained their original molecular structure through the processing and 
sterilization steps. Polymer was affected by the gamma-irradiation used in the 
sterilization and the molar weights were decreased, substantially. By utilizing 
genetically engineered bioluminescent bacteria, the effect of the released antibiotics 
from the most promising composites against the osteomyelitis-causing bacteria was 
shown. Moreover, the method of using bioluminescent bacteria in the inhibition zone 
tests was proven to be an efficient method. The method also gave more information on 
the reactions of the bacteria than conventional inhibition zone testing. 
ȕ-TCP did not have a considerable effect on the hydrolytic degradation behavior of any 
of the composites and nor did the antibiotics. The hydrolytic degradation of the polymer 
component proceeded very similarly, following first order kinetics, in all the studied 
composites, with and without antibiotics. 
The materials developed in this work offer great potential to be developed into material 
for the treatment of osteomyelitis and other bone related infections. The properties of 
the antibiotic-releasing composites show desirable drug release and degradation 
behavior and are also effective against osteomyelitis-causing bacteria. With these 
materials, osteomyelitis patients, who are going through surgical debridement of the 
infected tissue, could be treated in one stage instead of two stages, which is nowadays 
the standard method when non-biodegradable gentamycin releasing PMMA beads are 
used to eradicate the bacteria remaining in the tissue. Because every operation carries a 
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risk for the patient, reducing the number of surgical operations is beneficial. There is, 
however, need for the further development of these composite materials and in vivo 
studies to prove the efficacy of the materials also in a living organism. 
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1H NMR spectrum of pure rifampicin and PLCL+R 
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Abstract 
There is an increasing need for synthetic bone substitute materials that decrease the 
need  for  allografts  and  autografts.  In  this  study,  composites  of  ȕ-TCP  and  a  
biodegradable poly(L-lactide-co-İ-caprolactone) were manufactured using extrusion to 
form biodegradable composites with high ȕ-TCP contents for osteoconductivity. The 
hydrolytic degradation of the composites containing 0, 10, 20, 35 and 50% of ȕ-TCP 
was studied in vitro for 52 weeks. During the study, it was observed that ȕ-TCP did not 
have an effect on the degradation rate of the polymer matrix. However, the crystallinity 
of the materials increased throughout the test series and changes in Tgs were also 
observed as the comonomer ratio of the polymer matrix changed as the degradation 
proceeded. The results show that the materials have desirable degradation properties 
and, thus, possess great potential as bioabsorbable and osteoconductive bone filling 
materials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Due to the problems associated with autografts and allografts, there is an obvious need 
in orthopaedics for synthetic bone substitute materials that are easy to handle in surgical 
conditions and do not carry the risk of infection or suffer from limited availability (1). 
An optimal material that is biodegradable, bioactive, and easy to handle has not been 
found as yet. The currently available polymers or ceramics alone do not provide a 
sufficient solution to this problem. Numerous studies have been published where the 
properties of biodegradable polymers and bioceramics have been combined to form 
composites (2-5). Such composites have promising properties for use in the fabrication 
of scaffolds for bone tissue engineering applications (6,7). 
In order to overcome the problems of autografts and allografts, ȕ-tricalcium phosphate 
ȕ-TCP), a bioresorbable ceramic, is used as a bone graft substitute due to its 
osteoconductive properties (1,8). This material is clinically used, for example, as 
granules and blocks (9). ȕ-TCP has the same Ca/P ratio as the amorphous inorganic 
phase of bone (7) and does not dissolve as quickly as Į-TCP (9). According to Aunoble 
et al. (10), 60 wt-% of ȕ-TCP in poly-L-lactide is as active as plain ȕ-TCP with regard 
to osteogenesis. This fact supports the idea that composites combine the advantageous 
properties of biodegradable polymers and bioceramics. 
The mechanical and hydrolytic degradation properties of poly-İ-caprolactone and poly-
L-lactide are very different as homopolymers. Both polymers have proven 
biocompatibility and are Food and Drug Administration (FDA) approved for a wide 
range of applications in the biomedical field (11). Via the copolymerization of the 
monomers, lactide (D, L or DL), and İ-caprolactone, interesting properties can be 
 
 
 
 
achieved that combine the elasticity, good processability and drug releasing properties 
of poly-İ-caprolactone as well as mechanical properties and faster degradability via the 
hydrolysis of polylactides (11-18). 
Many groups have studied the composites of poly-İ-caprolactone or polylactide and 
various bioceramics (19-25). However, the reported research results of in vitro testing 
have usually concentrated on relatively short periods of time, often less than a month 
(22,26) or less than 26 weeks (4,21).  Reports of the studies performed on copolymers 
of lactide and İ-caprolactone can be found, but the majority of them concentrate on 
copolymers of D,L-lactide and İ-caprolactone or different comonomer ratios than the 
one reported in this study. 
In  this  study,  various  ratios  of  a  filler,  ȕ-tricalcium  phosphate,  and  a  bioabsorbable  
polymer, poly(L-lactide-co-İ-caprolactone) with the comonomer ratio of 70/30, were 
extrusion compounded in order to create a material that is biodegradable, 
osteoconductive and easy to handle. The properties as well as the potential of the 
composites for use as bone graft substitutes were examined in a long term in vitro test 
lasting  for  52  weeks.  Despite  the  fact  that  some  of  the  composites  had  high  ȕ-TCP  
content, they showed good processability and handling properties as well as promising 
degradation behaviour. Special attention will be paid in the report to the effect of 
various ȕ-TCP contents on the degradation of the composites. 
Materials and Methods 
Materials 
Medical grade poly(L-lactide-co-İ-caprolactone) with the comonomer ratio of 70/30  
and  initial  Mw of 229 000 g/mol was purchased from Purac Biomaterials (the 
 
 
 
 
Netherlands), and ȕ-tricalcium phosphate (granule size < 38 ȝm) was purchased from 
Plasma Biotal Ltd (United Kingdom). Sörensen buffer solution was prepared according 
to the standard ISO 15814 (27). The chemicals used for the buffer solution (Na2HPO4 
and KH2PO4) were purchased from J.T. Baker (the Netherlands). For the phosphate 
dissolution testing, Tris buffer solution was used and it was prepared using Tris Base 
Ultra Pure (C4H11NO3)  (ICN  Biomedicals,  USA)  and  Trizma  HCl  (C4H11NO3×HCl) 
(Sigma-Aldrich, Germany). Other chemicals used for the determination of phosphate 
release from the composites were ammoniumheptamolybdate (Merck, Germany), L(+)-
ascorbic acid (Merck, Germany), acetic acid (J.T. Baker, the Netherlands), sodium 
acetate (Merck, Germany) and sulphuric acid (J.T. Baker, the Netherlands). 
Processing 
Dried (72 h in vacuum at room temperature) polymer and ȕ-TCP powder were 
processed into rod-shaped billets with a diameter of approximately 2.5 mm with a co-
rotating custom-built intermeshing twin-screw extruder (L/D ratio = 22.5) in a nitrogen 
atmosphere. Temperature range in the extruder was 25-130 °C. PLCL copolymer and ȕ-
TCP were delivered in the process with separate gravimetric screw feeders and the 
mixing of the components took place in the extruder. Total feed rate of the components 
was 200g/h in all of the cases. A haul-off unit was used to guide the extrudate from the 
die  and  the  diameter  of  the  billets  was  fine-tuned  adjusting  the  speed  of  the  haul-off  
unit. Four different composites and a plain copolymer were processed. The ȕ-TCP-
contents of the composites were 10, 20, 35 and 50 wt-% and the composites are denoted 
as PLCL + 10% TCP, PLCL + 20% TCP, PLCL + 35% TCP, and PLCL + 50% TCP, 
respectively. Pellet shaped samples (length approximately 2.5 mm) were cut from the 
 
 
 
 
billets. Before degradation studies were carried out, the samples were packed and 
sterilized using gamma irradiation (minimum dose 25 kGy). 
In vitro procedure 
Degradation tests were conducted at 37°C in vitro following the standard ISO 15814 
(27). First, weighed test samples were placed in brown glass bottles with 20 ml 
Sörensen buffer solution. A test sample consisted of 15 pellets weighing approximately 
300 mg in total  and five parallel  test  samples were tested at  each time point.  Then the 
bottles  were  placed  in  a  shaking  bath  at  37°C.  The  pH  of  the  buffer  solution  was  
measured periodically with a calibrated pH meter and the buffer solutions were changed 
every two weeks in the beginning of the test series and once a week as the degradation 
accelerated. Test samples were withdrawn at predetermined time points of 2, 4, 6, 8, 10, 
12, 16, 20, 26, 39 and 52 weeks. 
Methods of analysis 
Residual monomer 
The determination of residual L-lactide and İ-caprolactone monomer contents was 
performed by Ramboll Analytics Oy (Lahti, Finland). The İ-caprolactone and L-lactide 
contents were measured after chloroform extraction of the samples using gas 
chromatography (DC8000, CE Instruments, Rodano, Italy) and an FI-detector after 
chloroform dilution. The measuring resolution was 0.02%. The monomer contents of 
the processed samples were analyzed from three time points in the processing batch. 
Two  parallel  samples  were  taken  from  the  beginning,  middle  and  the  end  of  the  
processing batch. Additionally, the monomer content of the raw material was measured. 
 
 
 
 
Molecular weights 
The molecular weights (number average, Mn,  and  weight  average,  Mw, molecular 
weights) and polydispersity values of the copolymer were determined at room 
temperature by size exclusion chromatography (SEC) (Waters Associates system 
equipped with a Waters 717plus autosampler, a Waters 510 HPLC solvent pump, four 
linear PL gel columns (104, 105, 103 and 100 Å) connected in series, and a Waters 2414 
differential refractometer). Chloroform (Riedel-de Haën AG, stabilized with 1% 
ethanol) was used as solvent and eluent. The samples were filtered through a 0.5 ȝm 
Millex SR filter. The injected volume was 200 ȝl and the flow rate was 1.0 ml/min. 
Monodisperse polystyrene standards were used for primary calibration. Two parallel 
samples were analyzed at each time point. 
Mass loss and water absorption 
After the test samples were withdrawn from the shaking bath, they were rinsed twice 
with distilled water and the surfaces of the pellets were carefully wiped with tissue 
paper. The test samples were weighed immediately after wiping. The test samples were 
dried for at least three days at ambient conditions and for one week in vacuum. After 
vacuum drying, the test samples were weighed again to obtain the dry masses. Dried test 
samples were stored in a desiccator for further analysis. 
The mass loss was calculated as the difference between the mass of the initial test 
sample and the mass of the dried test sample divided by the initial mass of the test 
sample. The water absorption was calculated as the difference between the mass of the 
wet test sample and the mass of the dried test sample divided by the mass of the dried 
test sample. 
 
 
 
 
Thermal properties 
Thermal analysis was performed using DSC Q1000 differential scanning calorimeter 
(TA Instruments,  Delaware,  USA). To ensure similar thermal histories of the samples,  
they were heated twice and cooled rapidly in between. The heating rate was 20 °C/min, 
the cooling rate 50 °C/min, and the temperature range was -60 °C to +200 °C. Nitrogen 
was used as the sweeping gas. The results were analyzed using Universal Analysis 
Software. Second heating cycle was used for the analysis of glass transition 
temperatures (Tg)  and first  heating cycle for the analysis of melting temperatures (Tm) 
and enthalpies (ǻHf). Five parallel samples were tested for each material and time point. 
Averages and standard deviations were then calculated. 
Ceramic content and dissolution 
The ȕ-TCP content of the test samples was measured using thermogravimetric analysis 
(TGA Q500 (TA Instruments, Delaware, USA)). Approximately 20 mg of a sample was 
used and the samples were heated at a rate of 20°C/min up to 700°C. Five parallel 
samples were tested at each time point, and the results were then analyzed using 
Universal Analysis Software. 
The dissolution of phosphate ions from the composites was measured using a method 
described in ISO 6878 (28). In this method, the orthophosphate ions that have been 
dissolved in the buffer solution form an ammonium phosphomolybdate complex in 
acidic solution. This complex is then reduced by ascorbic acid into a blue complex. The 
absorbance of the complex was measured using a Unicam UV 500 spectometer 
(ThermoSpectronic, Cambridge, United Kingdom) at the wavelength of 700 nm. Five 
parallel samples of each composite weighing about 250-300 mg were tested once a 
week  up  to  48  weeks.  Plain  PLCL  was  used  as  a  negative  control  and  plain  ȕ-TCP  
 
 
 
 
samples weighing about 160 mg were tested as positive controls. Concentrations of the 
released phosphate ions were calculated with the help of a standard curve prepared with 
known concentrations of phosphate ions. 
Molecular structure 
The proton spectra of the samples were measured using a Varian Mercury 300 MHz 
NMR Spectrometer (Varian Associates Inc., Palo Alto, California, USA) at room 
temperature. Tetramethylsilane (TMS) was used as an internal standard, and chemical 
shifts were measured relative to TMS. The 1H NMR spectra were measured at room 
temperature in standard 5 mm tubes in deuterochloroform. The data were gathered until 
the quality of the spectrum was sufficient,  and the number of scans was 190-300. The 
proton NMR spectra of the samples were processed and analyzed using SpinWorks 3.1 
software. Phase correction and baseline correction were applied to all spectra. 
Information on the molecular composition and the comonomer ratio of the copolymer 
was obtained. 
Microstructure of the samples 
The microstructure of the composites was observed using scanning electron microscopy 
(Philips XL-30 SEM equipped with a LaB6 filament with SE and BSE detectors, 
Philips, the Netherlands) with an acceleration voltage of 12.0 kV.  The micrographs 
were taken both on the surface of the samples and on cryogenically fractured samples 
that were coated with gold (Edwards S150 Sputter Coater) prior to microstructure 
examination. An Energy Dispersive X-ray Spectrometer (Edax DX4 and eDXi 
software) was used to analyze the composition of the surfaces of the samples. 
 
 
 
 
The structure of the materials was also studied using micro-computed tomography (µ-
CT),  which  is  an  efficient  way  to  do  non-destructive  analysis  of  the  structure.  In  this  
study,  µ-CT  imaging  was  employed  to  analyse  pores  inside  the  material.  All  the  
imagings  were  done  by  MicroXCT-400 (Xradia,  Pleasanton,  CA,  USA)  and  the  same 
imaging parameters were applied for every sample. 40 kV as source voltage was used 
and 150 µA as source current. The isometric voxel size was 2.2 µm. No filters were 
utilized. Reconstruction was done by using Xradia’s XMReconstructor software. 
Images were segmented by manual thresholding using ImageJ (U.S. National Institutes 
of Health, Bethesda, Maryland, U.S.A). The same software was used for the analysis.  
Results and discussion 
The effects of processing and sterilization on the materials 
Processing using the twin-screw extruder degraded the matrix polymer only slightly. 
The average weight average molecular weight (Mw)  of  the  raw  material  was   
229 000 g/mol and after processing the Mw was 227 000 g/mol. However, the 
sterilization using gamma irradiation with the measured dose of 28.7-34.0 kGy, caused 
significant degradation. The Mw of the plain, processed polymer decreased 14% and the 
Mn decreased 29% during sterilization. The Mw of the composites decreased 18-29% 
and  Mn 31-43% with a tendency that gamma irradiation caused more degradation to 
those composites with higher ȕ-TCP contents There is almost linear dependency of the 
percentual decrease in the molecular weights versus the ȕ-TCP content in the samples, 
which is shown Figure 1. This may be attributed to the hydrophilicity of the ȕ-TCP 
which may have caused slight water absorption to the material as it was not stored in 
totally dry conditions before sterilization. As a result, the composites with higher ȕ-TCP 
content may have absorbed more water and thus were more degraded during 
 
 
 
 
sterilization. It has also been suggested that gamma irradiation may cause not only chain 
scission in the polymer chains but also cross-linking for pure poly-İ-caprolactone (29). 
This  would  have  been  seen  as  a  drop  in  the  Mn and an increase in the Mw of  the  
polymer. This kind of effect was not observed in this study. Gamma-irradiation caused a 
significant decrease both in number average and weight average molecular weights. 
This effect is well known on biodegradable polymers and is caused by the chain-
scission of the polymer chain due to high energy gamma irradiation (30) It has been 
reported by other authors as well (31,32). 
 
Figure 1. Decrease in weight average molecular weight (Mw) and number average 
molecular weight (Mn) during the sterilization step. 
For the raw material, the residual monomer contents were 0.08 wt-% for the L-lactide 
monomer and below detection limit (<0.02 wt%) for the İ-caprolactone monomer. No 
increase was seen in the content of either monomer during the processing event which 
indicates that the polymer did not decrease during processing and thus no monomers 
were generated during processing. Because there were no differences in the monomer 
 
 
 
 
contents of any of the manufactured materials, it can be assumed that the monomers did 
not cause differences in the hydrolytic degradation behaviour of the studied composites. 
(32). 
In vitro degradation of the materials 
Molecular structure 
1H NMR spectra were measured from five samples (PLCL raw material, PLCL 26 
weeks in vitro, PLCL 52 weeks in vitro, PLCL + 50% TCP 26 weeks in vitro and PLCL 
+ 50% TCP 52 weeks in vitro). The 1H NMR spectrum of plain PLCL raw material and 
the  assignment  of  the  signals  is  presented  in  Figure  2.  The  signal  of  the  -CH  group  
proton of the lactide comonomer appeared at į 5.16 as a multiplet. The signals of 
methyl protons of lactide and the aliphatic protons of caprolactone units (į 0.5-1.8) were 
overlapping with each other and accurate integration of the peaks was not possible, and 
they were not included in the calculations. The most informative signals were the 
signals of the Į-oxy methylene protons of the İ-caprolactone comonomer that appeared 
at į 4.05-4.13 and were clearly split into two signals according to the position in the 
polymer chain. The triplet at į 4.13 indicated the CH2 group in the İ-caprolactone 
fragment bonded to an L-lactide unit and the broader multiplet at į 4.05 indicates the Į-
oxy methylene group bonded to another İ-caprolactone unit. (33, 34) Additionally, the 
signal  at  į 2.3-2.4  that  corresponds  to  the  signal  of  the  methylene  proton  of  the  İ-
caprolactone that is bonded to the carbonyl group was split the same way. The triplet at 
į 2.4 indicates a group bonded to a L-lactide group and the broader multiplet  at  į 2.3 
corresponds to a group that is bonded to another İ-caprolactone group (33, 34). 
 
 
 
 
 
Figure 2. 1H NMR spectrum of the raw material poly(L-lactide-co-İ-caprolactone). 
The NMR results showed that the ratio of integrals for these two signals, and therefore 
the comonomer ratio, changed as the hydrolysis proceeded. The ratio of lactide to 
caprolactone (LA/CL) was increased from the initial proportion of the raw material 
68/32 to 80/20 for the plain copolymer at 52 weeks and 75/25 for the composite 
containing 50% ȕ-TCP at 52 weeks of hydrolysis. The comonomer ratios are presented 
in Table 1. The results of NMR measurements also demonstrated that the presence of ȕ-
TCP in the composite slowed down the change in the comonomer ratio. The change in 
the comonomer ratio of a copolymer of L-lactide and İ-caprolactone has also been 
observed by Jeong et al. (33). They suggested that the amorphous regions of the 
copolymer contain more caprolactone and are more easily attacked by water as water 
diffuses first into the amorphous regions of the polymer. Additionally, they found that 
the degradation and increase in the comonomer ratio LA/CL were slightly accelerated in 
vivo. The results of our studies indicate that although ȕ-TCP does not affect the 
 
 
 
 
degradation of the copolymer in a way that could be seen in the SEC measurements, it 
has an effect on which ester bonds the breaking of the polymer chain preferably occurs. 
Table 1. Results of the 1H NMR analysis. 
 
Because the properties of copolymers do not only depend on the comonomer 
composition but also on the distribution of the comonomers in the polymer chains, 
analysis of the microstructure of the polymer was also needed (35, 34). According to the 
text by Herbert (35), the number average sequence lengths of the comonomers can be 
calculated using Equations 1 and 2  
෤݊௅஺ = ଶሺ௅஺)ሺ௅஺ି஼௅)  (1) 
෤݊஼௅ = ଶሺ஼௅)ሺ௅஺ି஼௅)  (2) 
where (LA) and (CL) are the molar fractions of the L-lactide and İ-caprolactone 
comonomers in the copolymer and (LA-CL) is the average dyad relative fraction, which 
can be calculated from the 1H  NMR  data  of  the  copolymer.  The  calculation  is  well  
explained in an article by Fernández (34). Additionally the randomness factor, R, can be 
calculated using the Equation 3 
 
 
 
 
ܴ = (௅஺ି஼௅)
ଶ(௅஺)(஼௅)  (3) 
The randomness factor is 1 for a random copolymer and 0 for a block copolymer (34). 
The results of the average sequence length calculations and the randomness factor are 
presented in Table 1. 
First  of  all,  the  results  show  that  the  copolymer  is  rather  blocky,  having  R  values  
between 0.18-0.26, whereas the totally random copolymer would show the R value of 1. 
Randomness of the copolymers of lactides and İ-caprolactone are greatly affected by 
the polymerization conditions and depends on the polymerization temperature and time 
(13,15,30).  
The randomness of the studied copolymer samples is decreased as the degradation 
proceeds. The average sequence lengths of the comonomers show that L-lactide tends to 
form long blocks. The notable increase in the average sequence length of the L-lactide 
comonomer as the degradation proceeds shows that the shorter blocks of the L-lactide 
are removed from the polymer chains as the copolymer is hydrolytically degraded. 
There is also a slight increase in the İ-caprolactone sequence length as the degradation 
proceeds, which indicates that the sequence length is not much affected by the 
hydrolytic degradation although the İ-caprolactone comonomer fraction in the 
copolymer is decreased. 
The decrease of the randomness factor also supports the conclusion that the random 
parts of the copolymer are removed from the structure and more blocky structures 
remain as the degradation proceeds. In conclusion, the 1H NMR analysis shows that the 
copolymer is blocky having some random parts in the structure but the random parts are 
removed as the hydrolytic degradation proceeds and the blocky characteristic of the 
 
 
 
 
copolymer is increased. The bonds between the L-lactide and İ-caprolactone 
comonomers are most susceptible to hydrolytic degradation in this studied copolymer.  
Molecular weights 
The degradation of the composites was tested in Sörensen buffer solution, in vitro at 
37°C  and  pH  7.4.  The  decrease  of  the  molecular  weights  (both  Mw and  Mn)  of  the  
polymer matrix was rapid for the plain copolymer and for all the composites and obeys 
the first order kinetics with the degradation rate constants of 1.4Â10-3-1.7Â10-3 1/h. 
Although there were small differences in the molecular weights of the polymer matrix at 
the beginning of the hydrolysis test series, the degradation proceeded in all the 
composites following the same trend. There were no significant differences in the 
degradation behaviour during the 52-week test series between the different composites. 
The  same  kind  of  result  was  recently  reported  by  Daculsi  et  al.  (31)  who  studied  
composites of poly(96L/4D)lactide and ȕ-TCP with ȕ-TCP contents of 0, 10, and 24 wt-
%. In our study, the Mn of all the composites had already decreased approximately 96% 
of the initial value of the raw material after 20 weeks of hydrolysis at 37°C in pH 7.4. 
After 52 weeks, the decrease was 99%. The Mn values of the samples as a function of 
time in vitro up to 20 weeks are presented in Figure 3. The rapid decrease of molecular 
weights is typically caused by random scission of the hydrolytically labile ester bonds 
of the polymer backbone. This happens first in the amorphous parts of the polymer. (36) 
 
 
 
 
 
Figure 3. The number average molecular weight (Mn)  of  the  composites  of  poly(L-
lactide-co-e-caprolactone) (PLCL) 70/30 and ȕ-tricalcium phosphate (ȕ-TCP) as a 
function of time in vitro (n=2).  
The SEC distribution plots showed bimodality after 20 weeks for all the composites and 
the plain copolymer except for the samples with 10 wt-% of initial ȕ-TCP content that 
showed  emerging  bimodality  at  the  time  point  of  39  weeks.  An  example  of  the  
emerging bimodality is shown in Figure 4, where 20, 26 and 39-week SEC results of 
PLCL + TCP 20% are shown.  
Bimodality in the SEC distribution curve can be explained with the blocky structure of 
the copolymer, which is pronounced as the hydrolysis proceeds. The 1H NMR analysis 
of  the  plain  copolymer  and  PLCL  +  50%  TCP  showed  that  the  copolymer  is  rather  
blocky and the random parts are degrading first. This might cause an increase in a 
certain  part  of  the  SEC distribution  curve  as  the  blocky parts  consisting  mainly  of  L-
lactide  monomers  remain  in  the  copolymer  and  the  amount  of  other  parts  in  the  
copolymer is decreased. 
 
 
 
 
 
Figure 4. An example of the development of the bimodality in the size exclusion 
chromatography curves. The samples were poly(L-lactide-co-İ-caprolactone) (PLCL) + 
20% tricalcium phosphate (TCP) at 20, 26 and 39 weeks. 
Bimodality is often explained by the autocatalytic effect in the inner parts of the 
polymer (31,36-38), but it is not likely in this case because of the porous structure of the 
composites induced by the ȕ-TCP granules in the structure, which enables the short 
chain degradation products to escape from the inner parts on the samples and thus do 
not catalyse the degradation reaction. 
The polydispersity of the polymer matrix changed as the hydrolytic degradation 
proceeded (Figure 5). These changes are typical in the hydrolysis of biodegradable 
polymers. First, the molecular weight distribution was narrowed because chain scission 
reduced the number of long polymer chains. After reaching the lowest values at the 8-
week time point, the molecular weight distribution widened because of the introduction 
of short polymer chains resulting from the chain scission. PD reached the highest value 
 
 
 
 
at the time point of 12 weeks (1.8-2.7) and started to decrease again as the short 
molecular chains were short enough to be dissolved into the surrounding fluid.  
 
Figure 5. Development of the polydispersity of the poly(L-lactide-co-İ-caprolactone) 
(PLCL) during hydrolytic degradation of composites of PLCL and ȕ-tricalcium 
phosphate (TCP). 
Mass loss, water absorption and ȕ-TCP content of the materials 
The mass loss of the tested materials as a function of time in vitro is presented in Figure 
6  along  with  the  water  absorption  results.  The  mass  loss  of  the  plain  copolymer  was  
fastest and the mass loss of the composite containing 50% of ȕ-TCP was slowest. This 
is because the polymer degrades and disappears from the composites and ȕ-TCP 
dissolves slower than the polymer phase. This result is also supported by the phosphate 
dissolution test series, where very slow dissolution of ȕ-TCP was observed. The results 
are shown in Figure 7 as cumulative dissolution of the phosphate ions. The maximum 
values of 1000-2500 ȝg of ȕ-TCP at 52 weeks correspond to less than 10 wt-% of the 
total amount of ȕ-TCP in the samples. 
 
 
 
 
 
Figure 6. Mass loss and water absorption of the composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) seen as gained weight as a 
function of time in vitro. 
 
Figure 7. Dissolution of ȕ-tricalcium phosphate (TCP) from the composites of poly(L-
lactide-co-İ-caprolactone) (PLCL) and TCP. Plain PLCL was used as a negative and 
plain TCP as a positive control. 
 
 
 
 
From the ȕ-TCP content analysis, it can be seen that the increase in the ȕ-TCP-content 
of the test samples started at the same time as the mass loss of the samples (i.e. after 10 
weeks in hydrolysis) (Figure 8). At this time point, the Mw of  the  polymer  had  
decreased to a level of 12000-15000 g/mol and the Mn to a level of 4000-9000 g/mol, 
which apparently enabled the start of mass loss. In earlier studies, (37) the mass loss of 
pure poly-İ-caprolactone had begun when the Mw had  decreased  to  a  level  of  5000  
g/mol and for pure poly-DL-lactide to a level of 15 000 g/mol. 
 
Figure 8.  ȕ-tricalcium phosphate (TCP)-contents of the composites of poly(L-lactide-
co-İ-caprolactone) (PLCL) and TCP as a function of time in vitro. Results shown as 
averages with standard deviations (n=5). 
 
 
 
 
 
The increase in ȕ-TCP content of the composites was very clear and the fact that 
polymer degraded and was lost from the composites may be beneficial in the desired 
end application of this kind of composite material. ȕ-TCP is left in the bone cavity and 
as it is known to be an osteoconductive material (1), it may enhance bone ingrowth and 
healing. 
When only the polymer component in the composites was considered, the mass loss was 
slightly decelerated by increasing ȕ-TCP content. At the time point of 52 weeks, the 
mass  loss  of  the  polymer  component  of  the  composites  was  62% for  plain  PLCL and 
57% for the composite containing 50 % ȕ-TCP. The mass losses of the polymer 
composites containing 10-35% of ȕ-TCP fell between these values. 
Water absorption, which indicates the hydrophilicity of the material, of all the tested 
samples was small  during the first  ten weeks in vitro (Figure 6).  It  is  well  known that 
water diffuses first into the amorphous parts of the polymer and causes degradation. 
(30).  The composites containing ȕ-TCP showed greater water absorption than the pure 
copolymer  in  the  first  12  weeks  of  the  test  series,  after  which  the  behaviour  was  
changed. The water absorption of the plain polymer increased rapidly and at 20 weeks 
the  water  absorption  of  the  plain  polymer  was  already  over  60  wt-%.  After  this  time  
point, the wet masses of the plain polymer test samples were not measurable anymore. 
From the  12-week time point  on,  the  water  absorption  of  the  composites  with  high  ȕ-
TCP contents was less than for the composites with low ȕ-TCP contents. The wet 
masses of the composites were measurable up to 26 weeks. Since TCP is hydrophilic, 
the composites with high ȕ-TCP contents absorbed more water in the beginning of the 
in vitro time than pure polymer or the composites with less ȕ-TCP. When the polymer 
 
 
 
 
degradation had proceeded to a certain level i.e. the polymer chain scission had reached 
the point when mass loss is possible and there were more hydrophilic end groups of the 
polymer, the water absorption behaviour changed and the composites with no or little ȕ-
TCP absorbed more water. 
Changes in pH of the buffer solution 
The pH-values of the buffer solution in the in vitro test series were measured 
periodically and the buffer solution was changed (20 ml) every two weeks at the 
beginning of the test series. once a week after 10 weeks, and twice a week after the time 
point of 16 weeks. The pH mainly retained values between 7.2-7.5 and the pH was very 
stable in the first weeks of the test series. The results of the pH measurements are 
presented in Figure 9. A significant decrease in the pH-values was observed from the 
10th week  to  the  19th week  of  the  test  series.  At  the  10-week  time  point,  the  Mw had 
decreased to a level of 12 000 - 15 000 g/mol for all the composites and the plain 
copolymer and mass loss started. This was seen as the decrease in the pH values 
because the acidic degradation products of the polymer degradation were released to the 
hydrolysis medium. Throughout the in vitro test  series,  a  tendency  of  increasing  pH-
value towards the composites with higher ȕ-TCP contents was observed. This is likely 
due to the buffering effect of the ȕ-TCP that has also been observed earlier by other 
authors (39,40). 
 
 
 
 
 
Figure 9. Results  of  the  pH  measurements  in  the  in vitro degradation test series of 
composites of poly(L-lactide-co-İ-caprolactone) (PLCL) and ȕ-tricalcium phosphate 
(TCP). 
Bernstein et al. (3) reported results where composites of nanosized tricalcium phosphate 
and polycaprolactone with very high ȕ-TCP contents (85 vol-% and 95 vol-%) showed 
the same kind of dissolution behaviour as pure ȕ-TCP. They also proposed that ȕ-TCP 
may enhance the hydrolytic degradation of polycaprolactone due to the increased 
hydrophilicity. On the other hand, a buffering effect of the dissolution products of ȕ-
TCP against the acidic degradation products of the polymer has been proposed (39,40). 
This would lead to the slower degradation of the polymer component in the composite. 
These two factors work in opposite ways and, if simultaneous, their overall effect on the 
degradation may be evened out. In this study, no significant differences in the 
hydrolytic degradation behaviour of the studied composites compared with the plain 
poly(L-lactide-co-caprolactone) copolymer were observed.  
 
 
 
 
Thermal properties 
Tg,  Tm and ǻHf were measured using a differential scanning calorimeter (DSC) at a 
temperature range from -60°C to 200°C with a 20°C/min heating rate. The Tgs  of  the  
raw material determined during the first and second heating were 15°C and 23°C 
respectively. This corresponds quite well with the results of Ragaert et al. for the same 
commercial polymer (41). After processing, the Tgs (obtained from the second heating) 
of  all  the  composites  and  the  pure  copolymer  were  between  21°C  and  22°C.  DSC  
analysis revealed changes in the Tg as the hydrolysis proceeded. This can be seen in 
Figure 10, where the values from the second heating cycle are presented. The Tg started 
to decrease in the beginning of the in vitro test series and reached the lowest values at 
the 12-week time point (9°C – 14°C). During the same time period, the molecular 
weights of the samples decreased rapidly and this had a decreasing effect on the Tg. 
After 12 weeks, the Tgs started to increase and ended up at 34°C for the pure copolymer 
and at around 30-33°C for the composites at the 52-week time point. The Tgs  of  the  
samples were detectable only on the second heating scan from the 16-week time point 
on. At this point, the degradation of the polymers had proceeded to Mws of less than 10 
000 g/mol. The 1H NMR results showed that the caprolactone monomers disappeared 
from the copolymer as the hydrolysis went on and, therefore, L-lactide content 
increased. It is well known that the Tg is dependent on the comonomer composition of 
the copolymer. In the case of copolymers of lactide and İ-caprolactone, the Tg increases 
as the lactide content in the copolymer increases (42). The change in the Tg is 
significant even in small increments in the lactide content. 
 
 
 
 
 
Figure 10. Glass transition temperatures (Tg) of composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) as a function of time in vitro. 
Results shown as averages with standard deviations (n=5). 
Tms and ǻHfs  were  analyzed  from  the  first  heating  of  the  samples.  This  was  done  
because during the second heating the melting peaks did not appear anymore due to the 
fast cooling in the DSC analysis in which the polymer solidifies to an amorphous 
structure. The samples showed bimodality in the melting peaks from the 6-week time 
point on and the bimodality was seen especially clearly in the samples from the 16-week 
time point  on  until  the  39-week time point.  This  can  be  due  to  two different  kinds  of  
crystals in the sample (43). More probable reason for this according to Sarasua et al. 
(43) is the annealing during DSC scan, where imperfect crystals might have time to melt 
and recrystallize and then melt again in a few degrees higher temperature. It was 
observed that the melting temperatures increased from the 111-113°C at the 2-week 
time point to 116-120°C at the 16-week time point. After this, the melting temperatures 
decreased constantly and they were 107-110°C at the 52-week time point.  
 
 
 
 
Increasing melting enthalpies were recorded throughout the test series (Figure 11). The 
values were corrected to correspond to the polymer portion of the samples. They 
indicated increasing crystallinity as the amorphous parts of the polymer are the first to 
degrade. Also, the fact that shorter polymer chains can more easily rearrange themselves 
into crystals has an effect on the increasing crystallinity. The increase in crystallinity 
was largest in the plain copolymer and lowest in the composite containing 50 % of ȕ-
TCP. Absolute crystallinity values were not calculated because the theoretical value of 
100% crystalline poly(L-lactide-co-İ-caprolactone) 70/30 was not available. It has been 
reported that the sequence length of 14 is required for lactides to be able to crystallize 
(43).  Additionally,  it  has  also  been  suggested  that  in  a  copolymer  of  L-lactide  and  İ-
caprolactone, only the L-lactide is able to form crystals. These factors also explain the 
increasing crystallinity as the L-lactide fraction in the copolymer is increased during in 
vitro degradation. 
 
 
 
 
 
 
 
Figure 11. Melting  enthalpies  (ǻHf) of the composites of poly(L-lactide-co-İ-
caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) as a function of time in vitro. 
Results shown as averages with standard deviations (n=5). 
Microstucture 
SEM micrographs, which were taken both on the surface of the samples and on 
cryogenically fractured samples, showed some porosity in all the samples. The 
micrographs of the surface and cross section of composites containing 50% ȕ-TCP are 
shown in Figure 12. The appearance of the composites changed when the hydrolysis 
proceeded and the formation of smaller pores was observed. The majority of the pores 
were however smaller than 100 ȝm, and according to the literature, this is not enough to 
enhance bone ingrowth (44). 
 
 
 
 
 
Figure 12. Scanning electron microscopy (SEM) micrographs of the composites of 
poly(L-lactide-co-İ-caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) containing 
50 wt-% of TCP. (A) surface at 0 weeks, (B) cross section at 0 weeks, (C) surface at 26 
weeks, (D) cross section at 26 weeks, (E) surface at 52 weeks and (F) cross section at 52 
weeks (E and F are at higher magnification). 
The  porosity  of  the  samples  containing  50  %  of  ȕ-TCP  (at  0,  26  and  52  weeks)  was  
additionally imaged using ȝ-CT. Examples of the imaging are shown as Figure 13. The 
analysis showed surprisingly that the porosity decreased in the samples during 
 
 
 
 
hydrolysis test series. The porosity analysis results are presented as Table 2. Overall, the 
pore sizes and the porosity values were very small. Additionally, the pores were 
generally not interconnected. There may however reside an artefact in this analysis, 
because the samples were imaged dry. If the imaging would have been done wet, right 
after the samples were withdrawn from the incubator shaker, the results might have 
been different, because the samples may shrink during drying.  
 
Figure 13. Micro-computed tomography (ȝ-CT) imaging of samples of poly(L-lactide-
co-İ-caprolactone) (PLCL) and ȕ-tricalcium phosphate (TCP) containing 50% of TCP at 
0 weeks (left), 26 weeks (middle), and 52 weeks (right). 
Table 2. Results of the porosity analysis 
 
 
 
 
 
The  EDS  analysis  was  performed  both  on  the  outer  surfaces  of  the  samples  and  the  
cryogenically fractured surfaces of the samples. It showed that there were no significant 
differences  in  the  Ca/P  ratio  of  the  ȕ-TCP.  If  ȕ-TCP  was  dissolved  and  precipitated  
again as hydroxyapatite, the Ca/P molar ratio would have increased (it is initially 1.67 
for hydroxyapatite and 1.5 for ȕ-TCP) (1). However, this was not seen in the results of 
the EDS analysis. It should be noted that Sörensen phosphate buffer solution was used 
in our study, and bioactivity studies are usually performed using simulated body fluid as 
the buffer solution (26).  Similar kinds of composites comprising poly-Į-hydroxy acids 
and ȕ-TCP have been reported to show bioactivity that has been observed as the 
formation of hydroxyapatite on the surface of the composites when simulated body fluid 
has been used in in vitro studies as the buffer solution (2,3,26). 
There  were  also  very  small  amounts  of  sodium  and  potassium  present  in  the  samples  
that had been in hydrolysis for over 26 weeks. Na and K ions are present in the 
Sörensen phosphate buffer solution and have most likely not been totally washed from 
the samples during the rinsing of the samples with distilled water before drying. 
Conclusions 
Composites of poly(L-lactide-co-İ-caprolactone) with an initial comonomer ratio of 
70/30 and ȕ-tricalcium phosphate were studied in a long-term in vitro test series for up 
to 52 weeks. The degradation was studied and the effect of ȕ-TCP on the degradation of 
the composites was evaluated using various analysis methods. 
ȕ-TCP had only a slight effect on the degradation properties of the composites studied 
and the effect on the degradation properties was mainly seen in the water absorption 
behaviour,  as  ȕ-TCP  dissolution  was  very  slow  in  comparison  with  the  copolymer  
 
 
 
 
degradation. Mass loss and water absorption behaviour were significantly changed at 12 
weeks in vitro. At this point, the molecular weight of the polymer had decreased to a 
level that enables mass loss.  
Although the degradation of the tested composites proceeded similarly, there was a 
slight buffering effect of ȕ-TCP seen throughout the in vitro test series in the pH values 
of the hydrolysis medium. The effect of ȕ-TCP on the degradation was also seen in 1H 
NMR analysis. It showed that the presence of ȕ-TCP in the composites decelerated the 
change in the comonomer ratio as the hydrolysis proceeded. Additionally, the 
copolymer was noticed to have rather blocky structure, where the more amorphous parts 
degraded first leaving crystalline parts consisting mainly of L-lactide blocks in the 
structure.  
For the end use in bone applications, it is desirable that the polymer degrades relatively 
quickly, leaving the ȕ-TCP-particles behind to promote bone healing. The results 
presented here show that the ȕ-TCP content of the tested materials was constantly 
increased throughout the in vitro test series. Additionally, it was shown that even high 
ȕ-TCP contents can be compounded in the poly(L-lactide-co-İ-caprolactone) 70/30 
copolymer without significant effect on the degradation of the polymer. These 
composite materials show good processability, handling properties, and potential to be 
used as bone filling materials. In addition, the processing method is easy to scale up to 
commercial scale. 
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Introduction
The objective of this work was to develop ciprofloxacin releasing 
and bioabsorbable bone defect filler material that also contains 
a ceramic component to aid bone healing. In this study, the in 
vitro drug release and degradation behavior of biodegradable cip-
rofloxacin releasing bone filling material, which has high β-TCP 
content of up to 60 wt%, for enhanced osteoconductivity, was 
investigated. Additionally, the effect of the released antibiotic 
against a common osteomyelitis causing bacteria Pseudomonas 
aeruginosa was tested using the bioluminescence method. The 
required length of the controlled antibiotic delivery is from three 
to six months. This length of time is considered adequate in the 
treatment of osteomyelitis.1 Furthermore, the degradation of the 
fillers should occur within a similar time frame.
Osteomyelitis is a severe complication that is challenging to 
treat. It is caused by bacteria, commonly Staphylococcus aureus, 
Pseudomonas aeruginosa or Staphylococcus epidermidis and leads 
to bone destruction.2 Traditionally, osteomyelitis is treated by 
Osteomyelitis is a bacterial disease that can become chronic, and treatment often includes a surgical operation to remove 
infected bone. The aim of this study was to develop and investigate in vitro bone filling composite materials that release 
ciprofloxacin to kill any remaining bacteria and contain bioceramic to help the bone to heal. Three composites of poly(L-
lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin were compounded using twin-screw extrusion and 
sterilized by gamma irradiation. Drug release and degradation of the composites were investigated in vitro for 52 weeks. 
The composite with 50 wt% of β-Tcp had the most promising ciprofloxacin release profile. The ceramic component 
accelerated the drug release that occurred in three phases obeying first-order kinetics. Inhibition zone testing using 
bioluminescence showed that the released ciprofloxacin had effect in eradicating a common osteomyelitis causing 
bacteria Pseudomonas aeruginosa. During the in vitro degradation test series, molar weight of the polymer matrix of 
the composites decreased rapidly. Additionally, 1h-NMR analysis showed that the polymer had blocky structure and the 
comonomer ratio changed during hydrolysis. The tested composites showed great potential to be developed into bone 
filler materials for the treatment of osteomyelitis or other bone related infections.
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surgical debridement of the infected tissues followed by a long 
course of intravenous or parenteral antibiotics.3-6 Fractures, espe-
cially open ones, implant surfaces, and external fracture fixations 
are examples of situations that are known to enhance bacterial 
adhesion. These conditions, if left untreated, may lead to a bio-
film formation and osteomyelitis. These problems have been 
addressed in numerous reviews.7-9
The surgical debridement of the infected bone in the treating 
of osteomyelitis creates a defect in the bone called a dead space. 
Because bacteria may remain in the surrounding tissues, antibiot-
ics are also needed in the treatment. Adequate concentrations of 
the antibiotic on the site of the dead space are difficult to achieve 
due to the poor circulation of blood in the infected bone tissue. 
Local delivery of the antibiotics provides an efficient way of deliv-
ering the drug in situ and achieving therapeutic levels of the drug. 
One of the greatest advantages in local drug therapy is that sys-
temic adverse effects are avoided.10,11 The challenge is to keep the 
drug concentration at the therapeutic level and not to exceed toxic 
levels. Previous studies have shown that with local treatment, the 
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ε-caprolactone monomer contents of the processed samples were 
analyzed from two parallel samples of each manufactured com-
posite and the amounts of both monomers were very low. The 
average L-lactide monomer content after processing was 0.05-
mol% and caprolactone monomer content below 0.02-mol%. 
This indicates that no monomers were generated during process-
ing in any of the studied composites. Because there were no dif-
ferences in the monomer contents of the manufactured materials, 
it can be assumed that the monomers did not cause differences in 
the hydrolytic degradation behavior of the studied composites.25
Drug release from the materials. The initial ciprofloxa-
cin contents of the composites were measured as 7.0 ± 0.4 
wt% for PLCL + C, 8.1 ± 0.1 wt% for PLCL + TCP50 + C, 
and 7.5 ± 0.2 wt% for PLCL + TCP60 + C. The cumulative 
ciprofloxacin release from the studied materials is presented as 
Figure 1A, where the release occurring in three phases can be 
noticed. The first phase was the burst in the beginning of the 
drug release that lasted for one day. This is the phase when the 
drug molecules at the surface or near the surface are released.27,31 
Although initial burst, which is typical for drug releasing poly-
meric materials, has been claimed as unwanted phenomenon,28,29 
it may be beneficial when the target is to destroy remaining bac-
teria after the surgical debridement of infected tissue. If the burst 
is moderate, it may help to achieve the required antibiotic con-
centration in the tissue and eradicate bacteria or to prevent the 
attachment of bacteria to the operated bone or implant.10,30
The second phase was from the day 1 until day 32, when 
the ciprofloxacin release from PLCL + C was very slow and 
the release from the composites with 50 and 60 wt% of 
β-TCP occurred steadily. The second phase was diffusion con-
trolled31 and obeyed the first-order kinetics (R2 values 0.99 
for both of the composites containing 50 wt% and 60 wt% 
of β-TCP). In first order kinetics, the release rate of the drug 
is dependent on the concentration and obeys Equation 1: 
lnA = -kt + lnA
0
    (1)
where A is the drug load at the time t, A
0
 is the initial drug load, 
and k is the rate constant. This equation results in a straight line 
when the logarithm of the remaining drug in the sample is plot-
ted against time.
The third phase of the ciprofloxacin release started around day 
32 of the release tests, where the release from PLCL + C and 
PLCL + TCP50 + C accelerated. This can be seen as a change in 
the release profile at 32 d in Figure 1A. There was, however, no 
notable change in the release profile at this point for the compos-
ite with 60-wt% of β-TCP. This was probably due to the porous 
structure of the composite caused by the high β-TCP content 
that enabled a high diffusion rate of ciprofloxacin out of the poly-
mer matrix. In this case, the polymer degradation did not seem 
to have much of an effect on the ciprofloxacin release. After the 
phase change at 32 d, all the materials obeyed first-order kinet-
ics (R2 values 0.99 for all the tested materials) but with different 
slopes than seen in the second phase.
It was noticed that the β-TCP content of the composites 
had a considerable effect on the ciprofloxacin release (Fig. 1A). 
systemic drug concentrations in the blood or other tissues are sig-
nificantly lower than in the surrounding local tissues.11-17
Local biodegradable and antibiotic releasing systems have 
been studied both in vitro and in vivo11,12,15,16,18-22 and reviewed by 
many research groups.10 Koort et al. have studied ciprofloxacin 
releasing bone defect fillers with osteoconductive ceramic com-
ponent in a localized osteomyelitis rabbit model and the results 
have been promising. Ciprofloxacin was found to penetrate bone 
well and higher local concentrations of ciprofloxacin could be 
achieved than by using systemic administration.10,13,14,23
Mäkinen24 has proposed a new clinical treatment algorithm in 
the treatment of osteomyelitis based on osteoconductive materi-
als that release antibiotics locally. In this algorithm, the surgical 
debridement and the antibiotic treatment of the resulting dead 
space in the bone are performed in one operation. After treat-
ment, no surgical removal of the antibiotic releasing implants 
or bone grafting is required due to the bioabsorbable and osteo-
conductive nature of the implants. The fillers developed in the 
current study may provide the osteoconductive and antibiotic 
releasing materials that Mäkinen has proposed. However, there 
is need to test the most promising composites further in vivo to 
prove their efficacy in living tissues.
Results and Discussion
The effect of processing and sterilization on the materials. The 
composite materials were manufactured using twin-screw extru-
sion and the resulting composites had ceramic particles and cipro-
floxacin antibiotic evenly distributed in the polymer matrix due to 
the efficient mixing in the extrusion process. The composites are 
denoted PLCL + C [Poly(L-lactide-co-ε-caprolactone) (PLCL) 
with 8 wt% of ciprofloxacin in feed], PLCL + TCP50 + C [PLCL 
with 50 wt% of β-tricalcium phosphate (β-TCP) and 8 wt% 
of ciprofloxacin in feed] and PLCL + TCP60 + C (PLCL with 
50 wt% β-TCP and 8 wt% of ciprofloxacin in feed). Processing 
caused only minor degradation in the composites. The weight 
average molecular weight (M
w
) of the raw material was measured 
as 245,000 g/mol and the number average molecular weight (M
n
) 
150,000 g/mol. The processing of the composites caused a slight 
decrease both in the M
w
 and M
n
. The decrease in the M
w
 was 
8% for PLCL + C and 4% and 3% for the PLCL + TCP50 + 
C and the PLCL + TCP60 + C respectively and the decrease in 
the M
n
 was 12% for the PLCL + C and negligible (below 1%) 
for both PLCL + TCP50 + C and the PLCL + TCP60 + C. 
Polydispersity (PD) was slightly increased for PLCL + C (from 
1.6 to 1.7) but no change was observed for PLCL + TCP50 + C 
and PLCL + TCP60 + C. As was expected, the sterilization using 
gamma irradiation with the measured dose of 29–35 kGy caused 
considerable degradation to all the composites. Gamma irradia-
tion is known to affect polymers and cause degradation.25,26 The 
decrease was 20%, 45% and 50% for the PLCL + C, the PLCL 
+ TCP50 + C, and the PLCL + TCP60 + C respectively, when 
compared with the initial M
w
 of the raw material.
The residual monomer content of the raw material was 
0.08 wt% for the L-lactide monomer and below detection limit 
(< 0.02 wt%) for the ε-caprolactone monomer. The L-lactide and 
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As the steady zero order release is the ideal release profile in this 
case, the composite with 50% of β-TCP shows the most promis-
ing drug release properties for the treatment of osteomyelitis. The 
drug release of this composite continued up to 160 d with daily 
released concentrations above 2 μg/ml, which has been reported 
to be above the minimum inhibitory concentration (MIC) of the 
most common osteomyelitis pathogen Staphylococcus aureus.34,35 
The slow release period after 160 d when the daily release of cip-
rofloxacin was decreased below 2 μg/ml is of concern because it 
may allow the development of resistant bacteria.10 However, the 
β-TCP introduces porosity to the test 
samples and therefore enables acceler-
ated diffusion of the drug out of the 
polymer matrix. The processing of the 
PLCL copolymer with β-TCP particles 
produces voids at the interfaces of the 
materials. In addition to the increased 
diffusion, β-TCP also increases the 
roughness of the surface; thus, it 
increases the surface area of the pellets 
and provides more area for the diffu-
sion to happen. Other research groups 
have had rather similar results in studies 
concerning composites of bioceramics 
and biodegradable polymers containing 
antibiotics.16,18,22
Plain poly-ε-caprolactone is known 
to have good diffusion properties for 
low molecular weight substances (MW 
below 400 g/mol).32 However, the per-
meability falls when the ε-caprolactone 
content decreases in copolymers, 
e.g., in copolymer of DL-lactide and 
ε-caprolactone.33 The polymer stud-
ied here contains only 30% of the 
ε-caprolactone monomer and, there-
fore, the ciprofloxacin molecules that 
have a molar mass of 331 g/mol were 
not able to diffuse very well through the 
plain copolymer during the first 32 d.
At the time point of 32 d, the 
polymer degradation had apparently 
reached a level that enables acceler-
ated diffusion for the plain copolymer 
as well as the composite with 50 wt% 
of β-TCP. At this point, the M
w
 of the 
polymer had decreased to the level of 
30,000–34,000 g/mol and the M
n
 to 
the level of 17,000–20,000 g/mol. The 
mass loss of the test samples accelerated 
in a later stage of the test series, so in 
conclusion, the change in the diffusion 
properties due to the degradation of the 
polymer was most probably the reason 
for the acceleration of the drug release 
around 32 d.
The acceleration of the drug release can be easily seen in 
Figure 1B where the daily release of ciprofloxacin is presented. 
The release rate reached a peak at the time point of 50 d for all 
the tested materials, but the peak was most notable for the PLCL 
+ C. A very small acceleration peak could also be observed at the 
time point of 120 d. At this point, most of the drug had diffused 
out from the tested materials and, therefore, the degradation 
degree of PLCL did not cause a larger peak to the daily release of 
ciprofloxacin.
Figure 1. The cumulative (A) and daily (B) release of ciprofloxacin from composites of poly(L-lactide-
co-ε-caprolactone) (pLcL) and β-tricalcium phosphate (Tcp) with initial Tcp contents of 0 wt%, 
50 wt% and 60 wt% and initial ciprofloxacin (C) content of 8 wt%. Results shown as averages with 
standard deviations (n = 5).
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The light seen in the top row wells of Figure 3 is not actual light 
production from the bacteria, but a reflection from the wells in 
the lower row. The first signs of the antibacterial activity were 
already seen after two hours of incubation both visually (false 
color picture) and in the light intensity levels (photon counting). 
The formation of the inhibition zone can be seen in Figure 2 as 
a developing valley in the middle of the graphs with lower light 
intensity that gradually spreads toward the edge of the well. A 
region with very high light intensity can be seen surrounding the 
developing valley. The inhibition zone can also be seen in Figure 
3 as the dark blue zone in the middle of the wells that indi-
cates dead bacteria. The effectiveness of ciprofloxacin released 
from the pellets in eradicating the bacteria and forming clear 
inhibition zones around the pellets in the wells was clearly seen. 
Bright yellow and red in the areas around the inhibition zones 
indicated increased light production. This increased light pro-
duction preceded total decay in the light production. The reason 
for the decay in the light production was probably that when the 
bacteria came in contact with ciprofloxacin, the bacteria tried 
to survive by shutting down the non-vital systems consuming 
Adenosine triphosphate (ATP). As a result, more ATP was avail-
able for the bioluminescence pathway, and the light production 
increased.
In vitro degradation of the materials. Molecular structure. 
The 1H NMR spectra were measured from seven samples (raw 
material PLCL, PLCL + C at 0, 26 and 52 weeks in vitro and 
PLCL + TCP50 + C at 0, 26 and 52 weeks in vitro). Some signals 
drug release rate and behavior in vivo may be different from what 
has been observed in vitro.
At the time point of 180 d, the drug release had decreased to a 
negligible level and 93–97% of the total ciprofloxacin loaded in 
the composites had been released. The test series was continued 
up to 392 d, but no further release of ciprofloxacin was detected.
The effect of the released ciprofloxacin against Pseudomonas 
aeruginosa. We studied the effect of the released ciprofloxacin 
against a common osteomyelitis causing bacteria Pseudomonas 
aeruginosa. The composite for this experiment contained 50 
wt% of β-TCP and was chosen based on the most promising cip-
rofloxacin release results. A bacterial strain of P. aeruginosa engi-
neered to emit light was used in the bacterial culture. The results 
of our bioluminescence measurements are shown in Figure 2 as 
light intensity levels (photon counts). The measurements were 
taken in one well at different time points (0, 2, 4, 6, 8, 10, 12, 
14 and 16 h) of incubation. To illustrate the results, a 6-well 
plate cultured with P. aeruginosa and ciprofloxacin-releasing pel-
lets on the lower row and with control pellets without antibiotic 
on the top row after 16 h of incubation is shown in Figure 3, 
as a false color picture. The light intensity levels of the control 
wells are not shown in Figure 2 because there were no significant 
changes observed in light intensity levels when compared with 
the results of antibiotic releasing pellets. All the light production 
in the control wells shut down at the time point of 6 h. This may 
have been due to quorum sensing mechanism36 where the bac-
teria react to possible stress by turning off the light production. 
Figure 2. Light intensity level as photon counts of Pseudomonas aeruginosa exposed to one ciprofloxacin releasing pellet in the middle of a well. The 
results are presented at different time points of incubation. A is at the time point of 0 h, B at 2 h, C at 4 h, D at 6 h, E at 8 h, F at 10 h, G at 12 h, H at 14 h 
and I at 16 h. Note the different scales of the y-axes.
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results showed a similar effect of the changing of the comonomer 
ratio of the copolymer as the hydrolysis proceeds, as was seen in 
our earlier study with similar composites without ciprofloxacin 
(Ahola et al. Accepted to Journal of Biomaterials Applications). 
Jeong et al. have also reported this effect.37
Because the copolymer properties depend not only on the 
comonomer composition but also on the distribution of the 
comonomers in the polymer chains, analysis of the microstruc-
ture of the polymer was also needed.38,39 The number average 
sequence lengths of L-lactide and ε-caprolactone were calcu-
lated according to Herbert39 and Fernández38 using Equations 2 
and 3:
    (2)
    (3)
where (LA) and (CL) are the molar fractions of the L-lactide and 
ε-caprolactone comonomers in the copolymer and (LA - CL) is 
the average dyad relative fraction, which can be calculated from 
the 1H NMR data of the copolymer. The calculation is well 
explained in an article by Fernández.38 Additionally, the random-
ness factor, R, was calculated using Equation 4.
were overlapping and could not be used for the analysis. The 
most informative signals of the polymer are shown in Figure 4 
where a part of the PLCL raw material 1H NMR spectrum is 
seen. The polymer showed signals at δ 5.16 for the –CH group 
proton of the lactide comonomer, at δ 4.05–4.13 for the α-oxy 
methylene protons of the ε-caprolactone comonomer and at δ 
2.3–2.4 for the protons of the methylene group of ε-caprolactone 
that is bonded to the carbonyl group. The signals of the cap-
rolactone protons at δ 4.05–4.13 and at δ 2.3–2.4 were clearly 
split into two signals according to the position in the polymer 
chain. The triplet at δ 4.13 indicated the CH
2
 group in the 
ε-caprolactone fragment bonded to an L-lactide unit and the 
broader multiplet at δ 4.05 indicated the α-oxy methylene group 
bonded to another ε-caprolactone unit.37,38 The signal at δ 2.3–
2.4 was split the same way. The triplet at δ 2.4 indicated a group 
bonded to a L-lactide group and the broader multiplet at δ 2.3 
corresponded to a group that is bonded to another ε-caprolactone 
group.37,38 The comonomer ratios of the copolymer were calcu-
lated as the ratio of the integral of the signal at δ 5.16 to the aver-
age integrals of the caprolactone signals at δ 4.05–4.13 and at δ 
2.3–2.4.38 The 1H NMR analysis showed that the L-lactide to 
ε-caprolactone ratio was increased from 68/32 of the raw mate-
rial and the samples of 0 weeks to 76/24 of the PLCL + TCP50 
+ C at 52 weeks and 71/29 of the PLCL + C at 52 weeks. The 
Figure 3. Bioluminescence results of the ciprofloxacin containing (8 wt%) composites of poly(L-lactide-co-ε-caprolactone) and 50 wt% of β-tricalcium 
phosphate on a bacterial culture of light emitting Pseudomonas aeruginosa. pellets containing ciprofloxacin are on the lower row and corresponding 
composites without ciprofloxacin are on the top row and act as negative controls.
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proportion 1:1 in both ciprofloxacin containing samples. 
Additionally, the signals of cyclopropane proton at 3.55 ppm, 
and the 8 protons in the piperazine ring, which appeared as a 
multiplet at 3.25 ppm showed good agreement with the stoichio-
metric values 1:8. Based on these results, it can be concluded 
that the ciprofloxacin molecule has maintained its original struc-
ture throughout the processing and sterilization steps. This result 
supports the findings of Koort et al. who concluded that pro-
cessing and sterilization do not affect the bactericidal effect of 
ciprofloxacin.12-14,23
Molecular weights, mass loss and water absorption. At the start 
of the hydrolysis test series, the molecular weights of PLCL + 
TCP50 + C (M
w
 = 134,000 g/mol and M
n
 = 69,000 g/mol), and 
PLCL + TCP60 + C (M
w
 = 120,000 g/mol and M
n
 = 70,000 g/
mol) were considerably lower than of PLCL + C (M
w
 = 196,000 
g/mol and M
n
 = 90,000 g/mol). Despite the differences, the deg-
radation proceeded rapidly in all three composites and the differ-
ences were leveled out during the hydrolysis test series (Fig. 6A). 
There were no differences observed in the degradation behavior 
between the studied materials. We noticed the same kind of effect 
in our earlier study with composites without antibiotics (Ahola et 
al. Accepted to the Journal of Biomaterials Applications), as did 
Daculsi et al.26 At the time point of 4 weeks, the M
w
 values of the 
samples were already between 43,000 g/mol and 50,000 g/mol. 
The decrease of the molecular weight from this time point on was 
very similar for all the tested composites. After 52 weeks of hydro-
lysis at 37°C and pH 7.4, the molecular weights (both M
w
 and 
M
n
) of all the composites had decreased by 97–98% to 2–3% of 
the initial value of the raw material. Polydispersity of the polymer 
decreased slightly and steadily throughout the test series, from 
    (4)
The randomness factor is 1 for a random copolymer and 0 for 
a block copolymer.38 The results of the average sequence length 
calculations showed that the polymer is rather blocky, R having 
values of 0.25 for the raw material and the samples prior to in 
vitro testing. The R factor decreased during degradation of the 
polymer to 0.18 for PLCL + TCP50 + C to 0.23 for the PLCL + C 
at 52 weeks indicating that the more random parts of the copoly-
mer degrade first. The average sequence lengths of L-lactide were 
13 in the beginning of the test series and increased to 22 and 15 
for PLCL + TCP50 + C and PLCL + C respectively at 52 weeks. 
This also supports the fact that random parts of the copolymer 
having short blocks of the comonomers degraded first and thus 
the average sequence length was increased. The average sequence 
length of ε-caprolactone was not changed during hydrolysis and 
had values of 6–7 for all the analyzed samples.
Lemmouchi et al.40 have reported degradation results of 
ε-caprolactone and L-lactide having a comonomer ratio of 74/26 
(caprolactone to lactide) before hydrolysis, changed so that the 
amount of ε-caprolactone comonomer in the polymer increased 
and L-lactide decreased. This supports the interpretation that 
polymer degradation depends largely on the microstructure of 
the polymer and the amorphous parts degrade first despite the 
comonomer ratio.40
Signals of ciprofloxacin were visible only in the samples of 0 
weeks. At 26 or 52 weeks the ciprofloxacin content in the samples 
was low and under the limit that could be detected in NMR. 
The integrals of protons of the quinoline ring at 8.80 and 8.06 
ppm (Fig. 5) were in good agreement with the stoichiometric 
Figure 4. part of the 1h NMR spectrum of the poly(L-lactide-co-ε-caprolactone) raw material.
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the time scale of this study. The mass loss of the composites was 
almost linear during the whole 52-week test period (R2 values 
0.98).
Water absorption in PLCL + TCP50 + C and PLCL + TCP60 
+ C was greater than in PLCL + C during the first 10 weeks 
(Fig. 6B). After 20 weeks, this behavior changed as the water 
absorption of PLCL + C accelerated and it absorbed more water 
than the other tested composites. The polymer content in this 
composition was greater than in PLCL + TCP50 + C and PLCL 
+ TCP60 + C, and this naturally affected the total water absorp-
tion of the samples. As the degradation proceeded, there were 
more hydrophilic end groups in the polymer to absorb water. 
There was no notable difference in the water absorption between 
the composites with 50 wt% and 60 wt% of β-TCP. This might 
be due to the fact that the difference in the ceramic content in 
these composites was not enough to cause notable differences in 
the water absorption behavior.
β-TCP content of the materials. The relative amount of β-TCP, 
determined by thermogravimetric analysis, in the composites 
increased throughout the test series (Fig. 7A and B). This is 
because β-TCP dissolves very slowly compared with the polymer 
degradation (Ahola et al. Accepted to the Journal of Biomaterials 
Applications). This kind of behavior might be beneficial regard-
ing bone healing, as the polymer disappears from the site and the 
osteoconductive β-TCP particles remain to help bone ingrowth. 
Additionally, the voids at the interfaces between the ceramic par-
ticles and polymer matrix may also enable bone ingrowth.
Thermal properties. Compared with the similar composites 
without the ciprofloxacin antibiotic (Ahola et al. Accepted to the 
Journal of Biomaterials Applications), slightly higher T
g
s were 
measured after processing and sterilization. T
g
s were about 20°C 
for the composites without ciprofloxacin and 23°C for the com-
posites containing ciprofloxacin. The changes in the T
g
s of the 
1.7–2.2 at 0 weeks to 1.2–1.3 at 52 weeks. The decrease indicated 
that M
w
 decreased more rapidly than M
n
 and that the molecular 
mass distribution was narrowed. The degradation of the aliphatic 
polyesters is known to occur first in the amorphous sections of 
the polymer and via random chain scission.41 The random chain 
scission caused the molecular weight of the polymer to decrease 
rapidly following first order kinetics with k having values of 2.0 
× 10-3 1/h for the plain copolymer and 1.3 × 10-3 1/h for PLCL + 
TCP50 + C and 1.2 × 10-3 1/h for PLCL + TCP60 + C.
The SEC distribution plots showed emerging bimodality 
at 16 weeks for all the tested materials. In our earlier studies, 
the same kind of bimodality was present in composites without 
ciprofloxacin antibiotic (Ahola et al. Accepted to the Journal 
of Biomaterials Applications) beginning from the 20th week of 
the test series. Bimodality in the SEC distribution curve can be 
explained with the blocky structure of the copolymer, which was 
shown by the 1H NMR analysis. The random parts of the copo-
lymer degrade first, which might cause an increase in a certain 
part of the SEC distribution curve as the blocky parts consisting 
mainly of L-lactide monomers remain in the copolymer.
The mass loss of the test samples was steady and started from 
the very beginning of the test series (Fig. 6B). The first part of the 
mass loss was due to the drug release as ciprofloxacin was released 
from the composites. When the mass loss caused by the cipro-
floxacin release was taken into account, it could be concluded 
that the mass loss caused by the polymer erosion started after 6 
weeks for PLCL + TCP50 + C and PLCL + TCP60 + C and after 
4 weeks for PLCL + C. The mass loss in the very beginning of 
the test series was greater for PLCL + TCP50 + C and PLCL + 
TCP60 + C than for PLCL + C, which correlated well with the 
drug release data. The dissolution of β-TCP was very slow as 
was also noted in our earlier study (Ahola et al. Accepted to the 
Journal of Biomaterials Applications) and it was not significant in 
Figure 5. part of the 1h NMR spectrum of poly(L-lactide-co-ε-caprolactone) and ciprofloxacin after processing and positions of the peaks assigned to 
the protons in the ciprofloxacin molecule.
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copolymer changed as the degrada-
tion proceeded. This change was 
seen in the 1H NMR analysis as an 
increase in the L-lactide content and 
decrease in ε-caprolactone content. 
The same kind of trend in T
g
:s was 
observed with composites with-
out ciprofloxacin, but it was more 
noticeable and the T
g
:s decreased to 
12–15°C during the first 12 weeks of 
the test series and started to increase 
after that (Ahola et al. Accepted to the 
Journal of Biomaterials Applications). 
T
g
s of copolymers of L-lactide and 
ε-caprolactone are known to be 
strongly dependent on the comono-
mer composition. The T
g
 increases 
dramatically even with small incre-
ments of the L-lactide content.32 The 
melting temperatures and melting 
enthalpies were analyzed from the 
first heating of the samples because 
during the second heating, the melt-
ing peaks did not appear anymore 
due to the fast cooling in the DSC 
analysis. Most of the samples showed 
clear bimodality in the melting peaks 
indicating two kinds of crystals in the 
polymer. The reason for the bimo-
dality may be imperfect crystals in 
the polymer which may be annealed 
during DSC scan. As a result, they 
melt, recrystallize and melt again in 
higher temperature, which shows a 
bimodal melting peak in the DSC 
scan.44 There were no clear trends in 
the melting temperatures of the com-
posites. The bimodal melting peaks 
appeared mainly between 80°C and 
120°C. There was a small decrease in 
the values between weeks 4 and 20 
and a tendency to cold-crystallization 
at the 26th week.
Melting enthalpies, which describe 
the crystallinity of the polymer, were 
analyzed and corrected to correspond to the combined polymer 
and ciprofloxacin part of the composites. There was a dramatic 
increase in the crystallinity of the composites from the beginning 
of the test series until the time point of 6 weeks. After this, the 
crystallinity started to decrease until the 20 weeks time point and 
then started to increase again (Fig. 8B). With the composite with-
out β-TCP, the same behavior was observed, but it was consider-
ably weaker. When compared with similar composites without 
ciprofloxacin, there was a considerable difference in the changes 
in melting enthalpies. The melting enthalpy of the composites 
without ciprofloxacin increased steadily until the time point of 
materials during the in vitro test series are shown in Figure 8A. 
During the in vitro test series, there was a slow decrease in the 
T
g
:s of the composites with ciprofloxacin until week 20 when the 
T
g
s gradually decreased to 18°C. At the same time, the M
w
s of 
the polymers decreased dramatically affecting also the T
g
. This 
behavior is well known with biodegradable polymers.42,43 After 
the time point of 20 weeks, the T
g
:s began to increase ending 
up at 30°C for PLCL + TCP50 + C and PLCL + TCP60 + C 
and 23°C for PLCL + C at 52 weeks. At this time period, the 
loss of the short polymer chains has an increasing effect on the 
T
g
42 as well as the fact that the ratio of the comonomers in the 
Figure 6. The weight average molar weight (Mw) (A), and mass loss and water absorption (B) of the 
studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-
caprolactone) (pLcL), β-tricalcium phosphate (Tcp) and ciprofloxacin (C) with initial Tcp contents of  
0 wt%, 50 wt%, and 60 wt% and ciprofloxacin content of 8 wt%. error bars in part B are not visible due 
to the small values of standard deviations (n = 5).
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were delivered to the process with separate gravimetric screw feed-
ers. The mixing of the components took place in the extruder. A 
haul-off unit was used to guide the extrudate from the die and 
the diameter of the billets was fine-tuned adjusting the speed of 
the haul-off unit. Three different composites were processed. 
Each composite had 8 wt% ciprofloxacin antibiotic in feed and 
different β-TCP contents (0, 50 and 60 wt%). These composites 
are denoted PLCL + C, PLCL + TCP50 + C and PLCL + TCP60 
+ C respectively. The billets were cut into approximately 2.5 mm 
long pellet-shaped samples. Before degradation and drug release 
tests were performed, the samples were packed and sterilized 
using gamma irradiation (minimum dose 25 kGy).
Drug release study. The drug release tests were conducted at 
37°C in vitro. Weighed test samples (each test sample consisted 
of 15 pellets) were placed in brown glass bottles along with 20 ml 
Sörensen buffer solution. Five parallel test samples were tested for 
each composite material. The bottles were placed in an incubator 
shaker at 37°C. At predetermined time intervals, the buffer solu-
tion was withdrawn from each of the bottles and replaced with 
fresh solution. The amount of buffer solution and the periodical 
26 weeks (Ahola et al., accepted to the Journal of Biomaterials 
Applications). In conclusion, the dramatic increase and decrease 
in melting enthalpies during weeks 0–20 is attributed to the pres-
ence of ciprofloxacin in the composites. The overall increase in 
the crystallinity of the polymer as hydrolysis proceeds is probably 
due to the increased proportion of L-lactide blocks in the copoly-
mer as the amorphous and more random parts of the copolymer 
degrade first, which was shown by the 1H-NMR analysis. The 
L-lactide blocks are able to rearrange and form crystals due to the 
increased mobility of the polymer chains.
Microstructure. SEM micrographs showed pores of different 
sizes in the samples containing β-TCP. No notable differences 
were seen in the structures of composites with 50 wt% and 60 
wt% of β-TCP. In the samples without β-TCP, no pores were 
seen after processing of the material, but some very small pores 
were formed during the in vitro study. In the Figure 9, SEM 
micrographs of composites with 60 wt% of β-TCP are shown. In 
the inner parts of the samples, porosity was seen throughout the 
hydrolysis test series (Fig. 9A–C). Pores reaching the size of 100–
200 μm were observed as well as smaller pores. Additionally, the 
surfaces of the pellet-shaped samples were porous (Fig. 9D–F). 
The pores were created around the ceramic particles in the pro-
cess when the composite in melt phase was drawn from the die of 
the extruder because there was practically no adhesion between 
the ceramic particles and the polymer.
Pores of a size over 100 μm have been reported to enhance 
bone ingrowth45 and would, therefore, be beneficial in the heal-
ing phase of the bone after the infection causing bacteria have 
been eradicated. Smaller pores are critical because they enable 
liquid, nutrition, and waste to flow in the material to and from 
the cells.
Materials and Methods
Materials. The copolymer that was used as the matrix in the 
composites was medical grade poly(L-lactide-co-ε-caprolactone) 
(PLCL, Purac Biomaterials) with the comonomer ratio of 70/30 
and M
w
 of 246,000 g/mol. β-Tricalcium phosphate (β-TCP) 
(granule size < 38 μm) was used as the ceramic component and it 
was purchased from Plasma Biotal Ltd. Ciprofloxacin antibiotic 
(M = 331.4 g/mol) was purchased from Uquifa. Sörensen phos-
phate buffer solution was prepared according to the standard ISO 
1581446 and the chemicals used for the buffer solution (Na
2
HPO
4
 
and KH
2
PO
4
) were purchased from J.T. Baker. The chemicals 
used for the bioluminescence bacterial cultures were: Gentamicin 
sulfate (Sigma-Aldrich), Isopropyl-β-D-thiogalaktopyranoside 
(IPTG) (Fermentas, Lithuania), Trypton (Lab M Limited), 
Yeast extract (Lab M Limited), Sodium Chloride (Merck), Agar 
(Merck).
Processing. The components of the composite materials, that 
are PLCL polymer, β-TCP, and ciprofloxacin antibiotic, were 
dried for 72 h in vacuum at room temperature before processing. 
The materials were processed into rod-shaped billets with a diam-
eter of approximately 2.5 mm with a co-rotating, custom-built 
intermeshing twin-screw extruder (L/D ratio 22.5) in a nitrogen 
atmosphere. PLCL copolymer, β-TCP and rifampicin antibiotic 
Figure 7. β-tricalcium phosphate (Tcp) contents of the studied com-
posites as a function of time in vitro. The composites comprised of 
poly(L-lactide-co-ε-caprolactone) (pLcL) and β-tricalcium phosphate 
(Tcp) with initial Tcp contents of 50 wt% and 60 wt% and ciprofloxacin 
(c) content of 8 wt%. Results shown as averages with standard devia-
tions (n = 5).
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Inhibition zone testing using bio-
luminescence imaging. The effect of 
a ciprofloxacin releasing composite 
material against a common osteomy-
elitis causing bacteria Pseudomonas 
aeruginosa was tested using biolumi-
nescence imaging based on the ability 
of genetically engineered bacteria to 
emit light.47,48 In the bioluminescence 
method, the luminescence and the 
changes in it emitted by living micro-
organisms are measured. The changes 
in the luminescence are caused by lux 
gene-coded luciferase, which respond 
to the target analyte in a dose-depen-
dent manner.47,48
The antibiotic containing compos-
ite material chosen for this study was 
the composite containing 50 wt% of 
β-TCP (PLCL + TCP50 + C) based 
on the most promising drug release 
results. Composite of PLCL and 50 
wt% β-TCP without antibiotics was 
used as control.
An engineered bacteria strain of 
Pseudomonas aeruginosa PAO-LAC 
carrying plasmid pUCP24GW49 was 
used as the biosensor. The P. aerugi-
nosa here had been engineered to act 
as a SOS-response sensor, thereby pro-
viding information of the agents that 
influence chromosomal DNA homeo-
stasis, among others. The bacteria were 
cultured on antibiotic plates overnight 
at 30°C and 300 rpm (1 mM IPTG, 
10 μg/ml gentamycin), and suitable 
colonies were moved into liquid cul-
turing in LB (5 g/l yeast extract, 10 g/l 
tryptone and 5 g/l NaCl). If the bac-
teria did not produce luminescence as 
wished in the morning, 1/50 dilution 
was made in a culture tube and it was 
incubated at 37°C and 300 rpm for 
three hours. The level of luminescence 
of the cultures was measured by using 
Plate ChameleonTM multilabel counter 
1.001 (Hidex Ltd.), and at volume of 200 μl. Counts of 1.1–2.3 × 
106 were found satisfying.
Layers of LB-agar (agar 15 g/l, 2 ml) were cast into 6-well 
plate, and the controls and antibiotic containing composite pellets 
were placed on top of them (one pellet per well). Bacteria were 
mixed with soft LB-agar (7.5 g/l) solution and cast on top of the 
first layers. The amount of bacterial culture was dependent on the 
luminescence level. After solidification, the plate was taken to the 
imaging station of Xenogen VivoVision IVIS® Lumina lumines-
cence camera (Caliper LifeSciences). Pictures were taken every 20 
change to fresh buffer solution enabled sink conditions to be valid 
throughout the test series. The amount of released ciprofloxacin 
was determined from the buffer solution using a Unicam UV 500 
spectrometer (ThermoSpectronic, Cambridge, United Kingdom) 
at maximum absorption wavelength of 271 nm. A wavelength 
area from 190 to 400 nm was scanned in order to detect possible 
changes in the ciprofloxacin molecular structure that cause devia-
tion in the UV-spectrum. Ciprofloxacin concentrations were cal-
culated using Beer-Lambert law and with the help of a standard 
curve prepared with known concentrations of ciprofloxacin.
Figure 8. Glass transition temperatures (Tg) (A) and melting enthalpies (Δhf) (B) of the studied com-
posites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) 
(pLcL) and β-tricalcium phosphate (Tcp) with initial Tcp contents of 0 wt%, 50 wt% and 60 wt% and 
ciprofloxacin (C) content of 8 wt%. Results are shown as averages with standard deviations (n = 2–5).
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series were studied measuring and analyzing the proton NMR 
spectra of the samples. The NMR equipment used was a Varian 
Mercury 300 MHz NMR Spectrometer (Varian Associates 
Inc.) and the measurements were done at room temperature in 
standard 5 mm tubes in deuterochloroform. Tetramethylsilane 
(TMS) was used as an internal standard, and chemical shifts 
were measured relative to TMS. The data were acquired until 
the quality of the spectrum was sufficient and the number of 
scans was about 400. The proton NMR spectra of the samples 
were processed and analyzed using SpinWorks 3.1 software. 
Phase correction and baseline correction were applied to all 
spectra.
Molecular weights. The molecular weights (number average, 
M
n
, and weight average, M
w
, molecular weights) and polydis-
persity (PD) of the copolymer during the in vitro degradation 
test series were determined at room temperature by size exclusion 
chromatography (SEC) (Waters Associates system was equipped 
with a Waters 717plus autosampler, a Waters 510 HPLC solvent 
pump, four linear PL gel columns (104, 105, 103 and 100 Å) con-
nected in series, and a Waters 2414 differential refractometer). 
Chloroform (Riedel-de Haën Ag, stabilized with 1% ethanol) 
was used as a solvent and eluent. Before injection, the samples 
were filtered through a 0.5 μm Millex SR filter. The injected vol-
ume was 200 μl and the flow rate was 1.0 ml/min. Monodisperse 
polystyrene standards were used for primary calibration. One to 
two parallel samples were measured at each time point for each 
composite.
Mass loss and water absorption. For the water absorption analy-
sis, the test samples were withdrawn from the incubator shaker 
and rinsed twice with distilled water. The surfaces of the test 
samples were then wiped carefully with tissue paper and the test 
samples were weighed immediately after wiping. The weighed test 
samples were dried for at least three days at ambient conditions 
min for 16 h with exposure time of 30 sec. The pictures were ana-
lyzed using Living Image® 3.1 program (Caliper LifeSciences).
In vitro degradation study. Degradation tests were conducted 
according to the standard ISO 1581446 at 37°C in vitro. Five par-
allel test samples, each consisting of 15 pellets, of each composite 
material were tested at each time point. First, weighed test sam-
ples were placed in brown glass bottles with 20 ml Sörensen buf-
fer solution. Then, the bottles were placed in an incubator shaker 
at 37°C. The pH of the buffer solution was measured periodically 
with a calibrated pH meter and the buffer solutions were changed 
every two days at the beginning of the test series, due to fast drug 
release and the fact that we wanted to avoid drug accumulation 
in the buffer solution. After five weeks, the buffer solution was 
changed twice a week and after ten weeks, once a week. Test sam-
ples were withdrawn at predetermined time points, which were 2, 
4, 6, 8, 12, 16, 20, 26, 30 and 52 weeks.
Methods of analysis.  Residual monomer. Ramboll Analytics 
Oy performed the determination of residual L-lactide and 
ε-caprolactone monomer contents. The ε-caprolactone and 
L-lactide contents were measured after chloroform extrac-
tion of the samples using gas chromatography (DC8000, CE 
Instruments) and an FI-detector after chloroform dilution. The 
measuring resolution was 0.02%.
Initial drug content. Five samples of about 150 mg were 
weighed from each manufactured composition and dissolved in 
50 ml of chloroform (J.T. Baker). The amount of ciprofloxacin in 
the chloroform solution was determined using a Unicam UV 540 
Spectrophotometer (ThermoSpectronic) at a maximum absorp-
tion wavelength of 284 nm. The concentrations of ciprofloxacin 
in the solutions were calculated with the help of a standard curve 
prepared with known concentrations of ciprofloxacin.
Molecular structure. The molecular structures of the PLCL 
copolymer and ciprofloxacin antibiotic during degradation test 
Figure 9. seM micrographs of the composites of poly(L-lactide-co-ε-caprolactone), 60 wt% β-tricalcium phosphate and ciprofloxacin. (A–C) fractured 
surfaces after 0 weeks, 26 weeks, and 52 weeks in vitro, respectively. (D–F) specimen surfaces after 0 weeks, 26 weeks and 52 weeks in vitro, respec-
tively.
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Conclusions
The tested composites with high β-TCP contents show desirable 
ciprofloxacin releasing properties as ciprofloxacin was steadily 
released during 160 d in concentrations above the MIC of 
Staphylococcus aureus. This is within the desired range when the 
objective is the treatment of osteomyelitis. The release obeyed 
first-order kinetics having a phase change at 32 d of the release 
test period. The increased porosity, introduced by β-TCP par-
ticles, enhanced the release of ciprofloxacin and removed the 
long lag phase in the ciprofloxacin release of the plain copolymer. 
1H-NMR analysis showed that processing and sterilization did 
not affect the ciprofloxacin molecular structure. Additionally, 
the effect against a common osteomyelitis causing bacteria 
Pseudomonas aeruginosa was shown in cell culture study utilizing 
bioluminescence.
The polymer matrix of the composites, poly(L-lactide-co-ε-
caprolactone) copolymer, was found to have very blocky struc-
ture where the L-lactide comonomers formed long blocks in the 
polymer structure. This also influenced the increase in crystal-
linity as the polymer degradation proceeded. The decrease in 
the molecular weight of the copolymer matrix followed the first-
order kinetics. The composites with high β-TCP contents, espe-
cially the composite with 50 wt% of β-TCP, show great potential 
to be developed into a product for the treatment of osteomyelitis 
and other bone related infections. However, in vivo studies as 
well as clinical studies are needed to establish the effect of these 
materials when they are implanted in living tissue.
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and for one week in vacuum. After vacuum drying, the test sam-
ples were weighed again to obtain the dry masses for the mass loss 
calculations. The dried test samples were stored in a desiccator for 
further analysis.
The mass loss was calculated as the difference between the ini-
tial mass of the test sample and the mass of the dried test sample 
divided by the initial mass of the test sample. The water absorp-
tion was calculated as the difference between the mass of the wet 
test sample and the mass of the dried test sample divided by the 
mass of the dried test sample
Ceramic content. The β-TCP content of the test samples was 
measured using thermogravimetric analysis (TGA Q500, TA 
Instruments). Samples of approximately 20 mg were used and 
they were heated at a rate of 20°C/min up to 700°C. Universal 
Analysis Software was used for the analysis of the results. Five 
parallel samples of each composition were analyzed at each time 
point and the results were calculated as averages and standard 
deviations.
Thermal properties. Thermal analysis was performed using a 
differential scanning calorimeter DSC Q1000 (TA Instruments). 
Nitrogen was used as the sweeping gas. To ensure the samples 
had a similar thermal history, they were heated twice and cooled 
rapidly in between. The heating rate was 20°C/min, the cool-
ing rate was 50°C/min and the temperature range was -60°C to 
+200°C. Glass transition temperatures (T
g
) were obtained from 
the second heating and melting temperatures and enthalpies (T
m
 
and ΔH
f
 respectively) were obtained from the first heating cycle. 
Although absolute crystallinity values could not be calculated 
because the theoretical value of 100% crystalline poly(L-lactide-
co-ε-caprolactone) 70/30 was not available, relative changes in 
the crystallinity were observed. Two to five parallel samples were 
tested for each composite material and time point. The results 
were analyzed using Universal Analysis Software and averages 
and standard deviations were calculated.
Microstructure of the samples. The microstructure of the com-
posites was observed using scanning electron microscopy (Philips 
XL-30 SEM equipped with a LaB6 filament, Philips) with an 
acceleration voltage of 12.0 kV. The micrographs were taken both 
on the surface of the samples and on cryogenically fractured sam-
ples, which were coated with gold (Edwards S150 Sputter Coater) 
prior to microstructure examination.
References
1. Galanakis N, Giamarellou H, Moussas T, Dounis E. 
Chronic osteomyelitis caused by multi-resistant Gram-
negative bacteria: evaluation of treatment with newer 
quinolones after prolonged follow-up. J Antimicrob 
Chemother 1997; 39:241-6; PMID:9069546; http://
dx.doi.org/10.1093/jac/39.2.241.
2. Chihara S, Segreti J. Osteomyelitis. Dis Mon 
2010; 56:6-31; http://dx.doi.org/10.1016/j.dis-
amonth.2009.07.001.
3. Parsons B, Strauss E. Surgical management of chronic 
osteomyelitis. Am J Surg 2004; 188(Suppl):57-66; 
PMID:15223504; http://dx.doi.org/10.1016/S0002-
9610(03)00292-7.
4. Soundrapandian C, Datta S, Sa B. Drug-eluting 
implants for osteomyelitis. Crit Rev Ther Drug Carrier 
Syst 2007; 24:493-545; PMID:18298388; http://
dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v24.
i6.10.
5. Farhad R, Roger PM, Albert C, Pélligri C, Touati 
C, Dellamonica P, et al. Six weeks antibiotic therapy 
for all bone infections: results of a cohort study. 
Eur J Clin Microbiol Infect Dis 2010; 29:217-22; 
PMID:20012334; http://dx.doi.org/10.1007/s10096-
009-0842-1.
6. Haidar R, Der Boghossian A, Atiyeh B. Duration 
of post-surgical antibiotics in chronic osteomy-
elitis: empiric or evidence-based? Int J Infect Dis 
2010; 14:e752-8; PMID:20471296; http://dx.doi.
org/10.1016/j.ijid.2010.01.005.
7. Jain A, Gupta Y, Agrawal R, Khare P, Jain SK. 
Biofilms--a microbial life perspective: a critical review. 
Crit Rev Ther Drug Carrier Syst 2007; 24:393-
443; PMID:18197780; http://dx.doi.org/10.1615/
CritRevTherDrugCarrierSyst.v24.i5.10.
8. Harris LG, Richards RG. Staphylococci and implant 
surfaces: a review. Injury 2006; 37(Suppl 2):S3-14; 
PMID:16651069; http://dx.doi.org/10.1016/j.inju-
ry.2006.04.003.
9. Esposito S, Leone S. Prosthetic joint infections: 
microbiology, diagnosis, management and preven-
tion. Int J Antimicrob Agents 2008; 32:287-93; 
PMID:18617373; http://dx.doi.org/10.1016/j.ijan-
timicag.2008.03.010.
10. Zilberman M, Elsner JJ. Antibiotic-eluting medical 
devices for various applications. J Control Release 
2008; 130:202-15; PMID:18687500; http://dx.doi.
org/10.1016/j.jconrel.2008.05.020.
11. Garvin KL, Miyano JA, Robinson D, Giger D, 
Novak J, Radio S. Polylactide/polyglycolide antibiotic 
implants in the treatment of osteomyelitis. A canine 
model. J Bone Joint Surg Am 1994; 76:1500-6; 
PMID:7929497.
12. Mäkinen TJ, Veiranto M, Lankinen P, Moritz N, 
Jalava J, Törmälä P, et al. In vitro and in vivo release 
of ciprofloxacin from osteoconductive bone defect 
filler. J Antimicrob Chemother 2005; 56:1063-8; 
PMID:16234335; http://dx.doi.org/10.1093/jac/
dki366.
www.landesbioscience.com Biomatter e23162-13
37. Jeong SI, Kim BS, Lee YM, Ihn KJ, Kim SH, 
Kim YH. Morphology of elastic poly(L-lactide-co-ε-
caprolactone) copolymers and in vitro and in vivo deg-
radation behavior of their scaffolds. Biomacromolecules 
2004; 5:1303-9; PMID:15244444; http://dx.doi.
org/10.1021/bm049921i.
38. Fernández J, Etxeberria A, Sarasua JR. Synthesis, 
structure and properties of poly(L-lactide-co-ε-
caprolactone) statistical copolymers. J Mech Behav 
Biomed Mater 2012; 9:100-12; PMID:22498288; 
http://dx.doi.org/10.1016/j.jmbbm.2012.01.003.
39. Herbert IR. Statistical analysis of copolymer sequence 
distribution. In: Ibbet RN, ed. NMR Spectroscopy of 
Polymers. London: Blackie Academic & Professional, 
1993:50-79.
40. Lemmouchi Y, Schacht E, Lootens C. In vitro release 
of trypanocidal drugs from biodegradable implants 
based on poly(ε-caprolactone) and poly(D,L-lactide). 
J Control Release 1998; 55:79-85; PMID:9795018; 
http://dx.doi.org/10.1016/S0168-3659(98)00021-2.
41. Li S. Hydrolytic degradation characteristics of aliphatic 
polyesters derived from lactic and glycolic acids. J 
Biomed Mater Res 1999; 48:342-53; PMID:10398040; 
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 0 2 / ( S I C I ) 1 0 9 7 -
4636(1999)48:3<342::AID-JBM20>3.0.CO;2-7.
42. Ahmed J, Zhang J, Song Z, Varshney SK. Thermal 
properties of polylactides - effect of molecular mass and 
nature of lactide isomer. J Therm Anal Calor 2008:1-8.
43. Li S, Garreau H, Vert M. Structure-property rela-
tionships in the case of the degradation of massive 
poly(α-hydroxy acids) in aqueous media - part 3 
influence of the morphology of poly(l-lactic acid). J 
Mater Sci Mater Med 1990; 1:198-206; http://dx.doi.
org/10.1007/BF00701077.
44. Sarasua J,  Prud’homme RE, Wisniewski M, Le Borgne 
A, Spassky N. Crystallization and melting behavior 
of polylactides. Macromolecules 1998; 31:3895-905; 
http://dx.doi.org/10.1021/ma971545p.
45. Shore EC, Holmes E. Porous hydroxyapatite. In: Hench 
LL, Wilson J, eds. An Introduction to Bioceramics. 
Singapore: World Scientific Publishing, 1993:181-198.
46. ISO 15814. Implants for surgery – copolymers and 
blends based in polylactide – in vitro degradation test-
ing.
47. Su L, Jia W, Hou C, Lei Y. Microbial biosensors: 
a review. Biosens Bioelectron 2011; 26:1788-99; 
PMID:20951023; http://dx.doi.org/10.1016/j.
bios.2010.09.005.
48. Galluzzi L, Karp M. Whole cell strategies based on lux 
genes for high throughput applications toward new 
antimicrobials. Comb Chem High Throughput Screen 
2006; 9:501-14; PMID:16925511; http://dx.doi.
org/10.2174/138620706777935351.
49. Moir DT, Ming Di, Opperman T, Schweizer HP, 
Bowlin TL. A high-throughput, homogeneous, bio-
luminescent assay for Pseudomonas aeruginosa gyrase 
inhibitors and other DNA-damaging agents. J Biomol 
Screen 2007; 12:855-64; PMID:17644773; http://
dx.doi.org/10.1177/1087057107304729.
25. Paakinaho K, Ellä V, Syrjälä S, Kellomäki M. Melt 
spinning of poly(l/d)lactide 96/4: Effects of molecular 
weight and melt processing on hydrolytic degradation. 
Polym Degrad Stabil 2009; 94:438-42; http://dx.doi.
org/10.1016/j.polymdegradstab.2008.11.010.
26. Daculsi G, Goyenvalle E, Cognet R, Aguado E, Suokas 
EO. Osteoconductive properties of poly(96L/4D-
lactide)/beta-tricalcium phosphate in long term 
animal model. Biomaterials 2011; 32:3166-77; 
PMID:21315446; http://dx.doi.org/10.1016/j.bioma-
terials.2011.01.033.
27. Duvvuri S, Gaurav Janoria K, Mitra AK. Effect of 
polymer blending on the release of ganciclovir from 
PLGA microspheres. Pharm Res 2006; 23:215-23; 
PMID:16320000; http://dx.doi.org/10.1007/s11095-
005-9042-6.
28. Zamoume O, Thibault S, Regnié G, Mecherri MO, 
Fiallo M, Sharrock P. Macroporous calcium phosphate 
ceramic implants for sustained drug delivery. Mater Sci 
Eng C 2011; 31:1352-6; http://dx.doi.org/10.1016/j.
msec.2011.04.020.
29. Kankilic B, Bayramli E, Kilic E, Dağdeviren S, 
Korkusuz F. Vancomycin containing PLLA/β-TCP 
controls MRSA in vitro. Clin Orthop Relat Res 
2011; 469:3222-8; PMID:21918801; http://dx.doi.
org/10.1007/s11999-011-2082-9.
30. Luginbuehl V, Ruffieux K, Hess C, Reichardt D, von 
Rechenberg B, Nuss K. Controlled release of tetracy-
cline from biodegradable β-tricalcium phosphate com-
posites. J Biomed Mater Res B Appl Biomater 2010; 
92:341-52; PMID:19904817.
31. Baker R. Controlled Release of Biologically Active 
Agents. New York: John Wiley & Sons, 1987.
32. Pitt CG. Poly-ε-caprolactone and its copolymers In: 
Chasin M, Langer R, eds. Biodegradable Polymers as 
Drug Delivery Systems. New York: Marcel Dekker Inc., 
1990:71-120.
33. Pitt CG, Jeffcoat AR, Zweidinger RA, Schindler A. 
Sustained drug delivery systems. I. The permeabil-
ity of poly(ε-caprolactone), poly(DL-lactic acid), and 
their copolymers. J Biomed Mater Res 1979; 13:497-
507; PMID:438232; http://dx.doi.org/10.1002/
jbm.820130313.
34. Bowker KE, Wootton M, Rogers CA, Lewis R, 
Holt HA, MacGowan AP. Comparison of in-vitro 
pharmacodynamics of once and twice daily cipro-
floxacin. J Antimicrob Chemother 1999; 44:661-
7; PMID:10552983; http://dx.doi.org/10.1093/
jac/44.5.661.
35. Mouriño V, Boccaccini AR. Bone tissue engineer-
ing therapeutics: controlled drug delivery in three-
dimensional scaffolds. J R Soc Interface 2010; 7:209-
27; PMID:19864265; http://dx.doi.org/10.1098/
rsif.2009.0379.
36. Holden MTG, Ram Chhabra S, de Nys R, Stead P, 
Bainton NJ, Hill PJ, et al. Quorum-sensing cross talk: 
isolation and chemical characterization of cyclic dipep-
tides from Pseudomonas aeruginosa and other gram-
negative bacteria. Mol Microbiol 1999; 33:1254-66; 
PMID:10510239; http://dx.doi.org/10.1046/j.1365-
2958.1999.01577.x.
13. Koort JK, Suokas E, Veiranto M, Mäkinen TJ, Jalava J, 
Törmälä P, et al. In vitro and in vivo testing of bioab-
sorbable antibiotic containing bone filler for osteomy-
elitis treatment. J Biomed Mater Res A 2006; 78:532-
40; PMID:16736479; http://dx.doi.org/10.1002/
jbm.a.30766.
14. Koort JK, Makinen TJ, Suokas E, Veiranto M, Jalava J, 
Tormala P, et al. Sustained release of ciprofloxacin from 
an osteoconductive poly(DL)-lactide implant. Acta 
Orthop 2008; 79:295-301; PMID:18484258; http://
dx.doi.org/10.1080/17453670710015111.
15. Mäkinen TJ, Veiranto M, Knuuti J, Jalava J, Törmälä 
P, Aro HT. Efficacy of bioabsorbable antibiotic con-
taining bone screw in the prevention of biomaterial-
related infection due to Staphylococcus aureus. Bone 
2005; 36:292-9; PMID:15780955; http://dx.doi.
org/10.1016/j.bone.2004.11.009.
16. Miyai T, Ito A, Tamazawa G, Matsuno T, Sogo 
Y, Nakamura C, et al. Antibiotic-loaded poly-ε-
caprolactone and porous β-tricalcium phosphate 
composite for treating osteomyelitis. Biomaterials 
2008; 29:350-8; PMID:17977596; http://dx.doi.
org/10.1016/j.biomaterials.2007.09.040.
17. Lucke M, Wildemann B, Sadoni S, Surke C, Schiller 
R, Stemberger A, et al. Systemic versus local applica-
tion of gentamicin in prophylaxis of implant-related 
osteomyelitis in a rat model. Bone 2005; 36:770-
8; PMID:15794930; http://dx.doi.org/10.1016/j.
bone.2005.01.008.
18. Alvarez H, Castro C, Moujir L, Perera A, Delgado A, 
Soriano I, et al. Efficacy of ciprofloxacin implants in 
treating experimental osteomyelitis. J Biomed Mater Res 
B Appl Biomater 2008; 85:93-104; PMID:17696153; 
http://dx.doi.org/10.1002/jbm.b.30921.
19. Tiainen J, Knuutila K, Veiranto M, Suokas E, Törmälä 
P, Kaarela O, et al. Pull-out strength of multifunc-
tional bioabsorbable ciprofloxacin-releasing polylac-
tide-polyglycolide 80/20 tacks: an experimental study 
allograft cranial bone. J Craniofac Surg 2009; 20:58-
61; PMID:19164990; http://dx.doi.org/10.1097/
SCS.0b013e318190df48.
20. Waknis V, Jonnalagadda S. Novel poly-DL-lactide-
polycaprolactone copolymer based flexible drug deliv-
ery system for sustained release of ciprofloxacin. Drug 
Deliv 2011; 18:236-45; PMID:21189060; http://
dx.doi.org/10.3109/10717544.2010.528070.
21. Castro C, Évora C, Baro M, Soriano I, Sánchez E. 
Two-month ciprofloxacin implants for multibacterial 
bone infections. Eur J Pharm Biopharm 2005; 60:401-
6; PMID:15996581; http://dx.doi.org/10.1016/j.
ejpb.2005.02.005.
22. Castro C, Sánchez E, Delgado A, Soriano I, Núñez 
P, Baro M, et al. Ciprofloxacin implants for bone 
infection. In vitro-in vivo characterization. J Control 
Release 2003; 93:341-54; PMID:14644584; http://
dx.doi.org/10.1016/j.jconrel.2003.09.004.
23. Koort JK, Mäkinen TJ, Suokas E, Veiranto M, Jalava 
J, Knuuti J, et al. Efficacy of ciprofloxacin-releas-
ing bioabsorbable osteoconductive bone defect filler 
for treatment of experimental osteomyelitis due to 
Staphylococcus aureus. Antimicrob Agents Chemother 
2005; 49:1502-8; PMID:15793132; http://dx.doi.
org/10.1128/AAC.49.4.1502-1508.2005.
24. Mäkinen T. Osteomyelitis and orthopedic implant 
infections, PhD thesis, University of Turku, 2005.
  
 
 
Publication III 
 
 
Ahola, N., Veiranto., M., Männistö, N., Karp, M., Rich, J., Efimov, A., Seppälä, J.  
and Kellomäki, M. 
Processing and sustained in vitro release of rifampicin containing composites to enhance the 
treatment of osteomyelitis 
Biomatter, 2 (2012), 213-225 
 
Reprinted according to the Creative Commons Attribution 3.0 Licence 
Copyright © 2012 The Authors 
Processing and sustained in vitro release
of rifampicin containing composites to enhance
the treatment of osteomyelitis
Niina Ahola,1,2,* Minna Veiranto,1,3 Noora Männistö,1 Matti Karp,4 Jaana Rich,5 Alexander Efimov,4 Jukka Seppälä5
and Minna Kellomäki1,2
1Department of Biomedical Engineering; Tampere University of Technology; Tampere, Finland; 2BioMediTech; Tampere, Finland; 3Bioretec Ltd; Tampere, Finland; 4Department of
Chemistry and Bioengineering; Tampere University of Technology; Tampere, Finland; 5Department of Biotechnology and Chemical Technology; School of Chemical Technology;
Aalto University; Espoo, Finland
Keywords: drug release, antibiotic, rifampicin, biodegradable, poly(L-lactide-co-caprolactone), polylactide
The objective in this study was to develop an osteoconductive, biodegradable and rifampicin releasing bone filling
composite material for the treatment of osteomyelitis, a bacterial infection of bone that is very difficult and expensive to
treat. The composite material will be used together with a ciprofloxacin releasing composite, because of the rapid
development of resistant bacteria when rifampicin is used alone. Three composites were manufactured by twin-screw
extrusion. The polymer matrix for the composites was poly(L-lactide-co-ε-caprolactone) 70/30 and all the composites
contained 8 wt% (weight percent) of rifampicin antibiotic. The b-TCP contents of the composites were 0 wt%, 50 wt%
and 60 wt%. The composites were sterilized by gamma irradiation before in vitro degradation and drug release tests. The
hydrolytical degradation of the studied composites proceeded quickly and the molecular weight of the polymer
component of the composites decreased rapidly. Rifampicin release occurred in four phases in which the high b-TCP
content of the samples, polymer degradation and mass loss all played a role in determining the phases. The ceramic
component was seen to have a positive effect on the drug release. The composite with 50 wt% of b-TCP showed the
most promising rifampicin release profile and it also showed activity against a common osteomyelitis causing bacteria
Pseudomonas aeruginosa. A clear inhibition zone was formed in 16 h incubation. Overall, the tested materials showed
great potential to be developed into a bone filler material for the treatment of osteomyelitis or other bone related
infections in combination with the ciprofloxacin releasing materials.
Introduction
This paper presents the in vitro degradation and drug release
results of three rifampicin releasing composite materials as well as
the effect of the most promising rifampicin releasing composite
against a common osteomyelitis causing bacteria Pseudomonas
aeruginosa. The materials are intended for use in the treatment of
osteomyelitis or other bone related infections together with the
ciprofloxacin releasing composite materials presented in our
accompanying study.1 The composites are bioabsorbable and
osteoconductive due to the degradation ability of the polymer
matrix (poly-L-lactide-co-ε-caprolactone) (PLCL) and the osteo-
coductive properties of the ceramic filler, β-tricalcium phosphate
(β-TCP). It is envisaged that these materials will enable the
simultaneous use of bone fillers that contain different antibiotics.
The surgeon applying the fillers will be able to decide which
antibiotics and in which ratio to use based on the condition of the
patient and the pathogen in question. Such materials have also
been requested in the literature.2
Osteomyelitis, which is very challenging and expensive to treat,
is a bone infection that is caused by bacteria, commonly
Staphylococcus aureus, Pseudomonas aeruginosa or Staphylococcus
epidermidis.3 Traditional treatment includes surgical debridement
of the infected tissue followed by long courses intravenously or
orally administered antibiotics.4 Poor blood circulation in the
infected bone tissue can prevent adequate antibiotic concentra-
tions in the infection site being achieved. To overcome this
problem, local antibiotic delivery has been applied with
commercially available gentamycin releasing Septopal1 beads.
The problem with this method of antibiotic delivery is that the
beads are not biodegradable and require surgical removal followed
by bone grafting.5,6
Rifampicin has been used together with ciprofloxacin and other
fluoroquinolones in the treatment of osteomyelitis or other bone
related infections. The use of rifampicin together with other
antibiotics in the treatment of Staphylococcus aureus infections has
been reviewed by Perlroth et al.7 In general, in in vivo and human
studies, the combination of ciprofloxacin with rifampicin was
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more effective than monotherapy especially in prosthetic device
infections and osteomyelitis.8 Rifampicin has also been studied
together with fluoroquinolones in the treatment of deep sternal
wound infections and studies have shown that using rifampicin
together with fluoroquinolones improves the outcome.9 The fact
that rifampicin is effective against bacterial biofilms encourages
the use of rifampicin together with other antibiotics.7,10
Rifampicin should never be used alone because resistant bacterial
strains develop quite rapidly as a result.7,10
In most of the studies reported about the combination therapy
of rifampicin with other antibiotics, the delivery route of the
antibiotics has been either intravenous or oral. With local
antibiotic treatment, bone tissue that lacks adequate blood
circulation can be effectively treated and the pathogens
eradicated.11-19 Previous studies have also shown that with local
treatment, the drug concentrations in the blood or other tissues
are low, at least a decade lower than in the surrounding
tissues,20-22 which naturally leads to decreased side effects like
nausea which has been reported often as the cause for
discontinuation of the therapy or continuing the therapy with
lower dose.8,10
In this study, the potential of the materials to release rifampicin
in adequate concentrations and the degradation were only tested
in vitro. There is still a need for in vivo and clinical testing of the
materials. The materials do, however, show great potential for use
in the treatment of osteomyelitis and other bone related infections
and are now ready to be tested further in vivo.
Results and Discussion
The effect of processing and sterilization on the materials. The
processing method used for the composite materials was twin-
screw extrusion and it can be assumed that the ceramic and drug
particles were evenly distributed due to the efficient mixing in the
extrusion process. The composites are denoted PLCL + R [poly
(L-lactide-co-ε-caprolactone) (PLCL) with 8 wt% of rifampicin in
feed], PLCL + TCP50 + R [PLCL with 50 wt% of β-tricalcium
phosphate (β-TCP) and 8 wt% of rifampicin in feed] and PLCL +
TCP60 + R (PLCL with 50 wt% β-TCP and 8 wt% of rifampicin
in feed). Processing did not cause degradation detectable with
SEC measurements. However, sterilization using gamma irra-
diation with a measured dose of 29–35 kGy caused significant
degradation, as was expected.23 The average molecular weight
(Mw) of the raw material was measured as 246,000 g/mol and the
number average molecular weight (Mn) 150,000 g/mol. The Mw
of the PLCL + R decreased 30% during the sterilization stage and
the Mw of the PLCL + TCP50 + R and PLCL + TCP60 + R
decreased 40% and 30%, respectively. The Mn decreased 40% for
all the composites during the sterilization stage. The polydisper-
sity of PLCL + R did not change during processing but increased
from 1.6 to 2.0 during sterilization. For PLCL + TCP50 + R and
PLCL + TCP60 + R, the PD decreased from 1.6 to 1.5 during
processing and increased slightly to 1.8 for PLCL + TCP50 + R
and 1.6 for PLCL + TCP60 + R.
The residual monomer content of the raw material measured
by gas chromatography was 0.08 wt% for L-lactide monomer and
below detection limit (, 0.02 wt%) for ε-caprolactone monomer.
The L-lactide and ε-caprolactone monomer contents of the
processed samples were analyzed from two points in the
processing batch and there were two parallel samples in both.
The L-lactide monomer content decreased slightly during
processing. It was 0.04–0.07 mol% and the caprolactone
monomer content was below 0.02 mol% for all tested samples.
Because there were no significant differences in the monomer
contents of the manufactured materials, it can be assumed that the
monomers did not cause differences in the hydrolytic degradation
behavior of the studied composites.24
UV measurements utilizing the isosbestic point. The UV-
measurements of rifampicin proved challenging due to the
oxidation of rifampicin to rifampicin quinone in aqueous
solutions and in the presence of atmospheric oxygen. This can
be seen as a change in the UV-spectrum of a rifampicin solution
as well as a change in the color of the solution.25 Rifampicin
quinone has a UV-spectrum partly similar to rifampicin and also
has antibacterial properties.25 The fact that rifampicin quinone
degrades further to other compounds that do not have absorbance
in the UV/V is area naturally affects the accuracy of this method.
Part of the rifampicin is undetected if it has already degraded. The
accuracy is highest when the measurements are made at short
intervals, not letting the dissolution medium stay unchanged for
long periods. However, as the release test period in this study was
long, part of the rifampicin that had oxidized to rifampicin
quinone, had time to degrade to other compounds that do not
have absorptivity in the UV/V is area, even if the measurements
were performed in short intervals. It has also been reported that
rifampicin degrades more in solutions with low rifampicin
concentration.26 On the other hand, Le Guellec et al. suggest
possible in vivo stabilization of the molecule.27
In the later stages of the release test period, it was noticed that
the degradation products of the polymer matrix induce a broad
UV-peak at the beginning of the scanned area (200–220 nm).
This broad peak, however, did not significantly interfere with the
use of the isosbestic point at 226 nm.
Rifampicin release from the materials. The measured initial
rifampicin contents were 6.5 wt% for PLCL + R, 7.9 wt% for
PLCL + TCP50 + R and 7.8 wt% for PLCL + TCP60 + R.
The cumulative release of rifampicin from the studied materials
is presented in Figure 1A. It can be seen that the release occurred
in four phases and that the β-TCP content of the composites had
a significant effect on the rifampicin release. Rifampicin release
from the PLCL + TCP60 + R was faster than from the PLCL +
TCP50 + R and reached 80% in 130 d. Rifampicin release from
the PLCL + TCP50 + R was slower but closer to zero order release
that is the desirable release profile in this case. After 150 d, the
release slowed down. The rifampicin release from PLCL + R
showed a lag phase at the beginning of the test series that lasted
about 50 d, during which time the release of the drug was very
slow. When compared with the ciprofloxacin release,1 the lag
phase lasted longer. This is likely due to the fact that the
rifampicin molecule is larger than ciprofloxacin, and this causes
slower diffusion through the polymer matrix and the polymer
degradation and mass loss have a stronger effect on the release.
214 Biomatter Volume 2 Issue 4
Because of the complex nature of the rifampicin release, the
phases of the release should be considered separately. There are
several factors affecting the drug release in this case including:
the geometry of the device (cylindrical with a rough surface),
high β-TCP content that introduces porosity to the matrix, the
properties of the polymer change as it degrades and mass loss.
The acceleration of the drug release around the inflection
points in the cumulative release curves (Fig. 1A) can be
easily seen in Figure 1B, where the daily release of rifampicin
is presented. The presence of the inflection points in the
cumulative release profile is characteristic for a release
mechanism that is a combination of diffusion and erosion
mechanisms.28
The first phase of the release was the burst at the beginning of
the release. It was during this phase that the rifampicin molecules
near the surface were released. The burst in the release was larger
than what was observed for ciprofloxacin releasing pellets.1
Rifampicin is more soluble in water than ciprofloxacin which
may be the reason for the larger burst. The second phase of the
release lasted approximately until the time point of 53 d. During
this phase, the release was mainly governed by diffusion and the
release from PLCL + R showed a lag phase with almost negligible
Figure 1. The cumulative (A) and daily (B) release of rifampicin (R) from composites of poly(L-lactide-co-ε-caprolactone) (PLCL) and b-tricalcium
phosphate (TCP) with initial TCP contents of 0 wt%, 50 wt% and 60 wt% and rifampicin content of 8 wt%. Results shown as averages with standard
deviations (n = 5).
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release. From these observations, it can be concluded that the
release of rifampicin could not occur solely by diffusion through
the plain polymer matrix. The addition of β-TCP to the polymer
matrix accelerated the release markedly. β-TCP was likely to
introduce porosity to the composite, and thus the rifampicin
release could occur via pore diffusion in the time period up to
53 d. The composites containing both rifampicin and β-TCP
can be classified as complex monolithic dispersions because of
the high amount of filler in the composite. In these cases, the
release of the drug is often proportional to the square root of
time, but the rate of the release is higher than what is predicted
by the Higuchi model.28 The second phase of the rifampicin
release from the composites was proportional to t1/2 with R2
having values of 0.99 for PLCL + TCP50 + R, and 0.98 for
PLCL + TCP60 + R. The results were also fitted to the to the
power law kinetics equation (Eqn. 1):28,29
M
M
ktt n

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where Mt/M∞ is the fractional drug release, k is the release rate
constant, t is time and n the release exponent. The rifampicin
release from PLCL + TCP50 + R and PLCL + TCP60 + R had n
values of 0.53 and 0.44 respectively. For cylindrical geometry and
Fickian diffusion, the diffusion release exponent n would have a
value of 0.45. For Case II diffusion (or anomalous diffusion), the
n has values of 0.45 , n , 1. The result suggests that the
rifampicin release occurs by Case II diffusion28 from the PLCL +
TCP50 and by Fickian diffusion from PLCL + TCP60 + R
during the second phase of the release.
In the third phase, the drug release was accelerated due to the
increased permeability of the polymer caused by degradation.
Additionally, the polymer erosion started to play a role in
increasing the release rate. With a non-eroding system, the drug
release would slowly decrease because it is often proportional to
the drug concentration in the device. In the case of a
biodegradable system, the increased permeability and polymer
erosion accelerate the release.28 Here, the third phase of the release
of PLCL + TCP50 + R obeyed again the t1/2 kinetics very well
(R2 = 0.99). The release from PLCL + TCP60 + R had at this
point reached 60% of the total cumulative release.
There was also a fourth phase to be seen in the release of PLCL
+ R and PLCL + TCP50 + R but not in the PLCL + TCP60 + R.
The fourth phase of the release was also not seen in the
ciprofloxacin release results.1 The inflection point in the release
curves was at the time point of 116 d. It coincided well with the
acceleration of mass loss from the composites. The mass loss was
already notable at that time and the Mw of the polymer had
decreased to the level of 9,000–14,000 g/mol. From the PLCL +
TCP60 + R, the available drug for release had apparently been
released already at this time point and thus no phase change was
seen there.
Rifampicin remaining in the samples after the in vitro test
series. At the time point of 250 d, the drug release had decreased
to an almost negligible level and 70–85% of the total rifampicin
loaded in the composites had been released. The test series was
continued for 392 d but no notable rifampicin release was
detected. The remaining rifampicin in the composites was
measured after the drug release test had been terminated. The
measurement was done in a similar way to the initial rifampicin
content measurements. The brownish red color of the pellet-
shaped samples indicated that some rifampicin remained in the
samples even though drug release had ceased. There has been
evidence about rifampicin being incorporated within the
crystalline parts of a polycaprolactone polymer and this might
be the case here although the crystals may be formed of L-lactide
units.30 The remaining portion of the initial rifampicin that was
measured after the termination of the test series was 10.7% for
PLCL + R, 5.0% for PLCL + TCP50 + R and 3.4% for PLCL +
TCP60 + R. When combined with the measured released
rifampicin, the total rifampicin amount detected did not reach
100%. The fact that rifampicin oxidizes to rifampicin quinone
which is further degraded to compounds with no UV-absorbance,
explains why part of the rifampicin seems to have disappeared.25
Unfortunately, this affects the accuracy of this method in
analyzing the released rifampicin. However, the method can be
used to estimate the rifampicin release and compare the
composites with each other. In in vivo conditions, the situation
may be different. Le Guellec et al.27 found that rifampicin stability
was better in rifampicin containing plasma samples taken from
patients treated with rifampicin than in plasma samples where
rifampicin was added in the laboratory. This improved stability
suggests that rifampicin may be more stable in vivo than in vitro.
Inhibition zone testing. The effect of the rifampicin releasing
composite containing 50 wt% of β-TCP against the common
osteomyelitis causing bacteria Pseudomonas aeruginosa was tested
using bioluminescence imaging. The results are illustrated with
Figure 2, where the bioluminescence imaging results (16 h
incubation) of a 6-well plate cultured with Pseudomonas aeruginosa
and rifampicin containing composite pellets are shown. The
antibiotic containing composite pellets are on the lower row and
control pellets without antibiotics are on the top row. The results
show that the composite material releases rifampicin in levels high
enough to eradicate Pseudomonas aeruginosa. The inhibition zone
can be seen as a dark blue area surrounding the antibiotic releasing
pellets in Figure 2. The blue area indicates dead bacteria whereas
the other colors indicate still living bacteria. First signs of the
forming inhibition zone were observed already after two hours of
incubation. If compared with the bioluminescence results of
ciprofloxacin releasing pellets1 the inhibition zone was smaller
with rifampicin. The larger molecular weight of rifampicin may
affect the diffusion of the antibiotic in agar and make it rather
slow, which is seen as the slow growth of the inhibition zone.
However, as seen in the drug release results, the initial burst was
larger with rifampicin releasing pellets than with ciprofloxacin
pellets and this is probably due to the better solubility of
rifampicin.
In vitro degradation of the composites. Molecular structure.
The 1H NMR spectra were measured from eight samples (raw
material PLCL, plain rifampicin, PLCL + R at 0, 26 and 52 weeks
and PLCL + TCP50 + R at 0, 26 and 52 weeks in vitro). The 1H
NMR signals of the polymer were assigned and the data were
analyzed in the same way as in our accompanying study.1 The
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results show a similar effect of change in the comonomer ratio of
the copolymer as the hydrolysis proceeded that was seen with
ciprofloxacin antibiotic containing composites.1 The L-lactide to
ε-caprolactone molar ratio was increased from 68/32 of the raw
material and the samples at 0 weeks to 77/23 of the PLCL +
TCP50 + C and 82/18 of the PLCL + C at 52 weeks. A similar
effect has also been reported by In Jeong et al.31
The microstructure of the copolymer was also studied similarly
to what was presented in our accompanying study.1 It was done
according to Herbert32 and Fernández.33 The results of the average
sequence length calculations showed the expected results based on
the findings of the ciprofloxacin containing materials.1 The PLCL
copolymer had a block structure with more random parts in
between. The randomness factor R had a value of 0.25 for the raw
material and close to that for the samples prior to in vitro testing.
The R factor decreased dramatically during the degradation of the
polymer to 0.18 for both PLCL + TCP50 + R and PLCL + R at
52 weeks. This decrease indicates that the more random parts of
the copolymer degrade first and the blocky structures that
comprise long L-lactide blocks remain in the structure. At the
beginning of the test series, the sequence lengths of L-lactide were
13 and increased to 23 and 31 for PLCL + TCP50 + R and PLCL
+ R at 52 weeks respectively. This supports the general
interpretation that random parts of the copolymer degrade first,
and thus the average sequence length is increased. The average
sequence length of ε-caprolactone was not significantly changed
during hydrolysis for any of the tested samples and had values of
5.5–7 for all the analyzed samples.
Signals of rifampicin were visible in the plain rifampicin sample
and for the composite samples only in the 0 week (after processing
and sterilization) samples. Due to the rather low sensitivity of
NMR, the low contents of rifampicin in the samples from the 26-
and 52-week time points were not seen in the NMR spectra. The
1H spectrum of plain rifampicin was compared with the spectra of
the 0 week samples. 1H NMR analysis reported by Cellai et al.
was also used when the signals were assigned to the protons of the
rifampicin molecule.34
Some of the rifampicin signals overlapped with the polymer
signal in the composite samples and could not be analyzed. These
were some of the protons in the ansa chain (protons 16, 18, 20,
21, 22, 2 and 31), protons 32 of the naphtalene ring, and protons
59 of the methyl group attached to the piperazinyl ring. The
signal assignment is presented as Figure 3 and the spectra can be
found as supplementary data.
The amide proton and the OH-groups of the naphthalene ring
were clearly visible at d 11.98 ppm, 13.11 ppm and 13.41 ppm,
Figure 2. Bioluminescence results of the rifampicin containing (8 wt%) composites of poly(L-lactide-co-ε-caprolactone) and 50 wt% of b-tricalcium
phosphate on a bacterial culture of light emitting Pseudomonas aeruginosa. Pellets containing rifampicin are on the lower row and corresponding
composites without rifampicin are on the top row and act as controls.
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respectively. Their chemical shifts were stable and the integrals
were in good stoichiometric ratio. The protons of the methylene
group located above the plane of the naphthalene ring (protons
45) showed a signal below 0 at d -0.31 ppm in plain unprocessed
rifampicin and processed PLCL + R and PLCL + TCP50 + R
samples. The fact that this signal is identical in all the samples
proves that the ansa chain has retained its original configuration.
If not, the signal of this group would have appeared elsewhere in
the spectrum. The ansa bridge protons 13, 14, 15, 17, 19, 23 and
25 were clearly visible, stable when compared between the
samples, and were in good stoichimetric agreement with the
rifampicin structure. The signals of the protons 37, 39 and 41 of
the methyl substituents of the ansa chain and the signals of the
protons 54 and 56 of the piperazine ring were in the shoulder of a
large polymer signal, and thus their accurate integration was not
possible. Additionally, signals of the equivalent protons 53 and 57
of piperazine ring appeared at d 3.02 overlapping with signals of
the protons 19 and 47 and thus could not be accurately
integrated. However, their combined integral showed that there
was no change between samples in either the positions of the
signals or their integrals.
As a conclusion of the NMR analysis of rifampicin, it can
be stated that no deviations of the original rifampicin structure
were found after the analysis of the composite samples and
plain rifampicin sample. Thus, rifampicin had maintained its
original structure during the processing and sterilization
stages.
Molecular weights, mass loss and water absorption. The decrease
of the molecular weights (both Mw and Mn) was rapid (Fig. 4A),
and when compared with the composites with ciprofloxacin
antibiotic reported in the accompanying study,1 there were no
significant differences in the degradation behavior. At the
beginning of the hydrolysis test series, the molecular weight of
the composites containing antibiotics degraded more rapidly than
composites without antibiotics,40 but the differences rapidly
leveled out. Overall, the degradation obeyed first order kinetics
with k values of 1.6  10−3 1/h for PLCL + R, 1.4  10−3 1/h for
PLCL + TCP50 + R, and 1.4  10−3 1/h for PLCL + TCP60 + R.
The values are very similar to those calculated for ciprofloxacin
containing composites.1 After 52 weeks of hydrolysis at 37°C and
pH 7.4, the molecular weights of all the composites had decreased
by 98% to 2% of the initial value of the raw material.
The SEC distribution plots showed emerging bimodality at 20
weeks for PLCL + R and clear bimodality at 39 weeks for PLCL +
TCP50 + R and PLCL + TCP60 + R. The same kind of
bimodality is present in composites with ciprofloxacin antibiotic1
beginning from the 20th week of the test series. Bimodality in the
SEC distribution suggest that the blocky structure of the
copolymer, shown by the 1H NMR analysis, causes the random
parts of the copolymer to degrade first and this might cause an
Figure 3. Chemical structure, atom numbering and the 1H chemical shifts of rifampicin.
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increase in a certain part of the SEC distribution curve as the
blocky parts comprising mainly L-lactide monomers remain in the
polymer structure.
The mass loss of the tested materials was small and steady
during the first ten weeks. (Fig. 4B) During the first six weeks, the
mass loss was caused by the rifampicin release from the polymer
matrix. After this time point, the mass loss of the polymer started.
At the time point of 10 weeks, the mass loss of PLCL + R
accelerated and had already reached 50% at 26 weeks. The mass
losses of PLCL + TCP50 + R and PLCL + TCP60 + R were
steady and proceeded similarly for both of the composites. The
same kind of behavior was seen in the water absorption of the
tested materials. The PLCL + R showed accelerated water
absorption after 10 weeks. When compared with the results of
ciprofloxacin containing composites,1 the acceleration of the water
absorption and mass loss started earlier. Rifampicin is likely to be
more hydrophilic due to its molecular structure, and thus
increases the water absorption of the material.
β-TCP contents of the materials. The proportion of β-TCP in the
composites was seen to increase as polymer degradation
proceeded, as shown in Figure 5. The increase in the proportion
of β-TCP accelerated after 10 weeks in vitro which correlates well
Figure 4. Weight average molar weight (Mw) (A), and mass loss and water absorption (B) of the studied composites as a function of time in vitro. The
composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and b-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of 0 wt%,
50 wt% and 60 wt% and rifampicin content of 8 wt%. Error bars in part B are not visible due to the small values of standard deviations.
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with the acceleration of the mass loss of the polymer matrix.
β-TCP remained in the samples due to the very slow dissolution
of β-TCP.40
Thermal properties. The changes in the glass transition
temperatures (Tg) of the materials during the in vitro test series
are shown in Figure 6A. The Tg values presented in Figure 6A
were taken from the second heating to ensure comparable values
of the samples as their thermal histories were similar. Tgs of
23–25°C were measured after processing and sterilization of the
composites. This is in agreement with the literature.35 During the
degradation test series, the Tgs of the rifampicin containing
composites decreased until week 12. The same kind of decrease
was observed with composites with ciprofloxacin but the decrease
time period was longer, up to the 20th week.1 During the first 12
weeks, the Mw of the polymer decreased dramatically, which is
known to affect the Tg of a polymer.36 Additionally, the solubility
of the drug in the polymer may play a role in the glass transition
of the polymers and may plasticize the polymer causing a decrease
in Tg. An increase in the Tg after 12 weeks in vitro was due to the
change in the comonomer ratio, seen in the 1H-NMR analysis of
the copolymer. The proportion of ε-caprolactone comonomer in
the polymer decreased and the L-lactide increased.
Melting temperatures and melting enthalpies were analyzed
from the first heating of the samples because during the second
heating, the melting peaks no longer appeared due to fast cooling
in the DSC analysis. Most of the samples showed clear bimodality
in the melting peaks the same way which was observed for
ciprofloxacin containing composites.1 Melting temperatures in
general showed a clear increase up to the 20th week in the test
series (data not shown). They increased from the initial value of
115°C to 120–126°C at 20 weeks. After that the melting
temperatures started to decrease again and ended up at 106–
109°C at 52 weeks.
Melting enthalpies, which describe the crystallinity of the
polymer, were analyzed and corrected to correspond to the
combined polymer and rifampicin part of the composites.
Although absolute crystallinity values could not be calculated
because the theoretical value of 100% crystalline poly(L-lactide-
co-ε-caprolactone) 70/30 was not available, relative changes in the
crystallinity were observed. There was a steady increase in the
crystallinity of the composites throughout the test series (Fig. 6B).
This indicates an increase in crystallinity as the amorphous parts
of the polymer degrade first. Furthermore, the fact that shorter
polymer chains are more easily able to rearrange themselves into
crystals has an effect on the increasing crystallinity.37 The 1H
NMR study showed that there were rather long L-lactide blocks
in the copolymer and their proportion increased as the more
amorphous random parts of the copolymer degraded. As the
polymer chains were broken into shorter fragments, these blocks
formed crystals when they were more able to rearrange themselves.
Additionally, it was observed that the composite without β-TCP
showed higher melting enthalpies than the composites with
β-TCP, especially from the 20-week time point on. This
observation suggests that the presence of β-TCP in the composites
may have an inhibiting effect on the crystallization.
Microstructure. Some porosity was seen in the composites
containing β-TCP throughout the degradation test series. The
material without β-TCP did not show significant porosity. The
differences between composites containing 50 wt% or 60 wt% of
β-TCP were not notable. SEM micrographs showed pores of
different sizes in the samples throughout the hydrolysis test series
(Fig. 7A–C). Pores up to the size of 100–200 mm were observed
as well as smaller pores. Additionally, the surfaces of the pellet-
shaped samples were porous. (Fig. 7D–F).
Rifampicin antibiotic, or ciprofloxacin antibiotic in the
accompanying article1 were not observed to affect the porosity
in any way.
Conclusion
The tested composites showed rifampicin release profile with four
phases. The composite containing 50 wt% of β-TCP had the
most promising steady release profile. The β-TCP was observed to
accelerate the rifampicin release. The release from the composite
Figure 5. b-tricalcium phosphate (TCP) contents of the studied
composites as a function of time in vitro. The composites comprised of
poly(L-lactide-co-ε-caprolactone) (PLCL), TCP, and rifampicin (R) with
initial TCP contents of 50 wt% (TCP50), and 60 wt% (TCP60) and
rifampicin content of 8 wt%. Results shown as averages with standard
deviations (n = 5). (A) PLC + 50% TCP + rifampcin and (B) PLC + 60% TCP
+ rifampcin.
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without β-TCP showed a long lag phase that was probably due to
the large size of the rifampicin molecule and low diffusivity of the
drug in the polymer. As the polymer degradation proceeded and
the permeability of the polymer increased, the rifampicin release
also accelerated. The decrease of the molecular weights was rapid
as was expected and the 1H NMR results showed a change in the
comonomer ratio toward an increasing lactide comonomer
content as degradation proceeded. Additionally, the polymer
was observed to have a rather blocky structure, having long
L-lactide blocks in the structure. The composite that contained
50 wt% of β-TCP showed activity in eradicating common
osteomyelitis causing bacteria Pseudomonas aeruginosa which was
seen as development of an inhibition zone in bacterial cultures
utilizing bioluminescence.
Because rifampicin should not be used alone, a ciprofloxacin
releasing composite material was developed in the accompanying
study1 for use with the rifampicin-releasing composite material
reported here. Both of the reported composite materials show
Figure 6. Glass transition temperatures (Tg) (A) and melting enthalpies (DHf) (B) of the copolymer in the studied composites as a function of time in vitro.
The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and b-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of
0 wt%, 50 wt% and 60 wt%. Results shown as averages with standard deviations (n = 2–5).
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potential to be developed into biodegradable, antibiotic releasing
and osteoconductive bone-grafting materials that can be used
together in the treatment of osteomyelitis and other bone related
infections. In vitro tests are always needed to select the optimal
composition of the materials for further studies and according to
the results reported here, the choice is the composite with 50 wt%
of β-TCP. However, preclinical followed by clinical studies are
needed to establish the effect of these materials when they are
implanted in living tissue both alone and together.
Materials and Methods
The processing and characterization methods, except UV-analysis,
follow the same principles as in our article concerning
ciprofloxacin releasing materials.1
Materials. Medical grade poly(L-lactide-co-ε-caprolactone)
(PLCL) with the comonomer ratio of 70/30 and Mw of
246,000 g/mol was purchased from Purac Biomaterials.
β-tricalcium phosphate (β-TCP) (granule size , 38 mm) was
purchased from Plasma Biotal Ltd. Rifampicin antibiotic
(molecular structure shown in Fig. 3) was purchased from
Orion Pharma. Sörensen buffer solution was prepared according
to the standard ISO 1581438 and the chemicals used for the buffer
solution (Na2HPO4 and KH2PO4) were purchased from J.T.
Baker. The chemicals used for the bioluminescence bacterial
cultures were: Gentamicin sulfate (Sigma-Aldrich), Isopropyl-β-
D-thiogalaktopyranoside (IPTG) (Fermentas), Trypton (Lab M
Limited), Yeast extract (Lab M Limited), Sodium Chloride
(Merck), Agar (Merck).
Processing and sterilization. Dried polymer, β-TCP powder,
and rifampicin (72 h in vacuum at room temperature) were
processed into rod-shaped billets with a diameter of approximately
2.5 mm with a co-rotating custom-built intermeshing twin-screw
extruder (L/D ratio = 22.5) in a nitrogen atmosphere. PLCL
copolymer, β-TCP and rifampicin antibiotic were delivered to the
process with separate gravimetric screw feeders. The mixing of the
components took place in the extruder. A haul-off unit was used
to guide the extrudate from the die and the diameter of the billets
was fine-tuned adjusting the speed of the haul-off unit. Three
different composites were processed. Each composite had 8 wt%
rifampicin antibiotic in feed and different β-TCP contents (0, 50
and 60 wt%). These composites are denoted PLCL + R, PLCL +
TCP50 + R and PLCL + TCP60 + R, respectively. Pellet-shaped
samples (length approximately 2.5 mm) were cut from the billets.
Before degradation tests were performed, the samples were packed
and sterilized using gamma irradiation (minimum dose 25 kGy).
Drug release study. Weighed test samples (each test sample
consisted of 15 pellets, approximately 300 mg in total) were
placed in brown glass bottles along with 20 ml Sörensen buffer
solution. Five parallel test samples were tested for each composite
material. The bottles were placed in an incubator shaker at 37°C.
At predetermined time intervals, the buffer solution was
withdrawn from each of the bottles and replaced with fresh
solution. The amount of buffer solution and the periodical change
to fresh buffer solution enabled sink conditions to be valid
throughout the test series. The amount of released rifampicin was
determined from the buffer solution using a Unicam UV 500
spectrometer (ThermoSpectronic) at isosbestic point at wave-
length of 226 nm. A wavelength area from 190 to 650 nm was
scanned in order to detect possible changes in the rifampicin
molecular structure which cause deviation in the UV-spectrum.
Rifampicin is known to oxidize to rifampicin quinone in mildly
alkaline aqueous solutions and in the presence of atmospheric
oxygen. This can be seen as a change in the UV-spectrum of a
rifampicin solution as well as a change in the color of the solution.
Rifampicin quinone has a partly similar UV-spectrum to
rifampicin and it also possesses antibacterial properties.25 At a
wavelength of 226 nm, an isosbestic point was found that could
be used in the rifampicin content measurements. At this point, we
can calculate the initial rifampicin content of the solution despite
Figure 7. SEM micrographs of the composites of poly(L-lactide-co-ε-caprolactone) (PLCL), 60 wt% of b-tricalcium phosphate (TCP) and rifampicin.
(A–C) fractured surfaces after 0 weeks, 26 weeks and 52 weeks in vitro respectively. (D–F) Outer surfaces after 0 weeks, 26 weeks and 52 weeks in vitro,
respectively.
222 Biomatter Volume 2 Issue 4
the fact that it has partly oxidized to rifampicin quinone, because
the absorbance of these compounds is the same at this wavelength.
The fact that rifampicin quinone degrades further to other
compounds without UV-absorbance, may affect the accuracy of
this method. The accuracy is at its best if the measurements are
made at short intervals, not letting the dissolution medium stay
unchanged for long periods.
Inhibition zone testing using bioluminescence imaging. The
effect of the antibiotic releasing composite materials against one of
the common osteomyelitis causing bacteria Pseudomonas aeruginosa,
which was used as a non-pathogenic model organism, was tested
using bioluminescence imaging based on the ability of genetically
engineered bacteria to emit light. The antibiotic containing
composite material chosen for this study was the composite
containing 50 wt% of β-TCP (PLCL + TCP50 + R) based on the
most promising drug release results. Composite of PLCL and 50 wt
% β-TCP without antibiotics was used as control.
An engineered bacteria strain of Pseudomonas aeruginosa PAO-
LAC carrying plasmid pUCP24GW39 was used as the biosensor.
The bacteria were cultured on antibiotic plates overnight at 30°C
and 300 rpm (1 mM IPTG, 10 mg/ml gentamycin), and suitable
colonies were moved into liquid culturing in LB (5 g/l yeast
extract, 10 g/l tryptone and 5 g/l NaCl). If the bacteria did not
produce luminescence as wished in the morning, 1/50 dilution
was made in a culture tube and it was incubated at 37°C and
300 rpm for three hours. The level of luminescence of the cultures
was measured by using Plate ChameleonTM multilabel counter
1.001 (Hidex Ltd.), and at volume of 200 ml. Counts of 1.1–2.3
 106 were found satisfying.
Layers of LB-agar (agar 15 g/l, 2 ml) were cast into 6-well plate,
and the controls and antibiotic containing composite pellets were
placed on top of them (each pellet into its own well). Bacteria
were mixed with soft LB-agar (7.5 g/l) solution and cast on top of
the first layers. The amount of bacterial culture was dependent on
the luminescence level. It was 350–500 ml/well. After solidifica-
tion, the plate was taken to the imaging station of Xenogen
VivoVision IVIS1 Lumina luminescence camera (Caliper
LifeSciences). Pictures were taken every 20 min for 16 h with
exposure time of 30 sec. The pictures were analyzed using Living
Image1 3.1 program (Caliper LifeSciences).
In vitro degradation study. Degradation tests were conducted
at 37°C in vitro following the standard ISO 15814.38 First,
weighed test samples (each test sample consisted of 15 pellets)
were placed in brown glass bottles along with 20 ml Sörensen
buffer solution. Five parallel test samples of each composite
material were tested at each time point. The bottles were placed in
an incubator shaker at 37°C. The pH of the buffer solution was
measured periodically with a calibrated pH meter and the buffer
solutions were changed every two weeks at the beginning of the
test series and once a week as the degradation accelerated. Test
samples were withdrawn at predetermined time points of 2, 4, 6,
8, 10, 12, 16, 20, 26, 30 and 52 weeks.
Methods of analysis. Residual monomer. The determination of
residual L-lactide and ε-caprolactone monomer contents before
and after processing was performed by Ramboll Analytics Oy. The
ε-caprolactone and L-lactide contents were measured after
chloroform extraction of the samples using gas chromatography
(DC8000, CE Instruments) and after chloroform dilution using
an FI-detector. The measuring resolution was 0.02%.
Initial drug content measurements. Samples of about 150 mg
were weighed from each manufactured composition and dissolved
in 50 ml of chloroform (J.T. Baker). The amount of rifampicin in
the chloroform solution was determined using a Unicam UV 540
Spectrophotometer (ThermoSpectronic) at a maximum absorp-
tion wavelength of 349 nm. The rifampicin concentration in the
solution was calculated using Beer-Lambert law and standard
curves prepared with known concentrations of rifampicin.
Mass loss, water absorption and pH. After the test samples were
withdrawn from the incubator shaker, they were rinsed twice with
distilled water and the surfaces were carefully wiped with tissue
paper. The test samples were weighed immediately after wiping.
The weighed test samples were dried for at least three days at
ambient conditions and for one week in vacuum. Finally, the test
samples were reweighed to obtain the dry masses. The dried test
samples were stored in a desiccator for further analysis.
The mass loss was calculated as the difference between the
initial mass of the test sample and the mass of the dried test
sample divided by the initial mass of the test sample. The water
absorption was calculated as the difference between the mass of
the wet test sample and the mass of the dried test sample divided
by the mass of the dried test sample.
Molecular weights. The molecular weights (number average,
Mn, and weight average, Mw, molecular weights) and poly-
dispersity (PD) of the copolymer were determined at room
temperature by size exclusion chromatography (SEC) (Waters
Associates system equipped with a Waters 717plus autosampler, a
Waters 510 HPLC solvent pump, four linear PL gel columns
(104, 105, 103 and 100 Å) connected in series, and a Waters 2414
differential refractometer). Chloroform (Riedel-de Haën Ag,
stabilized with 1% ethanol) was used as a solvent and eluent.
The samples were filtered through a 0.5 mmMillex SR (Millipore)
filter. The injected volume was 200 ml and the flow rate was
1.0 ml/min. Monodisperse polystyrene standards were used for
primary calibration.
Thermal properties. Thermal analysis was performed using
differential scanning calorimeter DSC Q1000 (TA Instruments).
Nitrogen was used as the sweeping gas. To ensure the samples
(4–6 mg) had a similar thermal history, they were heated twice
and cooled rapidly in between. The heating rate was 20°C/min,
the cooling rate was 50°C/min and the temperature range was -
60°C to +200°C. Glass transition temperatures (Tg) were obtained
from the second heating and melting temperatures and enthalpies
(Tm and DHf respectively) were obtained from the first heating
cycle. Two to five parallel samples were tested for each composite
material and time point. The results were analyzed using
Universal Analysis Software and averages and standard deviations
were calculated.
Ceramic content. The β-TCP content of the test samples was
measured using thermogravimetric analysis (TA Instruments).
Approximately 20 mg of a sample was used and the samples were
heated at a rate of 20°C/min up to 700°C. The results were
analyzed using Universal Analysis Software. Five parallel samples
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of each composition at each time point were analyzed and the
results were calculated as averages and standard deviations.
Molecular structure. The proton spectra of the samples were
measured using Varian Mercury 300 MHz NMR Spectrometer
(Varian Associates Inc.) at room temperature. Tetramethylsilane
(TMS) was used as an internal standard, and chemical shifts were
measured relative to TMS. The 1H NMR spectra were measured in
standard 5 mm tubes in deuterochloroform. The data were acquired
until the quality of the spectrum was sufficient and the number of
scans was about 512. The proton NMR spectra of the samples were
processed and analyzed using SpinWorks 3.1 and ACD/Spectrus
software. Phase correction and baseline correction were applied to all
spectra. Information on the molecular composition of rifampicin
and the comonomer ratio of the copolymer was obtained.
Microstructure of the samples. The microstructure of the
composites was observed using scanning electron microscopy
(Philips XL-30 SEM equipped with a LaB6 filament, Philips)
with an acceleration voltage of 12.0 kV. The micrographs were
taken both on the surface of the samples and on fractured samples
that were coated with gold (Edwards S150 Sputter Coater) prior
to microstructure examination.
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ABSTRACT
Aims: This study describes the potential of real-time bioluminescence imaging in evaluating
the antibiotic efficiency of two cylinder-shaped bioabsorbable antibiotic-releasing
composites by in vitro inhibition zone tests. The bacterial infections of bone tissue can
cause extensive hard and soft tissue damage and decrease the efficiency of oral antibiotic
therapy due to the poor blood circulation in the infected area. To overcome this problem,
new, locally antibiotic-releasing biodegradable composites have been developed.
Study Design & Methodology: The two composites evaluated in this study were
composed of poly(L-lactide-co-ε-caprolactone) matrix, β-tricalcium phosphate ceramic and
either ciprofloxacin or rifampicin antibiotic. The composites were tested with genetically
modified model pathogens of osteomyelitis (Pseudomonas aeruginosa and Staphylococcus
epidermidis) in vitro in inhibition zone tests using a method of real-time bioluminescence.
Results: The first signs of the effect of the released ciprofloxacin or rifampicin became
visible after four hours of incubation and were seen as changed bioluminescence around
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the composite pellet on a culture dish. Both of the composite types showed excellent effects
against the sensor bacteria within the diffusion area. Bioluminescence measurements
suggested that no survivor bacteria capable of evolving resistant strains were left inside the
inhibition zones. The S. epidermidis bacterial strain was an inhibition sensor and P.
aeruginosa was a stress sensor.
Conclusion: These results highlight the potential of the composite materials against the
pathogens of osteomyelitis. The approach allows continuous visual inspection of the
efficacy of the antibiotics against the bacteria.
Keywords: Bioluminescence; ciprofloxacin; controlled drug delivery; inhibition zone;
rifampicin.
1. INTRODUCTION
Osteomyelitis is a severe bacterial infection that can cause bone and soft tissue necrosis
[1,2]. A major problem in the treatment of osteomyelitis is the wide spectrum of pathogens,
i.e. staphylococcal, enterococcal, Pseudomonasand Salmonella species [1-4]. It is common
that infected bone has degenerated blood circulation that greatly affects the efficacy of
parenteral or intravascular antibiotics. To overcome this problem, local drug delivery systems
have been developed to deliver the antibiotics directly to the infected tissue. Local antibiotic
release, in the form of antibiotic-releasing implants, provides high local antibiotic
concentrations and also reduces side effects [1,4]. Additionally, they can reduce the cost of
drug therapy, increase the efficiency of drugs, and enhance patient compliance [4,5].
Osteomyelitis often requires surgical debridement of infected tissues that leaves a defect in
the bone called a dead space. Currently, dead spaces are often treated with gentamycin-
releasing poly(methyl methacrylate) beads that need to be removed later because they are
not bioabsorbable and require bone grafting after bead removal [6]. This method of
treatment is not optimal because it involves two surgeries. Bioabsorbable, osteconductive
and antibiotic-releasing composites offer the possibility to treat osteomyelitis in one stage
and to reduce both the risks for the patient and the costs. Such materials have been
requested in the literature and the research is going on to achieve these goals [7].
In the development phase of antibiotic-releasing materials, screening the materials before
preclinical testing is important to find the most promising materials. Often, the functionality of
such materials is evaluated by inhibition zone testing. Typically, inhibition zones are
measured using over-night-grown bacterial cultures, where the inhibition zone can be simply
measured [8,9]. In this study, real-time bioluminescence imaging was used to investigate the
potential and the antimicrobial activity of two bioabsorbable, antibiotic-releasing and cylinder-
shaped composites in in vitro inhibition zone tests.
Bioluminescence imaging has been used successfully, for example, to monitor the
antimicrobial efficacy of wound dressings in vitro [10], stem cell differentiation [11,12],
vascularization [13,14], apoptosis [12], gene therapy [15,16], inflammation of tissue [17],
implant-related bacterial infections [18,19] and in osteomyelitis animal model (mouse) [20].
The method, using whole bacteria cells as biosensors, offers several advantages: it is easy
to use, it is non-invasive, and it has high throughput and low costs [12,21]. In the case of
inhibition zone testing, bioluminescence imaging provides more information than the
conventional method because information on the bacteria and their reactions can be
followed in real time when exposed to the antibiotics [22]. Due to the light-emitting nature of
bioluminescent bacteria, the number of emitted photons can be detected real-time and the
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changes in light levels are proportional to the changes in the metabolism of the cells under
study [10,23-27].
The osteoconductive, bioabsorbable, and antibiotic-releasing composites used in this study
were developed for the treatment of osteomyelitis and their drug release and degradation
properties in vitro were tested in our earlier studies [28,29]. A steady-state drug release
period was observed after the initial burst in the beginning of the release [28,29]. Because
the materials have been tested only in in vitro conditions, it is possible that the actual
concentrations in tissue would be different due to differences in clearance from the tissue.
2. MATERIALS AND METHODS
2.1 Materials
Medical grade poly(L-lactide-co-ε-caprolactone) (PLCL) with the comonomer ratio of 70/30
and Mw of 246,000 g/mol was purchased from Purac Biomaterials (Gorinchem, theNetherlands). β-Tricalcium phosphate (β-TCP) (granule size < 38 μm) was purchased from
Plasma Biotal Ltd. (Buxton, Derbyshire, United Kingdom). Rifampicin was purchased from
Oriola (Espoo, Finland) and ciprofloxacin from Uquifa (Civac, Jiutepec-Morelos, Mexico).
Sörensen phosphate buffer solution was prepared and used according to the ISO 15814
standard [30]. The chemicals used for the buffer solution (Na2HPO4 and KH2PO4) werepurchased from J.T. Baker (Deventer, the Netherlands).
2.2 Processing of Composite Materials
Processing was done according to Ahola et al. [28,29]. In short: dried polymer (PLCL), β-
TCP (50 wt-%) and antibiotics (either rifampicin or ciprofloxacin) were processed with a
custom-built co-rotating twin-screw extruder in nitrogen atmosphere into rod-shaped billets,
with a diameter of approximately 2.5 mm. Three different composites were processed: one
composite had 8 wt-% of ciprofloxacin, one 8 wt-% of rifampicin and one with no antibiotic
served as a control material. Cylindrical-shaped samples (length approx. 2.5 mm) were cut
from the billets. Before inhibition zone testing, the samples were packed and gamma
irradiated (28.7-34.0 kGy) for sterility.
2.3 Bacteria and Plasmids
Two engineered, non-pathogenic bacterial strains cloned with bacterial luciferase reporter
genes were used as biosensor cells: Pseudomonas aeruginosa PAO-LAC carrying plasmid
pUCP24GW and integrated mini-Tn7-Gm-GW-LUX carrying the PA0614 promoter [31] and
Staphylococcus epidermidisATCC-14990 carrying plasmid pAT19-lux-hlaP-frp. Minimum
inhibitory concentrations (MIC) of ciprofloxacin against P. aeruginosa has been reported to
be 0.1-1.2 μg/ml [32,33] and against S. epidermidis 0.1-0.8 μg/ml [34]. For rifampicin, the
MIC reported against S. epidermidis is 0.015 μg/ml [35]. The values against P. aeruginosa
vary greatly and values of 32-64 μg/ml [36] and 8-16 μg/ml [37] have been reported.
2.4 Bioluminescence Imaging
Bacteria were cultured on antibiotic L-agar plates (10 g/L tryptone, 5 g/L yeast extract, 5 g/L
NaCl, 15 g/L agar; 10 g/L gentamycin for P. aeruginosa and 5 g/L erythromycin for S.
epidermidis) overnight at 30°C and suitable colonies were placed into 5 ml of liquid Luria-
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Bertani medium (LB; 5 g/L yeast extract, 10 g/L tryptone, 5 g/l NaCl in 1L). The bacteria
were cultured overnight at 30°C, shaken at 300 rpm, and suitable antibiotics were added.
The level of luminescence of the cultures was measured by using a Plate
ChameleonTMmultilabel counter 1.001 (Hidex Ltd, Turku, Finland). At a volume of 200 µl, 1.1-
2.3×106 counts for S. epidermidis and1.1-2 and 3×106 counts for P. aeruginosa were found
to be optimal for subsequent steps.
Plates were prepared by casting two layers of LB-agar into a 6-well plate. Controls and
antibiotic-containing composites were placed in the center of the bottom layer, one pellet per
well. Bacteria culture of 350-500 µl per well was mixed with 1 ml of soft LB-agar (agar
concentration 7.5 g/L) solution and cast on top. After solidification, the plate was taken to the
imaging station of a Xenogen Vivo Vision IVIS® Lumina CCD camera (Caliper Life Sciences,
USA). Images were taken every 20 minutes for 16 hours with an exposure time of 30
seconds. The images were analyzed using the Living Image® 3.1 program (Caliper Life
Sciences, USA). The ciprofloxacin and rifampicin-releasing composite pellets were tested
with both strains of bacteria after sterilization with gamma irradiation as well as after one and
two weeks immersion in Sörensen phosphate buffer solution (pH 7.4) at 37°C.
After each 16-h measurement cycle, the outcome of bioluminescence was verified by visual
inspection (halo around the antibiotic-releasing pellet showing no visual bacterial growth).
2.5 Interpretation of the Results
The results are presented as false color photos, where dark blue and purple were interpreted
as dead bacteria with no bioluminescence. The dark blue color resulted from internal
reflection from the high light levels in the stress zones. The red and yellow colors were
interpreted to indicate a situation where the bacteria are in contact with sub-inhibitory
concentrations of the antibiotics and produce a strong light emission that is presumably due
to the nonspecific activation of central metabolic pathways [22]. These red and yellow zones
are called stress zones (SZ). Green color was considered to be unaffected bacteria because
this was the usual intensity in the control wells.
3. RESULTS
We have previously introduced the preliminary results of ciprofloxacin releasing composites
[28] and rifampicin releasing composites[29] against Pseudomonas aeruginosa in
connection with the in vitro drug release results. Here, we want to show the differences
between the two bacteria Pseudomonas aeruginosa and Staphylococcus epidermidis. In
addition, we want to show the results of the antibiotic releasing composites after 1 week
immersion in Sörensen phosphate buffer solution (pH 7.4) at 37°C to simulate situation,
when the composites have been implanted in tissue and the antibiotic release has been
stabilized after the initial burst in the release. It is intended that the two composites will be
used together in the local treatment of osteomyelitis in such a way that the surgeon treating
the patient can decide the exact ratio of the antibiotics to be used.
The results of the bioluminescence imaging for the pellets tested directly after processing
and sterilization are presented in Figs. 1-4 as part A. The light emission levels for the same
samples are shown as photon counts in Figs. 1-4 as part B. The results of bioluminescence
imaging for the pellets that were kept immersed in Sörensen phosphate buffer solution (pH
7.4) at 37°C for one week are presented in Appendix as Figs. 1-4 part A and the light
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emission levels in Appendix as Figs. 1-4 part B. Because there were no major differences in
the antibiotic activity between the samples that had been in in vitro conditions for one or two
weeks, only the results for the samples that had been in in vitro conditions for one week are
presented.
Both S. epidermidisand P. aeruginosa responded to ciprofloxacin released from the
composite pellets that were tested directly after processing and sterilization (Figs. 1A and
2A, respectively). The yellow-red stress zone preceded the expanding inhibition zone that
was seen as an increasing blue zone in the middle of the well. The decrease in the
bioluminescence that suggested the death of bacteria near the composite material was
clearly visible after 6 hours for P. aeruginosa and after 10 hours for S. epidermidis. At the
time point of 12 hours, the inhibition zones had reached their maximum. After this, changes
were mainly detected in the light emission levels, which can be seen in Figs. 1B and 2B as
photon counts. In these graphs, high light emission, which represented the appearance of a
SZ, was seen at the edges of the inhibition zones.
When the ciprofloxacin-releasing composites that had been immersed in Sörensen
phosphate buffer solution (pH 7.4) at 37°C for a week were compared with those tested
directly after sterilization, the stress zones (SZ) appeared earlier (Appendix Figs. 1 and 2).
The SZs were, however, no larger in size, which indicated a longer presence of sub-
inhibitory concentration areas. The initial burst, as seen in the results of the pellets tested
directly after the sterilization step, was not present and the release of ciprofloxacin was
steadier but yet strong enough to kill the bacteria. The ciprofloxacin release resulted in
narrower inhibition zones that correlated well with the in vitro ciprofloxacin release study
conducted earlier [28].
Both bacteria also responded to rifampicin release (Figs. 3 and 4), but the inhibition zones
produced were much smaller than the zones produced by ciprofloxacin (Figs. 1 and 2). Due
to the larger molecular size of rifampicin compared with ciprofloxacin, the diffusion in agar is
probably slower and limited when compared with the diffusion of ciprofloxacin and, as a
result, the inhibition zone was smaller. The first signs of decreased bioluminescence could
already be seen after 4 hours for both of the studied bacteria. In the case of S. epidermidis,
the formation of inhibition zones began as an appearance of red and yellow SZs around the
antibiotic composites, but such behavior was not seen in the case of P. aeruginosa. The light
emission levels of S. epidermidis and P. aeruginosa are shown in Figs. 3B and 4B,
respectively.
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Fig. 1.(A) The development of the inhibitory zones was seen as growing blue areas in the
middle of the wells of cultured S. epidermidis and ciprofloxacin composite pellets (in triplicate
on the lower row). Pellets without antibiotic were used as controls (in triplicate on the top row).
The plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter
of one well is 35 mm. (B) Light intensity levels as photon counts of S. epidermidis exposed to
one ciprofloxacin releasing composite pellet in the middle of the well. The results are presented
at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the different scales of the y-axes.
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Fig. 2.(A) The development of the inhibitory zone was seen as growing blue areas in the middle
of the wells of cultured P. aeruginosa and ciprofloxacin composite pellets (in triplicate on the
lower row). Pellets without antibiotic were used as controls (in triplicate on the top row). The
plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter of
one well is 35 mm. (B) Light intensity levels as photon counts of P. aeruginosa exposed to one
ciprofloxacin releasing composite pellet in the middle of the well. The results are presented at
time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the different scales of the y-axes.
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Fig. 3.(A) The development of the inhibitory zones was seen as growing blue areas in the
middle of the wells of cultured S. epidermidis and rifampicin composite pellets (in triplicate on
the lower row). Pellets without antibiotics were used as controls (in triplicate on the top row).
The plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter
of one well is 35 mm.(B) Light intensity levels as photon counts of S. epidermidis exposed to
one rifampicin releasing composite pellet in the middle of the well. The results are presented at
time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the different scales of the y-axes.
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Fig. 4.(A) The development of the inhibitory zone was seen as growing blue areas in the middle
of the wells of cultures P. aeruginosa and rifampicin composite pellets (in triplicate on the
lower row). Pellets without antibiotic were used as controls (in triplicate on the top row). The
plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter of
one well is 35 mm. (B) Light intensity levels as photon counts of P. aeruginosa exposed to one
rifampicin releasing composite pellet in the middle of the well. The results are presented at time
points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the different scales of the y-axes.
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In the case of the rifampicin-releasing samples kept immersed in Sörensen phosphate buffer
solution (pH 7.4) at 37°C for one week, the initial burst was not present, as was also the
case with ciprofloxacin. There was also no significant change in light emission levels
(Appendix Figs. 3B and 4B), which indicated no clear inhibition.
In Fig. 5, the growth of the area of the inhibition zones is shown as a function of time. The
graphs indicate the size of the inhibition zone that one composite pellet, releasing either
ciprofloxacin or rifampicin, is capable of producing. The inhibition zone areas are presented
without and with stress zones (5 A and C without stress zones and 5 B and D with stress
zones). The graphs also show the differences in the effects between the different bacterial
species. With ciprofloxacin (Figure 5A), the inhibition zone of S. epidermidiswas around 9.0
cm2, but with P. aeruginosathe area was only half the size. When the ciprofloxacin-releasing
composites had been immersed in the Sörensen phosphate buffer solution at 37°C for a
week, the zone area decreased to around 8.0 cm2 for S. epidermidis and to 2.0 cm2 for P.
aeruginosa. With S. epidermidis, the inhibition zone of rifampicin was around 2.3 cm2
(Fig.5C),and only 0.4 cm2 after immersion in Sörensen phosphate buffer solution at 37°C.
For P. aeruginosa, the values were 1.5 and 0.2 cm2, respectively. When the stress zones
were included in the inhibition zones (Figs. 5B and 5D), the areas differed only slightly for S.
epidermidis. With P. aeruginosa the stress zones made a larger difference, which indicated
larger stress zones for P. aeruginosa.
Fig. 5. Measured area of the bioluminescence inhibitory zones with (A) ciprofloxacin,
(B) ciprofloxacin with stress zones included in the inhibitory zones, (C) rifampicin and
(D) rifampicin with stress zones included in the inhibitory zones (n=3). Results using
pellets that had been immersed in Sörensen phosphate buffer solution (pH 7.4) at
37°C for one week prior to testing are shown as well.
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4. DISCUSSION
The aim of this study was to demonstrate the potential of bioluminescence in inhibition zone
tests and to show that bioluminescence provides more information about the effects of
antibiotics on bacteria than the conventional over-night-grown inhibition zone
measurements. The possibility for real-time observation of the evolving inhibition zones and
so-called stress zones provides an insight in to how the antibiotics affect the bacteria.
The antibiotic-releasing composites studied here were cylindrical in shape and were
composed of bioabsorbable poly(L-lactide-co-ε-caprolactone) (PLCL) as the polymer matrix,
50 wt-% β-tricalciumphosphate (β-TCP), and either 8 wt-% of ciprofloxacin or rifampicin. It is
intended that the composites will be used together in the local treatment of osteomyelitis in
such a way that the surgeon treating the patient can decide the exact ratio of the antibiotics
to be used. The main advantage of this kind of composite implant is that removal after
treatment is not required due to the bioabsorbability of the composites. β-TCP acts as an
osteoconductive material and is capable of attracting osteoblasts. This can both facilitate
controlled drug release and enhance bone repair and regeneration [4,38-41].
The antibiotics used in this study, rifampicin and ciprofloxacin, have been widely used
because they are known to form an effective, synergistic combination even against bacterial
strains that are not susceptible to, for example, β-lactams or tetracyclines. A quinolone-
rifampicin treatment is safe and well tolerated by patients [2,4,42,43]. Ciprofloxacin is used
as the main antibiotic because it is an active fluoroquinolone that inhibits DNA gyrase and
stops DNA replication [22,44]. Rifampicin supports ciprofloxacin by inhibiting the emerging
resistant strains. It also penetrates biofilm well [45,46], which is an advantage because
osteomyelitis is often caused by bacteria forming biofilms. Some bacteria are more resistant
to antibiotics than others, a good example being the MRSA strain of S. aureus[22]. The use
of two or more antibiotics that have a synergistic action is frequently employed [22,47]
because this seems to prevent or inhibit the development of resistance.
The antibiotics used in the treatment of osteomyelitis must be active against a broad
spectrum of common disease-causing pathogens [4]. The treatment must also ensure that
no bacteria survive. If the duration of the treatment is too short or the antibiotic reaches the
infection site in sub-inhibitory concentrations, the remaining bacteria can cause clinical
failure and potentially develop resistance [1-3,48]. Often, two antibiotics are used together
because of their synergistic effect against the causative bacteria. The benefits of this kind of
treatment are accelerated bacterial count decline, a wider antibacterial spectrum and
reduction in the risk of resistant strain development to one of the antibiotics [49].
In the bioluminescence measurements conducted in this study, it was shown that both
ciprofloxacin and rifampicin caused very strong, non-specific activation of bioluminescence
in both of the model bacteria. The same kinds of reactions have been previously reported
several times in solution-based assays in the high-throughput assays of antimicrobial agents
in microtitreplate format [23,50,51]. Even though ciprofloxacin-releasing composite pellets
were shown to be more effective against bacteria than rifampicin-releasing ones, it was
noticed that rifampicin composites reached the level of total eradication earlier. This was
seen, when using rifampicin-releasing composites, as a faster decrease in luminescence in
the middle of inhibition zones (Figs. 3B and 4B). The fast response was most probably due
to the burst in the release that is caused when the composite materials first release the
antibiotic molecules on or near the surface as they are exposed to fluids. Here, rifampicin
caused a stronger burst than ciprofloxacin, as was seen in the in vitro drug release test
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conducted earlier [28,29]. The burst effect is a well-known phenomenon in controlled drug
delivery and is sometimes considered to be unwanted [52]. In the case of antibiotics,
however, reaching drug concentrations over the minimum inhibition concentration quickly is
crucial because antibiotic resistance is a serious problem worldwide. In this sense, a
moderate burst in the beginning of the release is useful. After the burst, the drug may be
released in a continuous manner that can last for weeks [4,28].
The formation of stress zones was more visible for the ciprofloxacin-releasing composites.
Within these zones, the concentration of antibiotic was considered to be too low to kill
bacteria, but still able to cause the up-regulation of certain promoters. As a part of this
regulation, the bacteria were presumably partially shutting down some of their metabolic
pathways and thus liberated more energy for the bioluminescence reaction.
S. epidermidisis a metabolic inhibition sensor and P. aeruginosais a stress sensor. P.
aeruginosa is constructed to respond to the threat caused by gyrase inhibitors such as
ciprofloxacin: up-regulation of luminescence genes only results if expression of the gyrAgene
is reduced and gyrase is inhibited by ciprofloxacin [31]. The shut-down of light emission,
especially in control wells (Fig. 2), may occur when the bacteria have reached the stationary
phase and the quantity of active gyrase is not reduced by inhibition [31]. Therefore, the
promoter in front of the luciferase reporter genes is efficiently shut down in non-stressing
conditions and results in a dark background over the control pellets. Another explanation
may be that the light emission levels of the wells affected by ciprofloxacin were very high
and because of the internal recalibration system of the equipment, the low background light
emission was under the detection limit. Thus, it may have seemed that there was no light
emission. The blue light that was seen in the control wells in Fig. 2 was probably only a
reflection of the strong light emission produced by the bacteria in contact with ciprofloxacin.
Because P. aeruginosais a stress and inhibition sensor, the light emission was up-regulated
as ciprofloxacin diffusion proceeded and turned off as bacteria died. This was seen as the
inhibition zone expanded within stress zone progression. Rifampicin being a transcriptional
inhibitor did not produce a similar stress effect with P. aeruginosa.
Because sub-inhibitory concentration levels of quinolones are enough to promote an SOS
response that regulates several promoters, sub-inhibitory concentration levels can lead to a
possible increased tolerance to DNA damage [44]. As a result, an inadequate antibiotic
release of the composites can cause the development of resistant bacterial strains. Most
promoters regulate virulence genes and survival and some promoters are also sensitive to
low concentrations of rifampicin [53]. It is, therefore, vital to decrease the formation of low
concentration release barriers in order to lower the mutation rate of these promoters.
Because the bioluminescence method uses light-emitting bacterial cultures from which the
range of the antibiotic release and the level of inhibition inside the zones formed can be
estimated and measured, the method can be used to screen the potency of antibiotic-
releasing systems before preclinical studies. Direct correlation between the light production
and viable light emitting bacteria has been reported several times and with several different
bacteria [10,23-27]. If toxic substances such as antibiotics kill the sensor bacteria, the
decrease in light emission correlates directly to the number of viable bacteria [24-26]. Thus,
bioluminescence seems to be a very suitable method for assessing the antimicrobial effects
of antibiotic-releasing materials.
By imaging the antibiotic release utilizing bioluminescence and a CCD camera in real-time, it
is easy to demonstrate whether the antibiotic-releasing capacity of the material is high
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enough to eradicate the bacteria without any potential survivors developing antibiotic
resistance. The antibiotic release from a small, ciprofloxacin-containing pellet seems to be
sufficient to kill all the bacteria inside the inhibition zones. The inhibition zones formed by
rifampicin-releasing material may, however, pose the risk of resistant strain formation if used
alone. Therefore, the materials must be used together in order to support each other and to
decrease the risk of resistance. In this study, we investigated the antibiotics separately in
order to highlight the differences more clearly. According to the results, the composite
materials have good potential to release antibiotics in concentrations high enough to
eradicate bacteria from tissues infected by pathogens of osteomyelitis.
5. CONCLUSION
The in vitro inhibition zone test using real-time bioluminescence was demonstrated to be an
efficient tool to observe the effects of the released antibiotics on the model pathogens of
osteomyelitis. The method provides more information on the effects against the bacteria than
the conventional over-night-grown bacterial cultures. Additionally, the potential of the new
antibiotic-releasing biodegradable composites were shown to be adequate on model
pathogens. However, it has to be kept in mind that the results presented here were obtained
using single antibiotic-releasing composite pellets. In real clinical cases, several of these
kinds of composite pellets would be used together. The therapeutic value of the release of
ciprofloxacin and rifampicin from composites needs to be demonstrated carefully in order to
validate the potential of new antibiotic-releasing composites in efficient antibiotic release.
Studying the composite material with bioluminescence inhibition tests helped to monitor the
efficiency of antibiotic release.
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APPENDIX
Figure. 1. (A) The development of the inhibitory zones was seen as growing blue areas in the
middle of the wells of cultured S. epidermidis and ciprofloxacin composite pellets, which had
been immersed in Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week (in
triplicate on the lower row). Pellets without antibiotic were used as controls (in triplicate on the
top row). The plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The
diameter of one well is 35 mm. (B) Light intensity levels as photon counts of S. epidermidis
exposed to one ciprofloxacin releasing composite pellet in the middle of the well. The pellet had
been immersed in Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week before the
experiment. The results are presented at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours.
Note the different scales of the y-axes.
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Figure 2.(A) The development of the inhibitory zones was seen as growing blue areas in the middle of
the wells of cultured P. aeruginosa and ciprofloxacin composite pellets, which had been immersed in
Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week (in triplicate on the lower row).
Pellets without antibiotic were used as controls (in triplicate on the top row). The plate was
photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter of one well is 35
mm. (B) Light intensity levels as photon counts of P. aeruginosa exposed to one ciprofloxacin
releasing composite pellet in the middle of the well. The pellet had been immersed in Sörensen
phosphate buffer solution (pH 7.4) at 37°C for one week before the experiment. The results are
presented at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the different scales of the y-
axes.
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Figure 3.(A) The development of the inhibitory zones was seen as growing blue areas in the
middle of the wells of cultured S. epidermidis and rifampicin composite pellets, which had been
immersed in Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week (in triplicate on
the lower row). Pellets without antibiotic were used as controls (in triplicate on the top row).
The plate was photographed at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter
of one well is 35 mm. (B) Light intensity levels as photon counts of S. epidermidis exposed to
one rifampicin releasing composite pellet in the middle of the well. The pellet had been
immersed in Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week before the
experiment. The results are presented at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours.
Note the different scales of the y-axes.
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Figure 4.(A) The development of the inhibitory zones was seen as growing blue areas in the middle of the
wells of cultured P. aeruginosa and rifampicin composite pellets, which had been immersed in Sörensen
phosphate buffer solution (pH 7.4) at 37°C for one week (in triplicate on the lower row). Pellets without
antibiotic were used as controls (in triplicate on the top row). The plate was photographed at time points of
0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. The diameter of one well is 35 mm. (B) Light intensity levels as photon
counts of P. aeruginosa exposed to one rifampicin releasing composite pellet in the middle of the well. The
pellet had been immersed in Sörensen phosphate buffer solution (pH 7.4) at 37°C for one week before the
experiment. The results are presented at time points of 0, 2, 4, 6, 8, 10, 12, 14, and 16 hours. Note the
different scales of the y-axes.
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